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Abstract
The main aggrecan catabolite, found in samples of synovial fluid from patients with arthritis, and 
released from cartilage explant cultures exposed to IL-1, both have the amino-terminal amino acid 
sequence 374ARGSV... (human sequence enumeration) corresponding to cleavage at the 
‘aggrecanase site’ within the IGD of aggrecan (Sandy et al., 1992, and Lohmander et a!., 1993). 
Loss of aggrecan is a primary event in the destruction of cartilage in arthritic disease. The Glu373- 
Ala374 bond (‘aggrecanase site’) within the IGD of the aggrecan core protein is cleaved by 
members of the ADAMTS family, including ADAMTS-4 and -5 (Tortorella et al, 1999, Abbaszade 
et al., 1999, and Sandy et al., 2000).
In this investigation the model system of chondrocyte-agarose cultures, pioneered by 
Aydelotte and Kuettner 1988, was used to study the degradation of aggrecan by ADAMTS-4 and -5 
in cartilaginous extracellular matrices.
Low molecular weight co-migrating ~37kD ADAMTS-4 and -5 isoforms were detected in 
apparently increased amounts in IL-1 a treated cultures compared to controls. These isoforms were 
bound by heparin and required de novo protein synthesis in the presence of IL-1 a for their 
generation. As previously reported, de novo protein synthesis in the presence of IL-1 a was also 
required for ‘IGD aggrecanase activity’ (Arner etal., 1998). Heparin bound media fractions from IL- 
1a treated cultures possessed ‘IGD aggrecanase activity’ against exogenous aggrecan, which was 
inhibited by the amino-terminal region of TIMP-3 and was shown to be due to a 37kD isoform of 
ADAMTS-4. This implicated low molecular weight isoforms of ADAMTS-4 in the aggrecanolysis 
detected in the presence of IL-1 a.
Carboxy-terminal truncation of furin cleaved ADAMTS-4 has previously been proposed as 
both an activation mechanism for the enzyme (Pratta et al., 2003, Kashiwagi et al., 2004, Gao et 
al., 2002, Gao et al., 2004 and Flannery et al., 2002) and a means of deregulation of the enzyme’s 
catalytic activity.( Gao et al., 2002, Gao et al., 2004, and Kashiwagi et al., 2004). Therefore high 
molecular weight Furin cleaved ADAMTS-4 isoforms may be required to play normal physiological 
roles, whereas the low molecular weight forms are likely to be the enzyme isoforms involved in the 
destruction of aggrecan and other proteoglycans in articular cartilage during arthritis.
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Chapter 1: Introduction
1.1 Articular Cartilage Morphology
To take the stress out of everyday movement the load bearing joints of the body are lined with 
articular cartilage. This aneural, avascular, alymphatic, hypocellular tissue acts to reduce friction 
and absorb impact. Articular cartilage is composed of a dense extracellular matrix controlled and 
secreted by the cells (chondrocytes) within it. The cells contribute less than 2% of the volume of 
mature adult articular cartilage; the remaining volume is occupied by collagens, proteoglycans and 
water. Water comprises 70% of the tissue’s wet weight, collagens 20%, proteoglycans 7% and 
other proteins around 1% (Poole etal., 2001, and Vertel 1995).
1.1.1 Articular Cartilage Chondrocytes
These are the only cell type present in articular cartilage and differ in both their morphology and 
metabolic activity between the various zones (see Figure 1.1). All contain an endoplasmic 
reticulum and Golgi apparatus necessary for matrix synthesis and secretion, but some may also 
contain intracytoplasmic filaments, lipid globules, glycogen and secretary vesicles. The cells are 
diffusely spread throughout the matrix allowing for no cell-cell contacts (Buckwalter and Hunziker 
1999). Some chondrocytes have short processes or microvilli extending from their surface out into 
the matrix. These structures may sense mechanical changes in the matrix and relay this 
information to the cells (Buckwalter and Hunziker 1999) giving a feedback mechanism allowing 
adaptation in the composition of the matrix macromolecules in response to changes in the physical 
state of the matrix.
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Superficial Zone
Mid Zone
Deep Zone
Calcified Cartilage
Subchondral Bone
Figure 1.1 Zones of articular cartilage (a) Mature rabbit articular cartilage (Jimenez and Hunziker 1992) and 
Benninghoff Arcades of Collagen fibrils (Benninghoff 1925)
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1.1.2 Morphological Zones
Mature articular cartilage may be divided into 4 overlapping zones (Figure 1.1a) running parallel to 
the cartilage surface. The arrangement of the cells within these zones is maintained by the 
collagen fibre organisation known as Benninghoff Arcades (Benninghoff 1925) (Figure 1.1b).
□ Adjacent to the joint cavity is the superficial zone which can be divided into two layers:
□ The surface acellular layer is composed of a layer of amorphous material (Juvelin et al., 
1996) covering a sheet of fine fibrils rich in type I collagen (Duance 1983)
□ The deeper cellular layer contains flattened or ellipsoid chondrocytes and a high 
collagen concentration (Duance et al., 1999). The balance of the proteoglycan types 
present differs from that seen in other areas of the cartilage with a lower concentration 
overall, and of that which is present a high concentration is composed of small 
proteoglycans. PRG-4, also known as Superficial Zone Protein (SZP) is a novel 
proteoglycan synthesised by superficial zone chondrocytes of articular cartilage and 
was first identified by Schumacher et al., in 1994. PRG-4 was shown to be 
intracellularly located in superficial zone chondrocytes in bovine articular cartilage as 
well as being present in the fine layer of matrix at the articular surface (Schumacher et 
al., 1999) (see Section 1.2.2.7).
The dense collagen fibrils present in the superficial zone of articular cartilage lead to a 
greater tensile strength, as they lie parallel to the surface of the zone.
□ The transitional, mid or intermediate zone lies below the superficial / surface zone and 
contains oval or rounded cells in groups of up to 2 or 3. Compared to the superficial zone this 
region has a higher proteoglycan concentration, lower collagen concentration and collagen 
fibrils of larger diameter. The collagen fibrils in this region are mainly type II collagen. Unique 
to this area of cartilage is Cartilage Intermediate Layer Protein (CILP) (see Section 1.2.3.3) 
(Lorenzo etal., 1998a).
□ The deep or radial zone contains large rounded cells in groups of 2, 4, 6 or 8 arranged in
columns running perpendicular to the cartilage surface. Of all the zones this has the highest
proteoglycan concentration, the lowest collagen concentration and the largest diameter
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collagen fibrils (Buckwalter and Hunziker 1999). The collagen fibres pass into the so-called 
tidemark seen in decalcified cartilage between the deep and calcified zones.
□ The calcified zone rests on the underlying subchondral bone. Here the matrix contains crystals 
of calcium salts and, as in the deep zone, the cells are found in groups of up to 8.
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1.2 Articular Cartilage Extracellular Matrix Components
The articular cartilage matrix is composed of tissue fluid and the matrix macromolecules that give 
the tissue form and structure. The cartilage structural macromolecules, collagens, proteoglycans 
and non-collagenous proteins contribute 20-40% of the wet weight of the tissue (Buckwalter and 
Hunziker 1999). The three classes of macromolecules differ in their concentrations and their 
contributions to the mechanical properties of the tissue. Collagens contribute 60% of the dry weight 
of cartilage, proteoglycans 25-35% and non-collagenous proteins and glycoproteins 15-20% 
(Buckwalter and Hunziker 1999). The collagen fibril meshwork gives cartilage its form and tensile 
strength (Buckwalter and Mow 1992). Proteoglycans and non-collagenous proteins bind to the 
collagen meshwork or become mechanically trapped within it. The major proteoglycan of articular 
cartilage is aggrecan, which has numerous glycosaminoglycan chains attached to its core protein. 
These form a highly compressible structure when fully hydrated (see Section 1.2.2). Some non- 
collagenous proteins stabilize the matrix framework and others facilitate association of 
chondrocytes with the matrix (see Section 1.2.3).
1.2.1 Collagens
Collagens are the most abundant family of proteins in mammals. They form fibrous elements and 
are the most ubiquitous structures in most connective tissues. To qualify as a collagen a protein 
must contain a segment of at least 20 residues where every third residue is a glycine in the 
sequence Gly-X-Y (Kadler 1996). In each chain this sequence forms a left-handed helix and the 
chains wind around each other in a right-handed super triple helix. Twenty seven members of the 
collagen family have now been identified (Myllyharju and Kivirikko 2001, Fitzgerald and Bateman 
2001, Gordon et al., 2000, Gordon et al., 2002, Hashimoto et al., 2002, and Sato et al., 2002), 
which are produced from over 30 genes, and they can be separated into classes according to their 
structure and functions as shown in Table 1.1 (Eyre 1991).
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Table 1.1 Collagen family members and their tissue distribution (adapted from Eyre 1991, Eyre 2002, Boot- 
Handford et al., 2003, and Koch et al., 2003). Blue shading indicates minor articular cartilage collagens 
whilst red shading indicates major articular cartilage collagens.
Collagen
Class
Co m m en ts C o lla g en
Type
T issue  D is tr ib u tio n
I skin, bone, tendon, intervertebral disc 
and cartilage
These contain a large triple helical II vitreous, cartilage, intervertebral disc
Fibril
Forming
domain with around 330 Gly-X-Y 
repeats per chain and are synthesised 
as large precursors and assemble into 
cross striated fibrils, with each 
molecule being displaced % of its 
length along the axis of the fibril 
relative to its nearest neighbour 
(Burgeson 1988)
III skin, blood vessels, cartilage, 
intervertebral disc
V skin, bone, tendon, intervertebral disc 
and cartilage
XI skin, bone, tendon, intervertebral disc 
and cartilage
XXIV developing cornea and bone
XXVII chondrocytes, developing stomach, 
lung, gonad, skin and tooth
Self assemble into networks and have 
longer non-collagenous domains than
IV basement membranes and stromal 
region of the cornea
Network
Forming
fibril forming collagens (Kadler et al., 
1996, and Prockop and Hulmes 1994). 
Monomers associate at their carboxy- 
termini to form dimers and at their 
amino-termini to form tetramers. The 
triple helical domains intertwine to form 
supercoiled structures (Hulmes 2001).
VIII Descement’s membrane and 
endothelial cells
X calcifying cartilage
IX vitreous, cartilage and intervertebral 
disc
Fibril XII skin, cartilage and intervertebral disc
Associated
These do not form fibrils themselves, 
but are found attached to the surface 
of pre-existing fibrils of the fibril 
forming collagens (Shaw and Olsen
XIV skin, cartilage and intervertebral disc
Collagens XV basement membranes and cartilage
with an XVI skin, lung and arterial smooth muscle
Interrupted XVIII most tissues, high levels in liver
Triple Helix 1991). XIX most tissues, basement membranes
(FACITs) XX corneal epithelium and tendon
XXI blood vessels and smooth muscle
XXII hair follicle
XXVI testis and ovary
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Other
Small
Groups
Beaded filaments VI most tissues including cartilage
Anchoring Fibrils for Basement 
Membranes
VII anchor stroma to basement 
membranes in skin and cornea
Transmembrane
XXIII prostate carcinoma
XIII most tissues including skin
XVII skin and muscle
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1.2.1.1 Major Articular Cartilage Collagens 
a Type II Collagen
The major collagen type of articular cartilage is type II making up 90% of the collagen present 
(Duance et al., 1999). This member of the fibril forming collagen family is made up of 3 identical 
polypeptide a1[ll] chains. In mature cartilage type II collagen forms fibrillar networks with thicker 
fibrils in the deep layers of the cartilage and finer fibrils enriched in the surface layers (Aydelotte 
and Kuettner 1988). Type II collagen fibrils co-assemble with the minor collagen types XI and IX to 
form heterotypic fibrils (see Figure 1.2) (Vaughan etal., 1988, and Mayne etal., 1993). A model for 
packing of collagen molecules into fibrils is shown in Figure 1.3. 
a Type IX Collagen
This member of the FACIT group of collagens is a heterotrimer with its 3 chains (a1[IX], a2[IX] and 
a3[IX]) being products of 3 different genes (Eyre and Wu 1995). The molecule has 3 triple helical 
collagenous domains (COL 1, 2 and 3), 4 non-collagenous domains (NC 1,2,3 and 4) (Duance et 
al., 1999) and is stabilised by interchain disulphide bonds. Unusually for a collagen it has a 
chondroitin sulphate glycosaminoglycan chain attached to the NC 3 domain of the a2 chain 
(McCormick et al., 1987) so is also classified as a proteoglycan. The proportion of this 
glycosaminoglycan bearing form varies between species and tissues. In the vitreous humour of the 
eye 100% is substituted (Bishop et al., 1994), whereas in human articular cartilage only a small 
percentage is substituted (Diab et al., 1996). Covalent cross links between the helical segments of 
type IX collagen and telopeptides of type II collagen suggest a bridging role for type IX between 
adjacent collagen fibres (see Figure 1.2) (Wu and Eyre 1989). 
a Type XI Collagen
Type XI is a fibril forming collagen made up of 3 distinct a chains (a1 [XI]a2[XI]a3[XI]). Together 
with type II and type IX collagen, type XI is co-assembled into heterotypic fibrils of articular 
cartilage (Mendler et al., 1989). Type XI collagen contains 2 collagenous domains (COL 1 and 2) 
and 3 non-collagenous domains (NC 1, 2 and 3). The NC 2 domain forms a kink that produces an 
angle between COL 1 and 2. The association of type XI with type II and type IX is shown in Figure 
1 .2 .
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Figure 1.2 Schematic diagram showing potential interaction between collagen types II, IX and XI in articular 
cartilage (Eyre et al., 1987)
Figure 1.3 Molecular packing of collagen fibrils (A) Longitudinal view of collagen molecules in staggered 
array. Each molecule can be considered as consisting of 5 molecular segments 1 to 5, of which the short 
section 5 is shown in black. (B) Transverse section of the radial packing model (Hulmes et al., 1995). 
Segments 5 (in black) are arranged in concentric layers separated by a distance of ~4nm. (C) Enlarged view 
of the boxed area in (b) showing molecules grouped together in the form of microfibrils. (Hulmes 2001)
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1.2.1.2 Minor Articular Cartilage Collagens
The other collagens present in articular cartilage are types I, III, V, VI, X, XII, XIV and XV;
□ Type I collagen is abundant in skin, bone and tendon but is only a very minor component of 
articular cartilage. It is a fibril forming collagen enriched in the 'lamina splendens' of the 
superficial zone of articular cartilage (Duance 1983).
□ Type III is a fibril forming collagen that has been detected in both normal (Wotton and 
Duance 1994) and osteoarthritic (Aigner et al., 1993) human articular cartilage, but only in 
the superficial zone.
□ Type V collagen has a high homology to type XI and both are members of the fibril forming 
collagen family.
□ Type VI collagen is found in most connective tissues including articular cartilage and forms 
microfibrils with a beaded appearance (Bruns 1984). It is involved in making up a 
pericellular fibrillar meshwork to protect the chondrocytes known as the chondron (Poole et 
al., 1992). Type VI collagen expression is upregulated in osteoarthritis (Chang and Poole 
1996).
□ Type X collagen has a restricted distribution in normal human articular cartilage where it is 
found only in the calcified cartilage below the tide mark (Gannon eta!., 1991, and Walker et 
al., 1995). Chondrocytes of osteoarthritic cartilage synthesise enhanced amounts of type X 
collagen (Von der Mark et al., 1992)
□ Types XII and XIV collagen are both members of the FACIT collagen family with partial 
homology to type IX (Dublet and Van der Rest 1991). Both types XII and XIV have been 
identified in bovine articular cartilage (Watt et al., 1992) where they may carry a chondroitin 
sulphate chain and therefore exist in a proteoglycan form (Van der Rest and Dublet 1996).
□ Type XV collagen has a widespread distribution in human tissues including heart, placenta 
and cartilage (Kivirikko et al., 1995). The a1[XV] chain contains a highly interrupted 
collagenous region of 577 residues and noncollagenous amino- and carboxy-terminal 
domains of 530 and 256 residues, respectively (Kivirikko etal., 1994).
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In cartilage, the size and composition of the fibrils are dependent on the stage of development and 
the source of the tissue (Jan Bos et al., 2001). In mammals, immature cartilage fibrils are of small 
(20nm) diameter (Keene etal., 1995). In contrast, in adult tissue there are two populations of fibrils: 
small diameter fibrils that have surface associated type IX, and thick fibrils with very little type IX 
but the small proteoglycan decorin attached to their surface (see Figure 1.2) (Hagg etal., 1998).
1.2.2 Cartilage Proteoglycans
Proteoglycans are extracellular matrix macromolecules present in varying amounts in all 
connective tissues and comprise over 20% of the dry weight of articular cartilage. They are 
composed of a protein core to which is attached one or more glycosaminoglycan (GAG) chains. 
Their properties and structure vary enormously allowing them to fulfil a diverse variety of biological 
roles.
Each proteoglycan contains one or two types of GAG chain as well as N- and O- 
glycosidically linked oligosaccharides, of the types found in glycoproteins. The core protein of 
proteoglycans is made on membrane bound ribosomes, and passes into the lumen of the 
endoplasmic reticulum (ER). The GAG chains are assembled on the protein core in the Golgi 
(Stryer 1995).
Proteoglycans can have limitless heterogeneity, because core proteins vary in MW (10,000- 
600,000kD), and GAG chains vary in length and number. Many proteoglycans, including aggrecan, 
syndecan and betaglycan contain two GAG chain types. The size and ratio of the GAG chains 
attached to proteoglycan core proteins may alter with aging and / or disease (Roughley and White 
1980, and West etal., 1999).
Proteoglycan core proteins can be sub-divided into various domains. All core proteins, by 
definition, contain a GAG substitution domain to which chondroitin, dermatan, keratan, heparan 
sulphates and heparin may be O-linked via serine or threonine residues, keratan sulphate may 
also be N-linked via asparagine residues. In addition to this, many proteoglycans are anchored to 
the cell surface, or to macromolecules in the extracellular matrix through specific domains in the
core protein. Some core proteins contain domains with as yet unidentified roles and properties.
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Many proteoglycans also interact with macromolecules of the extracellular matrix via their GAG 
chains. There are now more than 30 members of the proteoglycan superfamily, which can be 
grouped into families according to the GAGs they contain, where they are located, or the structure 
of their core proteins. In this discussion the proteoglycan family members covered in detail will only 
be those found in articular cartilage shown in Figure 1.5.
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Figure 1.5 Overview of the proteoglycans present in cartilage. Depicted is a cartilage chondrocyte. 
Associated with the cell surface are the transmembrane spanning syndecan proteoglycans, the GPI-linked 
heparan sulphate proteoglycan, glypican, and two forms of hyaluronan, namely hyaluronan bound to the 
hyaluronan synthase (HAS) and hyaluronan tethered to CD44. Aggrecan binds to cell surface-associated 
hyaluronan within the further removed extracellular matrix. Several small proteoglycans namely decorin, 
fibromodulin and type IX collagen have been shown to form strong associations with cartilage collagen fibrils 
(collagen types II, IX and XI). Other proteoglycans such as biglycan and perlecan are also present within 
cartilage but their localisation and binding partners have not been firmly identified (Knudson and Knudson 
2001).
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1.2.2.1 Glycosaminoglycans
Glycosaminoglycans (GAGs) are long chains of linear polysaccharides formed from repeating 
disaccharide units. One of the sugars of the disaccharide is always a hexosamine, which is usually 
N-acetylated (N-acetylgalactosamine or N-acetylglucosamine), usually the amino sugar is 
sulphated. The second sugar unit is uronic acid either glucuronic or iduronic acid. The 
disaccharides polymerise to give an unbranched polysaccharide chain. As there are sulphate or 
carboxyl groups on most of the sugar residues GAGs are highly negatively charged. Several types 
of GAG chain are commonly recognised; Chondroitin Sulphate (CS), Dermatan Sulphate (DS), 
Keratan Sulphate (KS), Heparan Sulphate (HS), Heparin and Hyaluronan (HA).
a Keratan Sulphate
Keratan sulphate (KS) was first isolated from cornea in which it is the principal glycosaminoglycan 
(Meyer et al., 1953). It is composed of a repeating chain of D-galactose joined to N- 
acetylglucosamine by a (31-4 linkage. Sulphation can occur on position 6 of each residue. The KS 
chains are unbranched and vary in length, from 5-10 units in intervertebral disc to 30-50 units in 
cornea. Unlike other GAGs KS also contains oligosaccharide branches (Dickenson etal., 1990).
KS is also found in bone, cartilage and cornea (Hjertquist and Lemperg 1972, and Baker et 
al., 1969). It is similar to the oligosaccharides of glycoproteins in the structure of its link region to 
proteoglycan core proteins and its sialic acid residues.
a Chondroitin and Chondroitin Sulphates
The name Chondroitin Sulphate (CS) derives from “Chondros” meaning cartilage from which it was
first isolated (Krukenberg 1884), but they are also found in bone and heart valves (Morner 1889,
and Muir 1958) The GAG chain of chondroitin and chondroitin sulphate is composed of repeating
units of D-glucuronic acid linked via (31-3 linkage to N-acetyl-D-galactosamine (Heineg&rd and
Paulsson 1984). Chondroitin sulphates are sulphated varieties of chondroitin, where the ester
sulphate group can be on carbon 4 giving chondroitin-4-sulphate (C-4-S) or on carbon 6 giving
chondroitin-6-sulphate (C-6-S). Chondroitin sulphates may have either or both residues substituted
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and if neither are sulphated the GAG is chondroitin. Most chondroitin sulphate chains are 
copolymers of segments of one chondroitin sulphate, or chondroitin, interrupted by segments of 
another.
The highest chondroitin sulphate, or chondroitin, content is in cartilage and intervertebral 
disc (up to 10% wet weight) (Sztrolovics et al., 2002). Nasal and epiphyseal cartilages contain a 
high proportion of C-4-S, whereas articular cartilage and the nucleus pulposus of the intervertebral 
disc, have a high C-6-S content. Aging articular cartilage contains a higher proportion of C-6-S 
than young cartilage (Roughley and White 1980, and West etal., 1999).
a Dermatan Sulphate
The name Dermatan Sulphate (DS) derives from "Dermis" meaning skin, as this is its major 
location although it is also found in other connective tissues including heart valves, sclera, tendon, 
aorta, cornea and cartilage (Sztrolovics et al., 2002). Dermatan sulphate is an isomer of 
chondroitin-4-sulphate in which the D-glucuronic acid undergoes epimerisation to form L-iduronic 
acid. Therefore the GAG chain of dermatan sulphate is composed of repeating units of L-iduronic 
acid linked via an a1-3 linkage to N-acetyl-D-galactosamine. L-lduronic acid residues may be 
sulphated in the 2 position. Although dermatan sulphate is often found in GAG chains interspersed 
with chondroitin sulphate units (Roden 1980), only one iduronic acid residue is required for the 
chain to be dermatan sulphate.
□ Heparin and Heparan Sulphate
The names Heparin and Heparan Sulphate (HS) derive from “Hepas” meaning liver, from which
they were first isolated (Oldberg etal., 1977). The chains of both GAGs are composed of repeating
units of either D-glucuronic or L-iduronic acid linked via a p1-4 linkage to N-acetyl-D-glucosamine,
both residues can be sulphated at the O- and N- positions. The GAG chain is a copolymer of the
two types of disaccharide and is the most complex of all the GAGs. Heparan sulphate and heparin
differ in their N-Sulphate and N-Acetyl contents and their localisation. Heparan sulphate contains a
higher acetylated glucosamine than heparin and is found in basement membranes and
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components of cell surfaces (Stevens and Austen 1989). In contrast, heparin contains a higher 
proportion of N-sulphate (up to 90%). It also plays a role in preventing the coagulation of blood, as 
it is abundant in mast cell granules (Le Trong etal., 1987).
a Hyaluronan
Hyaluronan (HA) is the simplest GAG its name derives from “hyaloid” meaning vitreous as it is 
found in the vitreous humour of the eye, as well as the extracellular matrix of connective tissue and 
synovial fluid (Meyer and Palmer 1934). The hyaluronan chain is composed of repeating units of D- 
glucuronic acid linked via p1-3 linkage to N-acetyl-D-glucosamine. It is a regular repeating 
sequence of up to 25,000 non-sulphated disaccharide units with a MW of 100,000 - 10,000,000.
Hyaluronan is found in variable amounts in the connective tissues of adults but is more 
prevalent in embryos where it facilitates cell migration during tissue morphogenesis (Toole et al., 
1977). In some connective tissues, such as umbilical cord and vitreous body it is the main GAG 
others, like cartilage, have a relatively low hyaluronan content (1%). Unlike all other GAGs it 
contains no sulphate and is not found covalently attached to proteins to form proteoglycans. 
However, it does form non-covalent complexes with proteoglycans in the extracellular matrix.
Hyaluronan has been used as the basis for a number of biodegradable polymers including 
Hyaff® 11, which is currently under investigation as a biomaterial onto which chondrocytes can be 
seeded and cultured for insertion into cartilage tears (Grigolo et al., 2001a, and Grigolo et al., 
2001b).
Some GAGs have been shown to bind growth factors affecting their potency in some cases growth 
factor activity is critically dependent upon GAGs as co-receptors. For example heparan and 
dermatan sulphate bind hepatocyte growth factor / scatter factor and effect a conformational 
change in the molecule altering its activity (Lyon et al., 2002).
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1.2.2.2 N- and O- Linked Oligosaccharides
Proteoglycan molecules often contain oligosaccharides linked through O- and N- glycosidic bonds. 
Since O-glycosidic oligosaccharides are structurally similar to the keratan sulphate type II linkage 
region it has been suggested that they are derived from the same carbohydrate core by differential 
processing (Lohmander et al., 1980, De Luca et al., 1980, and Nilsson et al., 1982). The role of 
oligosaccharides in the functions of proteoglycans is fairly unknown, but there is evidence that at 
least in the large proteoglycans they may cover the protein core maintaining the structure of the 
proteoglycans and protecting them against proteolytic activities (Bernard et al., 1983)
1.2.2.3 Linkage and Synthesis of GAG Chains and Oligosaccharides on the 
Proteoglycan Core Protein
With the exception of hyaluronan, which appears to be assembled as a free polysaccharide chain 
(Prehm 1983), all GAGs are synthesised as proteoglycans i.e. covalently linked to a core protein.
□ The linker sequence for chondroitin (sulphates), dermatan sulphate, heparan sulphate and 
heparin forms a bridge between the GAG chain proper and the polypeptide core as 
depicted in Figure 1.4 (Rod6n 1980). The linker sequence in the GAG chain is coupled via 
an O-glycosidic bond to a serine or threonine in the core protein via the hydroxyl group of 
the amino acid (Figure 1.4) (Muir and Hardingham 1975).
□ Linkage of keratan sulphate and oligosaccharides to the proteoglycan core protein can 
occur via N- or O- linked glycosylation. These two forms of linkage are used to distinguish 
the two forms of keratan sulphate found in mammals and divides oligosaccharides into N- 
and O-linked varieties. Corneal keratan sulphate (Type I Keratan Sulphate) and N-linked 
oligosaccharides are linked to an asparagine in the core protein via mannose and N-acetyl 
glucosamine residues (Bray et al., 1967, Choi and Meyer 1975, and Nilsson et al., 1983). 
Skeletal keratan sulphate (Type II Keratan Sulphate) and O-linked oligosaccharides are 
linked to serine or threonine residues via an N-acetyl galactosamine residue (Hoffman and 
Mashburn 1967, Choi and Meyer 1975, Stuhlsatz et al., 1989, and Hascall and Midura 
1989).
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Figure 1.4 Diagram to show the linkage of chondroitin, dermatan and heparan sulphate as well as heparin to 
the core protein of proteoglycans through Xylose - Galactose - Galactose - N-acetyl Galactosamine -  N- 
acetyl Glucuronic Acid which couple via an O-glycosidic bond to a serine or threonine in the core protein
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□ Hyaluronan is unique among GAGs since it appears to be synthesised as a free 
polysaccharide chain at the plasma membrane (Prehm 1984). The carbohydrate being built 
inside the membrane and pushed out into the extracellular space, the non-reducing end 
leading (Prehm 1983). Three different hyaluronan synthases have been cloned (Spicer et 
al., 1997). All GAGs other than hyaluronan are synthesised attached to the core protein of a 
proteoglycan, in the Golgi, by addition of monosaccharide units from the appropriate UDP- 
sugars to the non-reducing ends of nascent polysaccharide chains (Lindahl 1976, Roden 
1970, and Silbert and Reppucci 1976). Chain elongation is initiated by xylosylation of 
serines, catalysed by a xylosyl transferase using UDP-xylose as a sugar donor (Kjellin and 
Lindahl 1991). Whilst still in the Golgi many polymerised sugar residues are covalently 
modified by a series of sulphation (increasing negative charge) and epimerisation reactions 
(alters arrangement of atoms on sugar ring).
1.2.2.4 Aggrecan
Aggrecan is the major proteoglycan of articular cartilage and is a member of the hyalectin family of 
proteoglycans. Other Hyalectin or Lectican family members include versican (secreted by fibroblast 
cells) (Tan et al., 1993), brevican and neurocan (both of which are predominantly expressed in 
adult brain) (Kurazono et al., 2001, and Gary et al., 2000). All members of the hyalectin family have 
the ability to bind hyaluronan at their amino-terminal end and other matrix glycoproteins through 
their carboxy terminal G3 C-type lectin domains (Halberg et al., 1988, Watanabe et al., 1998, and 
Zhang etal., 1998).
The core protein of aggrecan has a molecular weight of around 250-300kD and consists of 
three globular domains, G1, G2 and G3, interspersed by rod-like segments. Between G1 and G2 is 
the interglobular domain (IGD). Keratan sulphate and chondroitin sulphate glycosaminoglycan 
attachment domains are located between the G2 and G3 domains (see Figure 1.6) (Paulsson et 
al., 1987). The amino-terminus comprises the G1 globular domain, which non-covalently interacts 
with hyaluronan and link protein (Kohda et al., 1996). The G1 domain contains three looped 
subdomains, A, B and B\ Both the B and B’ loops form disulphide bonding double loop structures
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called proteoglycan tandem repeat (PTR) units (Kohda et al., 1996). The PTR loop contains the 
functional site of the binding of aggrecan to hyaluronan (lozzo 1998). Aggrecan binds to link 
protein in a 1:1 ratio (Hardingham and Muir 1973, and Morgelin et al., 1994). The G1-hyaluronan- 
link protein complex is very stable essentially immobilising the aggrecan within the cartilage matrix. 
The secondary structure is significant and the hyaluronan binding region (comprising the G1 
domain) no longer binds hyaluronan under reducing conditions. Oegema suggested that newly 
synthesised aggrecan is not immediately incorporated into aggregates, and furthermore that this 
delayed aggregation is age dependent (Oegema 1980). Moreover Bayliss et al., suggested that 
newly synthesised aggrecan is processed in pools with different capacities for aggregation with 
hyaluronan and stabilisation by link protein, and that tissue compartments, possibly defined by 
extracellular pH, show differences with age and with disease state (Bayliss etal., 2000).
The G2 globular domain is separated from the G1 by a linear interglobular domain (IGD), 
which has two homologous PTRs but does not itself bind to hyaluronan. The large GAG substituted 
domain is located between globular domains G2 and G3 and contains both chondroitin sulphate 
and keratan sulphate binding regions. Some chains are attached outside of this region but only a 
small percentage of the total number of GAGs present.
The average aggrecan monomer has a molecular weight of 2.5 million Dalton, with up to 90% 
of its mass being contributed by approximately 100 chondroitin sulphate chains, 30 keratan 
sulphate chains and a number of N- and O- linked oligosaccharides that are covalently attached to 
the core protein (Nilsson et al., 1982, De Luca et al., 1980, Lohmander et al., 1980, and 
Hardingham 1986).
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Figure 1.6 Schematic representation of aggrecan, its domain structure and non-covalent interaction with 
hyaluronan stabilised by link protein (Vertel 1995)
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The carboxy terminus comprises the G3 domain that includes an Epidermal Growth Factor 
(EGF)-like module, a C-type lectin module and a complement regulatory protein module. 
Alternative splicing of the G3 domain has been reported (Murdoch et al., 2002) and the spliced 
form of the G3 domain lacking the EGF motifs is common in chondrocytes maintained in cell 
culture for even short periods of time (Grover and Roughley 1993). Roles have been suggested for 
the G3 domain in modulation of GAG attachment to the core protein and in regulation of core 
protein secretion (Chen et al., 2002a). The aggrecan G3 domain may interact with extracellular 
matrix components including tenascin (Aspberg etal., 1997) and fibulins (Aspberg etal., 1999, and 
Olin et al., 2001) as well as cell surface glycolipids (Miura et al., 1999). Around half the aggrecan 
molecules in the extracellular matrix of cartilage lack the G3 domain owing to proteolytic cleavage 
(Paulsson etal., 1987).
Aggrecan is packed into the cartilage matrix at up to 10 - 20% of its free solution volume 
(Vertel 1995). The GAG chains on each aggrecan monomer have a high concentration of negative 
charges associated with their carboxyl groups and extensive sulphate substitutions. These are held 
within the cartilage extracellular matrix by non-covalent association of aggrecan monomers with 
hyaluronan through the G1 domain and stabilised by link protein to form supramolecular 
aggregates (Morgelin etal., 1994). These form a highly compressible and resilient tissue when fully 
hydrated.
One of the first pathological features of joint degeneration is loss of aggrecan from the cartilage 
matrix preceding both overt collagen catabolism and joint erosion by some time. Following joint 
injury and subsequent joint disease there is a loss of aggrecan metabolites from the cartilage 
matrix into the synovial fluid (Lohmander 1991). Cleavage sites for many families of proteases are 
found along the length of the aggrecan core protein as shown in Table 1.2 (Sandy et al., 1992). 
Degradation of aggrecan is further discussed in Section 1.5.
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Table 1.2 A selection of the cleavage sites within the aggrecan core protein, the enzymes which utilise them and the 
'esultant neoepitopes.
Enzyme C lea va g e  S ite (s ) R eferen ces
MMPs including 
1,2,3,7, 9, 10, 13, 19 
and 20, and 
Cathepsin B
IPEN341 -  M2f f g v
C lea va g e  sites
WITHIN THE 
INTERGLOBULAR 
DOMAIN OF THE 
AGGRECAN CORE 
PROTEIN
Fosang etal., 1991, 1992, 1993, 
1994, 1996 and 1998 
Lark etal., 1995 
Stracke etal., 2000 
Little etal., 1999 
Mort etal., 1998
Cathepsin B NFFG344 -  ^ V G G E Fosang et al., 1992 
Mort and Buttle 1997
MMP-8 and 14 TEGE373 -  374ARGS 
IPEN341 -  ^ F F G V
Fosang et al., 1994 
Fosang et al., 1993 
Fosang etal., 1998
ADAMTS-1, -4 and -5 TEGE373 -  374ARGS
Kuno et al., 2000 
Sandy etal., 1991a 
Tortorella etal., 1999 
Tortorella etal., 2000a and b 
Tortorella et al., 2002 
Abbaszade et al., 1999 
Rodriguez-Manzaneque et al., 2002 
Sandy et al., 2002
MMP-1,-7, - 8 & - 1 3 TSED441 -  442LVVQ
C lea vag e  sites
WITHIN THE 
CHONDROITIN AND 
KERATAN SULPHATE 
ATTACHMENT REGIONS 
OF THE AGGRECAN 
CORE PROTEIN
Fosang etal., 1996 
Fosang et al., 1994 
Fosang etal., 1991
MMP-1 c r f g 656 -  657is a v Fosang et al., 1993
Cathepsin D VEEW680 -  “ ’ IVTQ Handley et al., 2001
ADAMTS-4 and -5
E L E 1545 _  1546G R G
k e e e 1714- 1715g l g s  
t a q e 1819 -  1820a g e g e  
is q e 1919 -  1920l c q r
Tortorella etal., 2000a and b 
Tortorella etal., 2002 
Lee etal., 2002
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1.2.2.5 Small leucine rich proteoglycans (SLRPsJ
All members of the small leucine rich proteoglycan family except chondroadherin and PRELP are 
able to bind collagen and are found along the surfaces of collagen fibrils in cartilage. There are 
three classes of small leucine rich proteoglycans and members from each class are found in 
cartilage.
□ Class I
Class I includes decorin and biglycan both of which are found in articular cartilage and bind 
TGF(3 sequestering its mitogenic activity (Yamaguchi et al., 1990, and Schonherr et al., 1998). 
In articular cartilage biglycan is found in the pericellular matrix while decorin is found in the 
interterritorial matrix (Bianco etal., 1990). The core proteins of biglycan and decorin are 50-60% 
homologous in their protein sequence, both have MW of around 37,000 with an extra 30,000 
being added by the GAG chains (Hocking et al., 1998). Each of the core proteins is divided into 
4 domains. At their amino-termini are GAG attachment regions, decorin carries a single 
chondroitin or dermatan sulphate chain whereas biglycan carries two such chains (Cheng et al., 
1994). A metallothioneine-like domain containing a disulphide bond between 2 cysteine 
residues divides the GAG attachment region from the leucine rich repeat domain. A 49 amino 
acid long region unique to these two proteoglycans forms the carboxy-terminus of both decorin 
and biglycan (Kresse etal., 1993).
Decorin is associated with collagen fibrils as a decorating proteoglycan (Gallagher et al., 
1983, Scott 1988, and Vogel et al., 1984). It is described as a horseshoe shaped molecule, and 
this arched structure as well as the dimensions of the curve, supports a model for decorin 
interaction with a single triple helix of collagen (Vynios et al., 2001). Since the concave surface 
of the decorin core protein is presumed to bind in the gap zone of the collagen fibril, the GAG 
chain located near the amino-terminus of decorin would be free to maintain fibril-fibril spacing. 
The message level for decorin in cartilage is by far the most abundant of all SLRP family 
members and shows increases with increasing age in human articular cartilage (Melching and 
Roughley 1989).
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The tissue localisation and the potential interaction with other cartilage matrix components 
have been less clearly defined for biglycan although is has been suggested as a positive 
regulator of bone formation and bone mass (Xu et al., 1998).
□ Class II
Class II SLRPs include fibromodulin, lumican, osteoadherin, keratocan and proline arginine-rich 
and leucine-rich repeat protein (PRELP), of which all except keratocan and osteoadherin are 
expressed in cartilage (Grover et al., 1995, Sommarin et al., 1998, and Melching and Roughley
1989). This group can be further sub-divided into three distinct subfamilies based on protein 
sequence homology. Fibromodulin and lumican constitute the first subfamily and exhibit -48% 
protein sequence identity (Hocking et al., 1998); keratocan and PRELP constitute the second 
subfamily with -55% protein identity (Bengtsson etal., 1995), whereas osteoadherin constitutes 
a distinct subfamily with 37-42% protein identity to other class II members (Somarin et al., 
1998).
All class II SLRPs share an identical cysteine rich region followed by a leucine rich repeat 
region. Class II members are primarily substituted with keratan sulphate chains, however 
polylactosamine (an unsulphated keratan sulphate) is found on both fibromodulin and keratocan 
(Plaas etal., 1993, and Corpuz etal., 1996).
PRELP exhibits protein sequence similarity to both lumican and fibromodulin and has four 
potential N-linked glycosylation sites. Thus although it is a member of the SLR proteins, it 
apparently functions as a cartilage matrix protein with the capacity for matrix organisation 
(Bengtsson etal., 1995).
Fibromodulin carries up to four keratan sulphate chains (Plaas et al., 1990) and has the 
ability to decorate the surface of collagen fibers and therefore may regulate fibril diameter 
(Hedlund et al., 1993). The message levels for fibromodulin and lumican show increases with 
increasing age in human articular cartilage (Melching and Roughley 1989).
Lumican is the major keratan sulphate proteoglycan in the cornea, but also shows 
widespread distribution in connective tissues, including articular cartilage (Melching and 
Roughley 1989, and Ying et al., 1997). It is interesting that in young cartilage lumican is found
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as a keratan sulphate proteoglycan while after IL-1 treatment chondrocytes synthesise and 
secrete the lumican protein devoid of GAG substitutions (Melching and Roughley 1999).
□ Class III
Epiphycan (PG-Lb) and mimecan (osteoglycan) which exhibit only -40% protein sequence 
identity are the two members of the class III SLRPs expressed in articular cartilage (Shinomura 
and Kimata 1992). These proteoglycans can be distinguished from other SLRPs by a unique 
cysteine-rich region consensus sequence (CX2CXCX6C) and by the presence of only six 
leucine-rich repeats (Johnson etal., 1997).
Epiphycan derives its name from epiphyseal cartilage where it was first isolated (Johnson 
et al., 1997). The GAG attachment region is composed of two serine residues with a consensus 
structure similar to aggrecan, decorin and biglycan. This region may contain either chondroitin 
sulphate or dermatan sulphate. Epiphycan can also be secreted as a glycoprotein. The 
expression of epiphycan during development of the growth plate lags behind that of aggrecan, 
and is excluded from both the layer of presumptive articular cartilage and the hypertrophic zone 
(Johnson etal., 1999).
Mimecan is abundantly expressed in sclera and cornea, but can also be found in non­
ocular tissues as a non-sulphated glycoprotein (Funderburgh et al., 1997, and Madisen et al.,
1990). Mimecan may play a role in controlling cell growth as illustrated by the ability of growth 
factors and cytokines to modulate its expression (Shanahan et al., 1997). At present there is no 
published information on the mechanisms by which mimecan exerts its biological function 
(Tasheva 2002).
1.2.2.6 Perlecan
Perlecan derives its name from its rotary shadowing appearance; a string of pearls (Paulsson et 
al., 1987, and Yurchenco et al., 1987). It is a large heparan sulphate proteoglycan with a core 
protein of ~467kD that is found in all basement membranes and a variety of other specialised 
tissues including the synovium, cartilage and developing bone (Sundaraj et al., 1995, and Handler 
etal., 1997).
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Perlecan is a complex molecule made up of five distinct domains with only domain I being 
unique (lozzo et al., 1994). Domain II shares homology with low-density lipoprotein receptor. 
Domain III is similar to the amino-termini of the short arms of laminins A and B. Domain IV is 
homologous to the Neural Cell Adhesion Molecule (N-CAM) (Tapanadechopone et al., 1999). At 
the carboxy terminus of perlecan domain V contains two epidermal growth factor (EGF)-like 
repeats and two Leucine Arginine Glutamine (LRE) tripeptides.
Perlecan can undergo self-aggregation and can also interact with laminin, nidogen and 
fibronectin (Hopf et al., 1999). Integrins have been proposed to function as cell surface receptors 
for perlecan. In adult articular cartilage perlecan is enriched in the pericellular matrix (Sundarraj et 
al., 1995).
Knockout mice lacking the Hspg2 gene (encoding perlecan) showed disorganisation in their 
cartilage chondrocyte arrangement as well as defective endochondral ossification. The cartilage 
matrix itself was deficient in collagen fibrils and glycosaminoglycans, and what was present was 
severely disorganised suggesting a role for perlecan in matrix structural organisation (Hirasawa et 
al., 1999). An alternatively spliced form of perlecan has recently been identified but its’ role has yet 
to be elucidated (Dodge etal., 2001).
1.2.2.7 Proteoglycan-4 (PRG-4)
A novel proteoglycan synthesised by superficial zone chondrocytes of articular cartilage was first 
identified and named superficial zone protein by Schumacher et al., in 1994. This protein is now 
known as PRG-4 and is secreted into experimental medium or synovial fluid in vivo, with little 
incorporation into the extracellular matrix. It has a molecular weight of 345kD and a multidomain 
structure comprising structural motifs at its amino-and carboxy-terminals including vitronectin-like 
domains, somatomedin-B type domains, an aggregation domain and a heparin-binding domain, as 
well as large and small mucin-like domains substituted with O-linked oligosaccharides (Flannery et 
al., 1999a). Due to its location and deduced structure PRG-4 has been suggested to play roles in 
cell proliferation, cytoprotection, lubrication, self-aggregation and matrix binding (Flannery et al., 
1999a).
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1.2.2.8 Cell Surface Proteoglycans
Chondrocytes express cell surface proteoglycans, members of the transmembrane family of 
syndecans and the phosphodidylinositol linked heparan sulphate proteoglycans glypicans (Grover 
and Roughley 1995, and Hall and Miyake 2000). 
a Syndecans
The syndecan family contains four members; syndecan-1 (syndecan), syndecan-2
(fibroglycan), syndecan-3 (N-syndecan) and syndecan-4 (ryudocan or amphyglycan), all of 
which are transmembrane heparan sulphate proteoglycans (Bernfield et al., 1992).
Syndecan family members are type-l integral membrane proteins with homologous
transmembrane and cytoplasmic domains (Pacifici and Molinaro 1980, and Saunders etal., 
1989). Syndecans may carry two or more heparan sulphate chains, alone or in combination 
with chondroitin sulphate, and these give them the potential to interact with basic Fibroblast 
Growth Factor (FGF), and modulate its interaction with its signalling receptor (Lyon et al., 
2002). All syndecans exhibit cell-type specific distribution, e.g. analyses of mRNA from 
articular chondrocytes demonstrated that message for syndecan-4 was of the highest 
abundance with some low level expression of syndecan-2 also detectable (Grover and 
Roughley 1995). In contrast syndecan-3 is expressed briefly and specifically during early 
stages of chondrogenesis (Hall and Miyake 2000). During maturation of the growth plate 
expression of syndecan-3 persists in the zone of proliferating chondrocytes, but is not 
detected in the layer of presumptive articular chondrocytes (Shimazu etal., 1996). 
a Glypicans
Glypicans are a family of cell surface transmembrane heparan sulphate proteoglycans 
comprising 5 members: glypican-1 (glypican), glypican-2 (cerebroglycan), glypican-3 (OCI- 
5), glypican-4 (K-glypican) and glypican-5. All members of this family possess an
extracellular region with a GAG attachment site as well as a carboxy-terminal GPI-anchor. 
Glypican family members are selectively expressed in different cell types and are mainly 
targeted to apical surfaces of cells (Tumova et al., 2000). Glypican-1 is expressed in 
cartilage (Grover and Roughley 1995)
1.2.3 Other Extracellular Matrix Molecules
In recent years numerous cartilage proteins that are neither collagens nor proteoglycans have 
been identified and characterised.
1.2.3.1 Fibronectin
Fibronectin consists of two 250kD polypeptide chains that are linked by a disulphide bond near to 
the carboxy-terminus. It is a rod like molecule with several domains that can specifically interact 
outside the cell. The various globular domains play different roles in extracellular matrix 
interactions with different domains binding to collagens, heparin, and heparan sulphate or cell 
surface receptors (see Potts and Campbell 1996 for review). The specific cell-binding domain of 
fibronectin contains an Arginine Glycine Aspartate (RGD) amino acid sequence which is involved 
in cell attachment through integrins (Main et al., 1992). Alternative splicing of fibronectin gene 
transcripts results in different protein isoforms. In adult canine and equine articular cartilage 50- 
80% of the fibronectin transcripts have a unique splicing pattern (Macleod et al., 1996). Certain 
parts of the fibronectin molecule are susceptible to proteolysis resulting in a series of fragments. 
Fragments of fibronectin may regulate cartilage metabolism possibly through increasing levels of 
catabolic cytokines, which in turn upregulate matrix protease expression and enhance degradation 
(Homandberg 1999). The carboxy-terminal domain of fibronectin has recently been shown to bind 
to ADAMTS-4 (see Sections 1.3.5 and 1.5.2) inhibiting its ability cleave aggrecan, however the 
physiological relevance of this is not known (Hashimoto et al., 2004).
1.2.3.2 Tenascins
Five members of the tenascin family have been identified tenascin-C (Erikson and Iglesias 1984),
tenascin-R, tenascin-W, tenascin-X and tenascin-Y (Jones and Jones 2000). Tenascin-C is said to
have a highly symmetrical structure taking the form of a hexabrachion i.e. six arms emanating from
a central core. This structure is formed from six polypeptide chains linked at their amino-termini via
a domain known as the Tenascin Assembly (TA) domain. The overall structure of all the tenascin
proteins is the same, although tenascin-C is the only one of the family known to form
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hexabrachions (Jones and Jones 2000). Tenascin-C has been found in cartilage, skin and bone 
marrow (Mackie 1997). Tenascin-R is expressed exclusively in the central nervous system 
(Rathjen et al., 1991). Tenascin-W is expressed predominantly in nervous tissue (Weber et al., 
1998). Both Tenascin-X and -Y are expressed in connective tissues (Matsumoto et al., 1994, and 
Tucker et a!., 1999). In connective tissues tenascins interact with and can be cleaved by matrix 
metalloproteinases (Streuli 1999). Tenascin-C and tenascin-R both bind with high affinity to the 
hyalectin family of proteoglycans with brevican-tenascin complexes in the brain and aggrecan- 
tenascin complexes in cartilage (Aspberg etal., 1995, and Aspberg etal., 1997).
1.2.3.3 Cartilage Intermediate Layer Protein (CILP)
Cartilage Intermediate Layer Protein (CILP) has a calculated molecular mass of 78.5kD. It contains 
30 cysteine residues and six putative N-glycosylation sites. Ten percent of its total mass is 
composed of N-linked oligosaccharides (Lorenzo et al., 1998b). The tissue distribution of CILP is 
limited to cartilage and specifically the intermediate zone mainly in interterritorial areas (Lorenzo et 
al., 1998b). Levels of the protein vary between cartilage types with tracheal cartilage having low 
levels and rib cartilage particularly high levels. CILP forms part of a group of matrix components 
whose expression is enhanced in the early stages of osteoarthritis and in aging cartilage (Lorenzo 
et al., 1998b). The reasons behind CILP's specific distribution pattern and its exact role have yet to 
be elucidated. However an autoimmune response to CILP has been suggested to be involved in 
the pathogenesis of inflammatory joint destruction (Kato etal., 2001).
1.2.3.4 Cartilage Oligomeric Matrix Protein (COMP)
COMP was initially identified in cartilage and its major site of expression is around chondrocytes, 
but it has also been purified from a number of other tissues including tendon, ligament and 
meniscus (Hauser et al., 1995). It is a 524kD homopentameric extracellular glycoprotein (Hedbom 
et al., 1992) that belongs to the thrombospondin family of proteins (Oldberg et al., 1992). Each 
COMP monomer is composed of an amino-terminal cysteine-rich domain, four EGF-like domains, 
eight calmodulin-like repeats and a carboxy-terminal globular domain (Delot et al., 1998). The
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cysteine rich domain is responsible for the assembly of monomers into pentamers via interchain 
disulphide bonds. The carboxy-terminal globular domain may be involved in binding cells (e.g. 
chondrocytes) and proteins in the extracellular matrix (Chen et al., 2002b). Levels of COMP in 
serum or synovial fluid samples have been used as a marker of cartilage degeneration in both 
rheumatoid and osteoarthritis patients (Saxne and Heinegard 1992, Vilim et al., 1997, and Vilim et 
al., 2002), however its exact biological role has yet to be ascertained, although it has been 
suggested to play a role in modulation of chondrocyte phenotype (Chen et al., 2002b).
1.2.3.5 Matrilins
Matrilin-1 was the first member of this now four strong family of cartilage proteoglycan associated 
proteins to be identified (Paulsson and Heineg&rd 1981). Matrilins all share a common domain 
structure composed of von Willebrand factor A domains (vWFA), EGF-like domains and a coiled 
coil a-helical module (Deak et al., 1999). The best-characterised member of the family is matrilin-1, 
which was initially identified due to its tight association with aggrecan (Paulsson and Heineg&rd 
1981), and has since been shown to covalently bind to the chondroitin sulphate region of the 
aggrecan core protein (Hauser et al., 1996). Matrilin-1 has also been shown to associate with 
cartilage collagen fibrils (Winterbottom et al., 1992). Based on its association with aggrecan and 
collagen fibrils it has been speculated that matrilin-1 functions in connecting the various 
supramolecular assemblies in cartilage (Deak et al., 1999) and the other members of the matrilin 
family are thought to have similar roles. Matrilin-1 gene expression, not normally seen, has been 
detected in articular cartilage chondrocytes from patients with osteoarthritis (Okimura et al., 1997) 
and increased serum levels of matrilin-1 can be used as a diagnostic marker for osteoarthritis 
(Meulenbelt et al., 1997, and Okimura et al., 1997). Matrilin-1 concentrations in serum are also 
elevated in relapsing polychondritis as well as in active rheumatoid arthritis (Saxne and Heineg&rd 
1989 and 1995).
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1.3 Cartilage Matrix Proteases and their Inhibitors
In the course of normal matrix turnover, and in disease states such as arthritis, articular cartilage 
matrix macromolecules can be cleaved and eventually broken down by members of several 
enzyme families including; serine proteases, cathepsins, MMPs, ADAMs and ADAMTSs.
4
1.3.1 Serine Proteases
Serine proteases are a large group of related proteins which function to hydrolyse other proteins. 
All serine proteases have the same mechanism of action. Their activity is dependent on a serine 
residue at the active site, hence their name. In mammals serine proteases play roles in many 
important processes including digestion, blood clotting and the complement system (Voet et al., 
2002). The active site of serine proteases is a cleft where the polypeptide substrate binds. The 
enzymes are inhibited by serpins, which inhibit the activity of their respective serine protease by 
mimicking the three-dimensional structure of the normal substrate of the protease (Imamura et al., 
2005). Serine proteases including plasmin, tissue plasminogen activator and urokinase-type 
plasminogen activator, plasma kallikrein, tissue kallikrein, tryptase and chymase are involved in 
extracellular matrix degradation, either by direct catalysis of matrix components, or by activating 
the various members of the MMP family (see Section 1.3.3)(Clark and Murphy 1999, and 
Chapman etal., 1996).
1.3.2 Cathepsins
Cathepsins are papain family cysteine proteases, which are involved in a variety of physiological 
processes including proenzyme activation, enzyme inactivation, antigen presentation, hormone 
maturation, tissue remodelling and bone matrix resorption (Rochefort et al., 2000, Linnervers et al., 
1997, Mort and Buttle 1997, and Fosang et al., 1992). They are glycoproteins and all contain an 
essential cysteine residue in their active site, but family members differ in some enzymatic 
properties, including substrate specificities and pH stability (Linnevers et al., 1997). The only 
members of the cathepsin family expressed in cartilage are cathepsins B and D (Mort and Buttle
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1997, and Woessner 1973, respectively). Under acidic conditions cathepsin D cleaves aggrecan, 
and these cleavage sites within the aggrecan core protein have been shown to be utilised in 
cartilage exposed to acidic pH in vitro (Handley et al., 2001).
1.3.3 Matrix Metalloproteinases (MMPs) / Matrixins
Matrix Metalloproteinases are a family of zinc metallo-endopeptidases secreted by cells, and are 
responsible for much of the turnover of matrix components such as collagens and proteoglycans in 
normal embryogenesis and remodelling as well as in many diseases such as arthritis, cancer 
periodontis and osteoporosis (Davidson et al., 1999, Herrera et al., 2002, Nabeshima et al., 2002, 
Vicenti et al., 1996, and Yamada et al., 2002). They are part of the "MB clan" of 
metalloproteinases, which contain the zinc-binding motif HEXXHXXGXXH at their active site. 
Members of the MB clan are generically referred to as ‘Metzincins’ as they all contain a conserved 
methionine that forms a turn eight residues downstream of the active site. The MB clan contains a 
number of families and MMPs are in family M10, which is further subdivided into A and B with 
MMPs being in subfamily A (also known as the matrixins).
Numbers identify MMPs from vertebrate species whereas those from invertebrates are only 
designated by trivial names. There are 25 human MMPs known at this point in time (Somerville et 
al., 2003) with over 30 having been described in all species (see Table 1.3). All MMPs share a 
common catalytic core with a zinc molecule in the active site.
Most MMPs are produced as zymogens with the exceptions being the Membrane Type 
(MT)-MMPs (Cawston 1998), with a signal sequence and propeptide domain containing a 
conserved cysteine that chelates the active zinc (Van Wart and Birkedal-Hansen 1990). The zinc 
atom requires four ligands, the fourth of which is the cysteine conserved in the prodomain in the 
inactive (zymogen) form. In the active form of the enzymes this site is occupied by water. The 
generally conserved sequence around the chelating cysteine (PRCGVP) has been named the 
"cysteine switch". MMP-23 lacks this conserved cysteine and has a very different propeptide 
domain. MMP-26 contains a mutated cysteine switch, which has recently been shown to be 
inactive (Marchenko et al., 2002). A subset of MMPs, including the membrane type MMPs (MMP-
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14 [MT1-MMP], MMP-15 [MT2-MMP], MMP-16 [MT3-MMP], MMP-17 [MT4-MMP], MMP-24 [MT5- 
MMP] and MMP-25 [MT6-MMP]) as well as MMPs -11, -21, -23 and -28 contain a basic 
prohormone convertase cleavage sequence (RRKR, RRRR, RKRR etc.) which may be cleaved by 
members of the Golgi associated Paired basic Amino acid Cleaving Enzyme (PACE) / Furin family 
of enzymes resulting in the loss of a peptide of about 10kD (Pei and Weiss 1996) and secretion of 
the enzymes to the cell surface in an active form (Cawston 1998). Once activated MMPs can 
cleave other MMPs to activate them. This is especially so of the membrane type (MT)-MMPs that 
are located at the cell surface and are thought to activate proMMPs once they have left the cells 
interior (Knauper et al., 2002, and d’Ortho et al., 1998). Secreted proMMPs are activated in vitro 
by proteinases and non-proteolytic agents such as SH-reactive agents and reactive oxygen 
(Nagase and Woessner 1999).
The catalytic domain of the MMPs is around 170 amino acids in length and includes a zinc- 
binding motif of the sequence HEXXHXXGXXH (Nagase and Woessner 1999). In addition to the 
catalytic zinc the catalytic domain also contains a structural zinc and 2-3 calcium ions that are 
required for stability and catalytic activity (Nagase and Woessner 1999). The active site forms a 
long groove that divides the domain and in the zymogen form of the enzyme the propeptide 
domain lies in reverse orientation in this groove, with the cysteine switch in close proximity to the 
active site zinc molecule. The MMPs differ in the geography of the active site groove, allowing for 
different substrate and inhibitor specificities. Differences in the depth of the S1 pocket of some 
MMPs has allowed generation of synthetic inhibitors that selectively bind the MMPs and contain 
zinc chelators to inhibit the active site. The peptidomimetic MMP inhibitors are being used in a 
number of clinical trials to inhibit MMP function in different diseases (Porter et al., 1994, Beckett et 
al., 1996, Karran etal., 1995, and Greenwald etal., 1994).
All but two MMPs (MMP-7 and -26) contain a regulatory subunit, the haemopexin domain, 
at the carboxy-terminus separated from the catalytic domain by a variable hinge region (shown in 
Figure 1.7). The haemopexin domain is a four-blade propeller, with a calcium-binding site nestled 
in the folds (Gomis-Ruth et al., 1996). Calcium seems to be required for some MMP-substrate 
interactions but not others. The haemopexin domain is in the vitronectin family and is known to
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bind heparin. Heparin has been shown to potentiate some MMP activities and MMPs are often 
found associated with heparan sulphate proteoglycans on the cell surface. The haemopexin 
domain is thought to confer much of the substrate specificity to the MMPs, and is involved in 
activation as well as inhibition of the MMPs (Tam et al., 2002, and Lehti et a!., 2002). Final 
activation of MMPs often includes shedding of the haemopexin domain, and the isolated 
haemopexin domain has been shown to inhibit intact MMPs (Tam et al., 2002). The hinge region 
also confers specificity to the MMPs, by setting the orientation of the haemopexin domain and the 
catalytic domain.
The membrane type MMPs (MMP-14 [MT1-MMP], MMP-15 [MT2-MMP], MMP-16 [MT3- 
MMP], MMP-17 [MT4-MMP], MMP-24 [MT5-MMP] and MMP-25 [MT6-MMP]) lack the carboxy- 
terminal haemopexin-like domain, but they do have a transmembrane domain that anchors them to 
the cell surface followed by a cytoplasmic domain (see Figure 1.7). The cytoplasmic domain is 
thought to be involved in cytoskeletal signalling cascades, and may be directly phosphorylated by 
various kinase cascades. MMP-17 (MT4-MMP) and MMP-25 (MT6-MMP) have no cytoplasmic 
domains and are thought to be GPI-anchored to the cell surface (Itoh et al., 1999, and Kojima et 
al., 2000).
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Figure 1.7 Domain organisation of zymogen forms of MMPs adapted from Alexander 2002
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MMPs-2 and -9 are unique among MMPs in that three fibronectin type II domains are 
inserted in their catalytic domains in the vicinity of the active site (Briknarov£ et al., 1999). These 
type II modules account for the affinity of MMP-2 for gelatin, type I and IV collagen, elastin and 
laminin (B&nyai and Patthy 1991, B&nyai et al., 1994, Shipley et al., 1996, Murphy et al., 1994, 
Steffensen et al., 1995, and Allan et al., 1995). The fibronectin-like domain of MMP-9 is an 
important determinant of the enzyme’s fibrillar collagen substrate specificity. It allows the enzyme 
to bind to and cleave collagen types V and XI, events which are thought to be involved in several 
normal physiological and pathological processes such as metastasis and arthritis (O’Farrell and 
Pourmotabbed 1998)
Expression of MMPs is turned on by a variety of agents acting through regulatory elements 
of the gene, particularly the Activating Protein (AP)-1 binding site (Goldring 1993, Cawston et al., 
1995, and Korzus et al., 1997). These agents include cytokines and growth factors. 
Proinflammatory cytokines such as Interleukin (IL)-1a, Osmium Tetroxide and Tumour Necrosis 
Factor (TNF)-a upregulate synthesis and secretion of MMPs (Cawston et al., 1998, and Koshy et 
al., 2002). Some growth factors such as epidermal growth factor and fibroblast growth factor have 
also been shown to upregulate MMP production (Kondapaka et al., 1997, Goldring 1993, and Liu 
et al., 2002). Down-regulation of MMPs is also possible and is achieved through mediators such as 
IL-10, IL-4 and transforming growth factor B (Van Roon et al., 1996). A family of protein inhibitors 
of MMPs have been identified and termed Tissue Inhibitors of MetalloProteinases (TIMPs) (see 
Section 1.3.6). Many synthetic MMP inhibitors have been produced including arylsulphonyl 
hydroxamic acids and 2-oxo-imidazolidine-4-carboxylic acid hydroxamides (Baxter et al., 2001, and 
Robinson et al., 2001, respectively) but they inhibit a broad spectrum of MMPs and their effects on 
the normal roles played by MMPs have yet to be ascertained. Recently synthetic inhibitors specific 
for gelatinases (MMPs -2 and -9) having minimal cross activity to other types of MMPs have been 
produced (Bernado et al., 2002)
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Table 1.3 Matrix Metalloproteinases (MMPs) able to cleave components of the cartilage extracellular matrix, 
their alternative names and domain composition (adapted from Alexander 2002, and Somerville et al., 2003)
MMP Pseudonyms Domain 
Organisation 
(F igure 1.7)
Substrates
MMP-1
Collagenase-,1, 
Fibroblast Collagenase, 
Tissue Collagenase, 
Interstitial Collagenase
B
Collagens I, II, III, VII, VIII, X, 
Aggrecan, Gelatin, 
MMP-2, MMP-9
MMP-2
Type IV Collagenase, 
Gelatinase A, 
TBE-1
C
Collagens I, II, III, IV, V, VII, X, XI, 
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin, 
MMP-9, MMP-13
MMP-3
Procollagenase, 
PTR1 protein, 
Stromelysin-1, 
Transin-1
B
Collagens II, III, IV, IX, X, XI 
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin. 
MMP-7, MMP-8, MMP-13
MMP-7
Matrilysin, Matrin, 
PUMP-1 Protease, 
Uterine Metalloproteinase
A
Collagens IV, X,
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin, 
MMP-1, MMP-2, MMP-9
MMP-8 Collagenase-2, Neutrophil 
Collagenase, PMNL
B
Collagens I, II, III, V, VII, VIII, X, 
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin
MMP-9 Type IV Collagenase, 
Gelatinase B
C Collagens IV, V, VII, X, XIV 
Aggrecan, Elastin, Fibronectin, Gelatin
MMP-10
Stromelysin-2,
Transin-2 B
Collagens III, IV, V 
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin, 
MMP-1, MMP-8
MMP-11 Stromelysin-3 D Aggrecan, Fibronectin, Laminin
MMP-12 HME, Macrophage 
Metalloelastase
B Collagen IV,
Elastin, Fibronectin, Gelatin, Laminin
MMP-13 Collagenase-3 B Collagen I, II, III, IV, 
Aggrecan, Gelatin
MMP-14 MT1-MMP F
Collagens I, II, III,
Aggrecan, Elastin, Fibronectin, Gelatin, Laminin, 
MMP-2, MMP-13
MMP-15 MT2-MMP F Fibronectin, Gelatin, Laminin, MMP-2
MMP-16 MT3-MMP F
Collagens I,III,
Gelatin, Aggrecan, Casein, Fibronectin, Laminin, 
Perlecan, Vitronectin
MMP-17 MT4-MMP H Fibrin, Gelatin
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MMP-19 RASI-1 B Collagen IV,
Fibronectin, Aggrecan, COMP, Laminin, Gelatin
MMP-20 Enalysin B Aggrecan, Amelogenin, COMP
MMP-23 CA-MMP Gelatin
MMP-24 MT5-MMP F Gelatin, Chondroitin Sulphate, Dermatan 
Sulphate, Fibronectin
MMP-25 MT6-MMP, Leukolysin H Collagen IV,
Gelatin, Fibronectin, Laminin-1
MMP-26 Matrilysin-2, Endometase A Collagen IV, Gelatin, Fibronectin
MMP-28 Epilysin D Casein
MMPs play roles in normal tissue morphogenesis, wound healing, nerve growth, bone 
remodelling, and embryonic development (Nagase and Woessner 1999), but they also play roles in 
pathological processes such as arthritis, cancer etc., (Davidson et al., 1999, Herrera et al., 2002, 
Nabeshima et al., 2002, Vicenti et al., 1996, and Yamada et al., 2002). For example in the later 
stages of cartilage degradation significant breakdown of type II collagen occurs through the action 
of collagenases (Hollander et al., 1994) and this may represent irreversible cartilage damage 
(Cawston etal., 1998).
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1.3.5 A Disintegrin and Metalloproteinase with Thrombospondin Motifs 
(ADAMTS)
A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) are a family of 
extracellular proteases found in both mammals and invertebrates (see Table 1.4). First isolated in 
1997 (Kuno et al., 1997), these proteases are clearly of high biological relevance, with expression 
being upregulated in cancer and tissue inflammation. All members of the ADAMTS family have 
similar structures (see Figure 1.8).
Like the ADAM family proteins the ADAMTS start at their amino-termini with a signal 
sequence. This is followed by a putative prodomain which varies in length between 220-300 amino 
acids, except for ADAMTS-13 which has an unusually short prodomain of 74 amino acids (Cal et 
al., 2002). Three cysteine residues are present within each prodomain, except in the case of 
ADAMTS-2, ADAMTS-3 and ADAMTS-14, which contain two and ADAMTS-13 that contains one 
(Cal et al., 2002).
A furin cleavage site with the consensus sequence RX(K/R)R marks the end of the 
prodomain of all the mammalian ADAMTSs (Molloy et al., 1992, Cal etal., 2002, Llamazares et al., 
2003, Abbaszade etal., 1999, Tortorella etal., 1999, and Kuno etal., 1997). ADAMTS-5 has three 
consensus sequences for Furin (Hurskainen et al., 1999) or another prohormone convertase and 
ADAMTS-6 and ADAMTS-7 have one such site each (Hurskainen et al., 1999). The most carboxy- 
terminal of the cleavage sites is likely to be the one utilised in the production of the mature active 
form of the protease. ADAMTS family members are also predicted to contain the cysteine switch 
described in members of the MMP family, although activation of ADAMTS proteins through a 
cysteine switch mechanism has not yet been described. It appears that the zymogen form of 
ADAMTS proteins resides intracellularly and that secreted enzyme is furin-processed (Apte 2004).
Following the prodomain is the ADAM metalloproteinase domain, which is well conserved
among all members of the family (Bode et al., 1993) The catalytic site consensus sequence
HEXGHXXGXXHD is present in all ADAMTS and therefore all the proteins are presumed to be
catalytically active (Molloy etal., 1992, and Tang 2001). Five cysteine residues are upstream of the
zinc binding sequence, while three are downstream, except in ADAMTS-2, -3 and -14 which each
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have three cysteines upstream and three downstream (Bode et al., 1993). ADAMTS-13 is unique 
in having three cysteines upstream of the zinc binding sequence and two downstream (Cal et al., 
2002). In common with all MMPs and reprolysins the zinc-binding signature in ADAMTSs is 
followed by a methionine residue forming the “Met-turn”, a tight turn arranged as a right-handed 
screw carboxy-terminal to the zinc-binding signature (Bode etal., 1993).
Following the catalytic domain is the disintegrin-like domain, a region of 60-90 amino acids 
with 35-45% protein sequence homology to the snake venom metalloproteinases (Huang et al., 
1997). The disintegrin-like domain contains eight cysteines in all ADAMTSs except ADAMTS-6, 
which has six (Hurskainen et al., 1999). Although the disintegrin domain is similar in its homology 
to the disintegrins this does not imply that it shares a similarity of function with these proteins.
A thrombospondin (TSP) motif homologous to the type-1 repeat of thrombospondins-1 and 
-2 follows the disintegrin-like domain (Bornstein 1992). The thrombospondin motifs distinguish the 
ADAMTSs from the ADAMs. The first TSP is very similar in all the ADAMTSs and is 48-54 amino 
acids long (Kuno et al., 1997). The downstream TSPs are much more variable in sequence. In 
some of the ADAMTSs the TSP motifs contain a consensus binding site (BBXB) for GAG chains. 
The thrombospondin motifs of the ADAMTSs have been proposed to interact with heparin in a 
similar way to the thrombospondin motifs of thrombospondins-1 and -2 (Bornstein 1992).
The first central TSP motif is followed by a cysteine rich domain containing 10 conserved 
cysteine residues that is poorly conserved between members of the ADAMTS family. This domain 
is so-called to distinguish it from the cysteine free spacer domain that follows it. The amino- 
terminal portion of the spacer domain contains several hydrophobic amino acids that are well 
conserved whereas the carboxy-terminal portion of the spacer domain is extremely variable.
A second set of TSP repeats follow the spacer domain and vary hugely in number between 
members of the ADAMTS family. ADAMTS-4 does not have any TSP repeats at this position with 
its carboxy-terminus being its spacer domain (Tortorella et al., 1999). In ADAMTS-9 and 20 there 
are short linker peptides which space the TSPs (Cal et al., 2002). In ADAMTS-12 a second long 
cysteine free spacer domain separates the two sets of TSP repeats forming a distinctive double 
array (Cal et al., 2002).
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The final domain of the ADAMTS family members may be formed by one of four so called 
“carboxy-terminal modules”. ADAMTS-9 and -20 contain a module only otherwise found in their 
ortholog Gon-1 (Llamazares et al., 2003). A number of ADAMTSs including ADAMTS-10 and -19 
contain a Protease LACunin (PLAC) domain whereas ADAMTS-2, -3 and -14 (the procollagen 
propeptidases) all contain a unique carboxy-terminal domain in which a PLAC domain is 
embedded (Cal et al., 2002). ADAMTS-13 is the only member of this family to contain Complement 
Cla/Clr, sea urchin Uegf protein, Bone morphogenetic protein 1(CUB) domains. There are two 
located at the carboxy-terminus (Cal et al., 2002).
An ADAMTS-like protein (ADAMTS-L) has recently been identified and cloned (Hirohata et 
al., 2002). It is composed of thrombospondin repeats with a spacer and cysteine rich region 
between them. The role of this protein has yet to be elucidated.
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Table 1.4 Mammalian members of the ADAMTS family their pseudonyms, chromosomal location, sites of expression 
and postulated functions (Arner 2002, Tang 2001, Tang and Hong 1999, Cal et al., 2002, Vazquez et al., 1999, 
Hurskainen etal., 1999, and Llamazares etal., 2003)
ADAMTS Pseu do nym s Hum an
C h r o m o so m a l
Lo catio n
Function S ites  of Expression
ADAMTS-1 METH-1,
KIA1356
21q21-q22 Inflammatory response, 
angiogenesis, organ 
morphogenesis
Embryonic lung, liver and kidney, adult 
cartilage,
ADAMTS-2 Procollagen N- 
proteinase
5q23-q24 Procollagen processing
ADAMTS-3 KIAA0366 4q21
ADAMTS-4 Aggrecanase- 
1, KIAA0688
1q21-q23 Aggrecan cleavage, 
Brevican cleavage
Synovium, cartilage, brain, placenta
ADAMTS-5 Aggrecanase- 
2, ADAMTS11
21q22.1-q22 Aggrecan cleavage Cartilage, brain, placenta
ADAMTS-6 5q13
ADAMTS-7 15pter-qter
ADAMTS-8 METH2 11q25 Angiogenesis
ADAMTS-9 KIAA1312 3p14.2
ADAMTS-10 19p13.3
ADAMTS-11 Also known as ADAMTS-5
ADAMTS-12 5q35 May play roles in 
pulmonary cells during 
foetal development or in 
tumour processes
ADAMTS-13 9q34 Foetal liver, adult prostate and brain, 
melanoma and colon carcinoma cells
ADAMTS-14 10q 21.3 May cleave type II 
procollagen in the 
absence of ADAMTS-2
Foetal lung and kidney
ADAMTS-15 11q25 Foetal kidney and Liver
ADAMTS-16 5p15 Foetal lung and kidney, adult brain
ADAMTS-17 15q24 Foetal lung, adult prostate and brain
ADAMTS-18 16q23 Foetal lung and liver, adult prostate and 
brain
ADAMTS-19 5q31 Foetal lung, osteosarcoma cell lines
ADAMTS-20 Testis and brain
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Signal 
Peptide
Metalloproteinase 
Domain
Thrombospondin-1
like Domain Thrombospondin-1 like
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'Sure 1.8 Predicted protein structures of members of the ADAMTS family in their zymogen form (adapted from 
“al etal2002, and Llamazares et al., 2003). 4 6
ADAMTS knockout mice have shown the possibility of redundancy within this protease 
family since ADAMTS-14 may cleave type II procollagen in the absence of ADAMTS-2 (Colige et 
al., 2002) (see Table 1.4). Unlike several of the MMP genes that are clustered in the mammalian 
genome the ADAMTS genes are rather well distributed amongst the human chromosomes (Tang 
and Hong 1999, and Tang 2001). Some members of the ADAMTS family are inhibited by Tissue 
Inhibitors of Metalloproteinases (TIMPs), which are discussed in Section 1.3.6 (Kashiwagi et al., 
2001, and Gendron et al., 2003). Synthetic inhibitors of MMPs also inhibit ADAMTS activity at 
different concentrations to those required for inhibition of MMP activity (Little et al., 2002a, Cherney 
et al., 2003, and Vankemmelbeke et al., 2003).
Most of the ADAMTS genes are expressed at low levels in adult tissues. However 
ADAMTS-1, 4 and 7 are relatively more abundant and ubiquitous (Tang and Hong 1999, and Tang
2001). The members of the ADAMTS family expressed in cartilage are ADAMTS-1, ADAMTS-4 
and ADAMTS-5 (Flannery et al., 1999b), although their expression is not cartilage specific. The 
ADAMTS family members expressed in articular cartilage are discussed below.
• ADAMTS-1
ADAMTS-1 was identified in a screen for genes involved in cancer cachexia and is highly 
upregulated in inflammation (Kuno et al., 1997). It is expressed at high levels in a variety of foetal 
tissues including placenta, brain, heart, lung, liver, spleen and kidney but is found at lower levels in 
adults (see Table 1.4). Inactivation of ADAMTS-1 leads to morphological defects in the kidneys, 
adrenal gland and adipose tissue in addition to growth retardation and infertility in females (Shelley 
et al., 2002). ADAMTS-1 can cleave aggrecan, versican and brevican although the relevance of 
these activities in vivo is unclear. Cleavage of aggrecan by ADAMTS-1 is further discussed in 
Section 1.5.
• ADAMTS-4
ADAMTS-4 was first isolated from Interleukin (IL)-1 stimulated bovine nasal cartilage, and the 
human ortholog cloned and expressed (Tortorella et al., 1999) It has since been shown to be 
expressed in heart, brain, placenta, lung and skeletal muscle (see Table 1.4) (Abbaszade et al.,
1999). Full length active human ADAMTS-4 has a predicted molecular weight of ~68kD and has
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been shown to undergo autocatalytic carboxy-terminal truncation to generate two discrete isoforms 
of 53 and 40kD (Flannery et al., 2002). The role of ADAMTS-4 in aggrecan cleavage during 
disease states such as arthritis is discussed in Section 1.5.
• ADAMTS-5
ADAMTS-5 was first isolated from IL-1 stimulated bovine nasal cartilage and the human ortholog 
sequenced and cloned (Abbaszade et al., 1999). At this time it was designated ADAMTS-11, 
however the protein had already been isolated, cloned and designated ADAMTS-5. When the 
sequences for ADAMTS-5 and ADAMTS-11 were shown to be orthologs of each other the protein 
was officially designated ADAMTS-5. ADAMTS-5 has since been shown to be highly expressed in 
placenta with lower levels in heart, liver and brain (Abbaszade et al., 1999). ADAMTS-5 levels 
during endochondral ossification increased during the hypertrophic stage (Makihira et al., 2003). 
This implies a role for ADAMTS-5 in aggrecan degradation during endochondral ossification. In 
growth plate cartilage the enzyme was also shown to be upregulated by thyroid hormone (Makihira 
et al., 2003). The role of ADAMTS-5 in aggrecan cleavage during disease states such as arthritis is 
discussed in Section 1.5.
1.3.6 Tissue Inhibitors of MetalloProteinases (TIMPs)
The family of Tissue Inhibitors of MetalloProteinases (TIMPs) currently comprises 4 members in 
humans: TIMP-1, -2, -3 and -4. These are homologous in sequence and have similar secondary 
and tertiary structures including 6 well conserved disulphide bonds. Mammalian TIMPs are two- 
domain molecules, having an amino-terminal domain of -125 amino acids and a smaller carboxy- 
terminal domain of -65 residues. Each domain is stabilised by three disulphide bonds (Williamson 
etal., 1990).
Inhibition studies with recombinant TIMPs have shown them to bind to MMPs with varying 
affinity implicating distinct functions in vivo (Brew et al., 2000, and Woessner 2002). Structural and 
functional studies of TIMP-1 and -2 (Murphy et al., 1991, Huang et al., 1997, Williamson et al., 
1997, and Gomis-Ruth 1997) have shown their inhibitory activity to reside in their amino-terminal 
domain.
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In addition to the inhibitory activity of TIMPs, some are also involved in activation of MMPs 
e.g. proMMP-2 is proposed to interact via its hemopexin domain with the carboxy-terminal regions 
of TIMPs -2, -3 and -4 (Overall et al.f 1999, Bigg et al., 1997 and Butler et al., 1998). Each of the 
TIMPs is bound to the cell surface by MT1-MMP. Another molecule of MT1-MMP must be present 
near by on the cell surface to activate the proMMP-2 since the MT1-MMP molecule bound to the 
TIMP is also inhibited by them (Strongin et al., 1995, and Butler et al., 1998). The association of 
two or more molecules of MT1-MMP in this way was recently shown by interactions of their 
hemopexin domains (Itoh et al., 2001). A similar activation has been suggested for proMMP-9 via 
interaction with TIMPs -1 and -3 (Butler etal., 1998, and Goldberg etal., 1992).
In addition to their interactions with MMPs TIMPs also inhibit other enzymes including 
members of the ADAM family (see Section 1.3.4). Inhibition of ADAM-10 by TIMP-3 has been 
shown to prevent shedding of cell surface anchored tumour necrosis factor (TNF)-a receptor 
(Smith etal., 1997), IL-6 receptor (Hargreaves etal., 1998) and syndecans -1 and -4 (Fitzgerald et 
al., 2000). Direct evidence of TIMP-3's ability to inhibit ADAM-17 and -10 has been established 
(Amour et al., 1998, and Hurskainen et al., 1999). More recently ADAM-10 has been shown to be 
inhibited by TIMP-1 and TIMP-3 whereas ADAM-17 is only inhibited by TIMP-3 (Amour et al.,
2000).
TIMP-1 inhibits most MMPs with Kj levels of 0.1 - 2.8nM (Murphy and Willenbrock 1995). 
TIMP-1 has a higher affinity for full length MMP-1 as compared with MMP-1 that lacks the carboxy- 
terminal hemopexin domain (Taylor et al., 1996). The removal of the hemopexin domain from 
MMPs often results in an approximately 5-fold to 20-fold increase in the Kj value, indicating that the 
hemopexin domain assists the interaction of TIMP-1 with MMPs (Nagase and Brew 2002).
TIMPs -2, -3 and -4 inhibit all MMPs so far tested. TIMP-2 binds to MMP-2 most tightly with 
the dissociation constant being such that the interaction is essentially irreversible (Hutton et al.,
1998). The tight nature of this interaction is largely due to the carboxy-terminal domain of TIMP-2 
and the carboxy-terminal domain of MMP-2 (Willenbrock et al., 1993). TIMP-3 binds to MMP-3 with 
relatively low affinity (K j = 67nM) (Kashiwagi etal., 2001).
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TIMP-3 has several properties distinct from those of other TIMPs, which include its ability to 
bind tightly to the extracellular matrix (Pavloff et al., 1992 and Yu et al., 2000), apoptotic effects on 
a number of cell types (Smith et al., 1997, and Baker et al., 1998) and inhibition of TACE (Smith et 
al., 1997). TIMP-3 was first isolated as a 21 kD protein secreted from chick fibroblasts transformed 
with Rous sarcoma virus and TIMP-3 has been localised to human chromosome 22 (Apte et al.,
1994) and binds via interaction of its amino-terminal domain to polyanionic components of the 
extracellular matrix (Yu et al., 2000). The amino-terminal domain of TIMP-3 has been shown to 
inhibit the catalytic activity of both ADAMTS-4 and -5 (see Sections 1.3.5 and 1.5.2) (Kashiwagi et 
al., 2001). It has since been shown that this interaction is not unique to TIMP-3 as TIMPs-1, -2 and 
-4 also bind to ADAMTS-4, but with much lower affinity than TIMP-3 (Hashimoto et al., 2001). 
TIMP-3 complexes have been pinpointed as causes of Sorsby's fundus dystrophy an autosomal 
dominant inherited retinal degenerative disease that leads to blindness (Yeow et al., 2002).
1.4 Articular Cartilage Disease States
1.4.1 Osteoarthritis
More than 2 million people visited their GP in the past year because of osteoarthritis (Arthritis 
Research Campaign 2005). At least 4.4 million people in the UK have X-ray evidence severe 
osteoarthritis in their knees (Arthritis Research Campaign 2005). Clinically osteoarthritis is 
characterised by joint pain, tenderness, limitation of movement, occasional effusion and variable 
degrees of inflammation without systemic effects (Kuettner and Goldberg 1995).
In the early stages of the disease the surface of cartilage, or even synovium in some 
individuals, becomes inflamed and swollen. There is a loss of proteoglycan molecules and other 
tissue components that results in loss of the water they entrapped within the matrix. Fissures and 
pits appear in the cartilage. As the disease progresses and more tissue is lost, the cartilage loses 
elasticity and fluid. It becomes increasingly prone to damage due to repetitive use and injury. 
Eventually large amounts of cartilage are destroyed, leaving the ends of the bone within the joint 
unprotected.
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The biological factors leading to the deterioration of cartilage in osteoarthritis are not 
entirely understood. One view of osteoarthritis is as a failure to maintain a balance between 
synthesis and degradation of matrix components. Synthesis of cartilage components appears to be 
dependent on a number of growth factors including insulin-like growth factor (IGF)-1 and 
Transforming Growth Factor (TGF)p. Despite the fact that IGF-1 has been shown to reduce the 
development of osteoarthritis in animal models (Rogachefsky et al., 1993), the evidence for its role 
in humans is conflicting, with increased (Dore et al., 1995), decreased and normal concentrations 
(Pagura et al., 2004) being detected in patients with osteoarthritis. The picture is equally confusing 
with TGFp (Creamer and Hochberg 1997). Degradative enzymes such as MMPs (see Section 
1.3.3) are found in increased concentrations in osteoarthritic cartilage, and their synthesis by 
chondrocytes can be stimulated by lnterleukin-1 a (Woessner 1994). Blockage of MMPs by 
doxycycline, in animal models, can reduce the severity of osteoarthritis lesions (Ryan etal., 1996). 
Other enzymes involved in the degradation of extracellular matrix components in osteoarthritis 
include members of the ADAMTS family (see Section 1.3.5) (Sandy et al., 1991a, llic et al., 1992, 
and Loulakis etal., 1992).
Subchondral bone changes are often seen on radiographs in patients with 
established osteoarthritis and increasingly these are viewed as an important cause of 
osteoarthritis, rather than the follow-on from cartilage damage.
Current treatment of osteoarthritis is purely to control symptoms because as yet there are 
no disease-modifying osteoarthritis drugs. The principal treatments in use are forms of pain control. 
Systematic reviews of both non-pharmacological therapies (e.g. exercise) and pharmacological 
therapies such as paracetemol and Non-steroidal Anti-Inflammatory Drugs (NSAID)(e.g. Aspirin) 
have been published (Towheed and Hochberg 1997a, Towheed and Hochberg 1997b and Puett 
and Griffin 1994).
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1.4.2 Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease where an unknown environmental agent such as a 
virus or toxin triggers an autoimmune response in genetically susceptible individuals (Schiff 2000). 
Factors increasing an individual’s susceptibility to rheumatoid arthritis include expression of the 
Human Leukocyte Antigen class II locus (Feldmann et al., 1996). Internationally around 1% of 
individuals are diagnosed with rheumatoid arthritis, with 10-20% of the patients going on to develop 
a permanent disability (Tsou etal., 2004).
It is generally accepted that the initial events in the development of rheumatoid arthritis is 
the proliferation of synovial cells with inflammation in the stroma of the synovial tissue (Zvaifler 
1983). The pathology of rheumatoid arthritis extends throughout the synovial joint with even the 
normally acellular synovial fluid becoming enriched with neutrophils and macrophages (Feldmann 
et al., 1996). The synovial membrane undergoes an increase in vascularity and infiltration of 
inflammatory cells, CD4+ T cells (Choy and Panayi 2001), macrophages, fibroblasts, mast cells 
(Bromley et al., 1984), polymorphonuclear leukocytes (Mohr and Menninger 1980), and displaced 
(probably dedifferentiated) chondrocytes (Allard etal., 1987).
At the junction of the synovial lining and the joint capsule a major source of tissue damage, 
termed the pannus, originates. This will eventually grow not only over the cartilage, but also into it, 
destroying the cartilage in the process (Tsou et al., 2004). Cells both within the synovial lining and 
the pannus secrete inflammatory cytokines (e.g. Interleukin-1 and Tumour Necrosis Factor a) (Chu 
et al., 1992) as well as MMPs (Choi and Panayi 2001).
Interleukin-1 and -6, and Tumour Necrosis Factor a are the important cytokines that drive
inflammation in rheumatoid arthritis (Kumar et al., 2001). There are many proteinases involved in
rheumatoid arthritis that are produced by different cell types. MMPs are primarily produced by
synovial fibroblasts and chondrocytes (Birkedal-Hansen et al., 1993, and Nagase et al., 1992).
Interleukin-1 a and Tumour Necrosis Factor a are able to stimulate the expression of adhesion
molecules that promote the recruitment of inflammatory cells into the joint. This includes
neutrophils that, once in a joint, release elastase and proteases that degrade the superficial zone
of the cartilage (Moore and Dorner 1993). Biologic disease modifying anti-rheumatic drugs have
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been developed that antagonise the actions of lnterleukin-1 and Tumour Necrosis Factor a (Olsen 
and Stein 2004, and O’Dell 2004).
1.5 Aggrecan Degradation in Health and Disease
One of the first pathological features of joint degeneration is loss of the cartilage proteoglycan 
aggrecan. This precedes both overt collagen catabolism and joint erosion by some time. Following 
joint injury and subsequent joint disease there is a loss of aggrecan metabolites from the cartilage 
matrix into the synovial fluid (Lohmander 1991). In the later stages of arthritis significant 
breakdown of type II collagen occurs (Hollander et al., 1994). This is thought to represent 
irreversible cartilage damage (Cawston etal., 1998).
1.5.1 Model Systems of Cartilage Aggrecan Degradation
Culture systems allow analysis of the metabolism of chondrocytes and their extracellular matrix.
There are several culture systems in use; cartilage explants, isolated chondrocyte monolayer
cultures, cultures of isolated chondrocytes suspended in agarose or alginate, and pellet cultures.
Articular cartilage explants and cultures of isolated chondrocytes in agarose gel offer
numerous advantages over those grown in monolayer culture where chondrocytes are prone to
dedifferentiation as the forces acting on the chondrocyte through the matrix have been removed.
The pressure of the matrix on the chondrocytes and its relatively poor perfusion of nutrients, in
mature cartilage, may contribute to maintaining the phenotype of the chondrocyte. Spirito et al.,
reported that the phenotype of bovine chondrocytes was maintained for longer in chondrocyte-
agarose cultures than parallel monolayer chondrocyte cultures (Spirito etal., 1993).
A number of studies using chondrocytes embedded in agarose as a model system to
investigate the effect of exogenous agents (such as TIMPs-1 and -2 and polysulphated
polysaccharides) on GAG release and chondrocyte phenotype have been published (Kuroki et al.,
2003, Verbruggen et al., 1999, and Verbruggen et al., 2000). Researchers have also used
chondrocyte-agarose cultures as a model system for the investigation of effects of hydrostatic
pressure on the structure and composition of the extracellular matrix secreted by chondrocytes
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(Toyoda et al., 2003a, Kelly et al., 2004, Quinn et al., 2002, Mauck et al., 2002, and Toyoda et al., 
2003b).
All culture systems used to study chondrocyte / matrix metabolism may be exposed to 
catabolic stimulants, mechanical loading or enzyme inhibitors and drugs. In cultures where no 
secreted matrix is present the effects of these conditions on the chondrocytes themselves may be 
investigated. Long term culture of chondrocytes embedded in agarose allows an extracellular 
matrix to be established around the chondrocytes, restoring the physical pressures exerted on the 
cells by the cartilage extracellular matrix. This matrix is almost free of the metabolites seen in 
explant matrices. Hence, the effects of catabolic stimulants, mechanical loading or enzyme 
inhibitors and drugs can be examined in an intact matrix without the complication of already 
present cartilage metabolites.
Pioneering the chondrocyte-agarose model system Aydelotte and Kuettner 1988 allowed 
bovine articular chondrocytes suspended in agarose to secrete a matrix, before the addition of 
catabolic enhancers such as IL-1 and retinoic acid to the culture medium. The morphology of the 
matrix was investigated using antibodies to cartilage proteoglycans before and after treatment with 
these catabolic enhancers. The results showed diminished proteoglycan synthesis and enhanced 
proteoglycan catabolism in the cultures treated with IL-1 and retinoic acid compared to controls. A 
more recent publication showed IL-1 (3 to suppress aggrecan synthesis in human articular 
chondrocytes embedded in agarose (Wang etal., 2001).
One of the major problems with agarose cultures is the difficulty of retrieving the cells, 
however a thermosensitive gel culture system has recently been described by An et al., 2001. The 
polymer described is a copolymer of poly (N-isopropylacrylamide) and acrylic acid and has the 
ability to polymerise at temperatures of 37 °C and over and liquefy when the temperature falls 
below 378 C. This new polymer allows recovery of over 90% of the cells.
Cartilage explant culture systems allow ex-vivo analysis of the metabolism of chondrocytes 
and their extracellular matrix. Extracellular matrix macromolecules and chondrocytes are arranged 
as they were in vivo so allowing analysis of their metabolism in a ‘native’ matrix. Alternative
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systems for culturing chondrocytes change the chondrocyte phenotype with respect to expression 
of the enzymes potentially involved in cartilage degeneration (Flannery etal., 1999c).
Little et al., used cartilage explant cultures from a variety of species to investigate aggrecan 
and link protein catabolism, showing ‘aggrecanases’ to perform the primary cleavage in both 
untreated and IL-1 stimulated explants (Little etal., 1999).
Cartilage explant cultures may be supplemented with enzyme inhibitors and other potential 
drugs to determine their effects on ‘native’ articular cartilage. Mason and Goh exposed bovine 
articular cartilage explants to sodium iodoacetate (a SH-dependent enzyme inhibitor). This was 
shown to inhibit proteoglycan synthesis and lactate production (Mason and Goh 1991).
However, in cartilage explant cultures the effects of such mediators may be obscured by 
the presence of matrix metabolites in the cartilage explant prior to its excision from the joint. In 
contrast the matrix secreted by chondrocytes embedded in agarose is almost free of the 
metabolites seen in explant matrices.
1.5.2 Degradation of Aggrecan in Vivo and in Vitro
For many years the degradation of aggrecan was thought to be carried out by MMPs. However, in
1991 Maniglia et al., reported a series of amino-terminal amino acid sequences on aggrecan
catabolites that were released from cartilage explant cultures exposed to IL-1 a. The existence of
these novel amino-terminal peptide sequences was soon confirmed by others (Sandy etal., 1991a,
llic et al., 1992, and Loulakis et al., 1992). These amino-terminal amino acid sequences did not
correspond to previously published cleavage sites for any known matrix protease including the
MMPs (Fosang et al., 1991, 1992 and 1996). The term ‘aggrecanase’ was used to describe the
unknown proteolytic enzyme able to cleave aggrecan at these sites (Hardingham and Fosang
1995). The major cleavage site described as an ‘aggrecanase site’ was located within the
interglobular domain (IGD) of the aggrecan core protein at the Glu373-Ala374 bond (Sandy et al.,
1991a and b). The main aggrecan catabolite, found in samples of synovial fluid from patients with
arthritis, and released from cartilage explant cultures exposed to IL-1, both had the amino-terminal
amino acid sequence 374ARGSV... (human sequence enumeration) corresponding to cleavage at
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the ‘aggrecanase site’ within the IGD of aggrecan (Sandy et al., 1992, and Lohmander et al., 
1993).
Aggrecan fragments have been identified in human articular cartilage extracts (Flannery et 
al., 1992) and synovial fluids (Fosang et al., 1995) that have been cleaved at the MMP susceptible 
Asn^-Phe342 bond located within the interglobular domain (IGD). Recent in vitro studies have 
indicated that the primary cleavage of aggrecan occurs at the Glu373-Ala 374 bond, the so-called 
‘aggrecanase site’, within the IGD of the aggrecan core protein during cartilage degradation and 
that cleavage by MMPs at the Asn341 -Phe342 bond may be a later event (Little et al., 1999, and Van 
Meurs etal., 1999).
Two ‘aggrecanases’ have so far been purified and cloned (Tortorella et al., 1999, and
Abbaszade et al., 1999), they were both found to be members of the a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS) family, ADAMTS-4 (Aggrecanase-1) and 
ADAMTS-5 (Aggrecanase-2). Both have similar specificity for the Glu373-Ala374 bond within the
interglobular domain of the aggrecan core protein (Tortorella etal., 1999).
Using an in vitro model of cartilage degradation it has been shown that ADAMTS-4 and -5 
are the enzymes responsible for the loss of aggrecan from explant cultures of articular cartilage 
stimulated with IL-1 a or TNFa (Tortorella et al., 2001). Immunodepletion of media taken from IL-1 a 
stimulated cartilage with an anti-ADAMTS-4 antibody led to a 75% reduction in ‘IGD aggrecanase 
activity’, whilst immunoprecipitation with an anti-ADAMTS-5 antibody led to a 15% decrease in 
‘IGD aggrecanase activity’ (Tortorella etal., 2001).
In addition to cleavage at the Glu373-Ala374 bond, ADAMTS-4 and -5 have been shown to 
cleave at four sites within the chondroitin sulphate rich region of the aggrecan core protein, 
between globular domains G2 and G3 (Tortorella et al., 2000b). These cleavages are at
q E L E 1480- 1481G R G T ................ KEEE1667-1668GLGS...........TAQE1771-1772AGEG... and ...VSQE1871-
1872LGQR.... ADAMTS-5 has also been shown to utilise a fifth cleavage site in the region spanning 
residues Gly1481 and 1667Glu (Tortorella et al., 2002). It has been suggested that these cleavages 
within the carboxy-terminal chondroitin sulphate binding domains of aggrecan occur more 
efficiently than cleavage within the interglobular domain at the Glu373-Ala374 bond (Tortorella et al.,
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2000b). ADAMTS-5 cleaves aggrecan approximately 2-fold slower than ADAMTS-4 (Tortorella et 
al., 2002).
Binding-competition experiments conducted using native and deglycosylated aggrecan 
provided evidence for interaction of the cysteine rich and spacer domains of ADAMTS-4 with the 
GAG chains of aggrecan (Flannery et al., 2002). This interaction between enzyme and substrate 
may facilitate cleavage of the aggrecan core protein by ADAMTS-4, suggesting that the GAG 
chains of aggrecan may be necessary for efficient ADAMTS-4 cleavage. ‘IGD aggrecanase activity’ 
has been shown to be inhibited by exogenous chondroitin sulphate or heparin (Sugimoto et al.,
1999). This suggests that these GAGs may compete for the binding of ADAMTS-4 to its aggrecan 
substrate.
Full length Furin-activated ADAMTS-4 has a predicted molecular weight of ~68kD and has 
been shown to undergo autocatalytic carboxy-terminal truncation to generate two discrete isoforms 
of 53 and 40kD (Flannery et al., 2002). These smaller isoforms have a reduced affinity of binding to 
sulphated GAGs. Carboxy-terminal sequencing and mass analysis revealed that the GAG binding 
thrombospondin type I motif was retained following autocatalysis, indicating that sites present in 
the carboxy-terminal cysteine rich and / or spacer domains also effect binding of full length 
ADAMTS-4 to sulphated GAGs (Flannery et al., 2002). It has recently been reported that carboxy- 
terminal truncation enhances the ‘IGD aggrecanase activity’ of ADAMTS-4, thus implying a 
potential regulatory function for the domains of the ADAMTS-4 carboxy-terminal region (Gao et al.,
2002).
Recent data indicates ADAMTS-4 to be constitutively expressed in chondrocyte 
monolayers and cartilage explants from both bovine nasal and articular cartilage, and that 
stimulation with IL-1 results in ‘aggrecanase’ activation (Pratta et al., 2003). Investigation of a 
series of ADAMTS-4 deletion mutants has shown full length ADAMTS-4 to be the most effective 
enzyme for aggrecan degradation as measured by GAG release (Kashiwagi et al., 2004). 
However, interestingly, activity at the Glu373 - Ala374 bond within the interglobular domain of 
aggrecan was increased in the deletion mutants lacking the cysteine rich and spacer domains 
(Kashiwagi et al., 2004). Treatment of porcine articular cartilage explants with IL-1a induced
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secretion of ADAMTS-4 isoforms of 46, 40 and 37kD, indicating carboxy-terminal truncation of 
ADAMTS-4 to have occurred (Kashiwagi et al., 2004). These lower molecular weight ADAMTS-4 
isoforms are predicted to have enhanced proteolytic activity along with decreased substrate 
specificity due to the loss of the carboxy-terminal GAG binding regions (Kashiwagi et al., 2004). 
This suggests that ADAMTS-4 may digest other cartilage proteins as well as aggrecan when it is 
present in carboxy-terminally truncated isoforms.
Recently published data indicated ADAMTS-4 to bind to the carboxy-terminal region of 
fibronectin (see Section 1.2.3.1) and that this interaction inhibits the enzymes activity against 
aggrecan (Hashimoto et al., 2004). However, the physiological relevance of this is not yet known.
ADAMTS-1 has also been shown to be able to cleave at the ‘IGD aggrecanase site’ in vitro 
(Kuno et al., 2000, and Rodriguez-Manzaneque et al., 2002), but only at supraphysiological 
concentrations and therefore its role in vivo has yet to be confirmed (Sandy and Verscharen 2001). 
The thrombospondin type I motifs of ADAMTS-1 bind to sulphated GAGs (Kuno and Matsushima 
1998) and, thus may serve to influence its substrate specificity. Along with ADAMTS-12, ADAMTS- 
1 can undergo proteolytic removal of its carboxy-terminal region resulting in removal of domains 
that can bind to sulphated GAGs (Rodriguez-Manzaneque et al., 2000, Cal et al., 2001, and Wei et 
al., 2002).
Since the roles of the three aggrecanases (ADAMTS-1, -4 and -5) in cartilage degradation 
have yet to be confirmed the term aggrecanase is used to refer to the enzymatic activity capable of 
cleaving the Glu373-Ala374 bond within the interglobular domain of aggrecan.
‘IGD aggrecanase activity’ has been identified associated with chondrocyte membranes 
(Billington et al., 1998). Here a combination of IL-1 a and oncostatin M was used to stimulate the 
chondrocytes before membrane purification. An enzyme activity associated with the membranes 
was able to cleave aggrecan at the Glu373-Ala374 bond. ‘IGD aggrecanase activity’ has been shown 
to associate with the extracellular matrix (Kuno and Matsushima 1998), but has also been shown 
to be a soluble activity (Hughes et al., 1998).
The functions of aggrecanases in organs other than cartilage require further investigation. 
Their activity has been shown to be soluble (llic et al., 2000). Unlike in cartilage, the activity of the
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enzymes in synovium, joint capsule (llic et al., 2000) and tendon (Rees et al., 2000) was not 
dependent on stimulation of the tissue with catabolic stimuli (e.g. IL-1 or TNF). Aggrecanases have 
also been shown to cleave versican and brevican (Rauch et al., 1991, Matthews et al., 2000, 
Sandy et al., 2001, and Yamada et al., 1995).
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1.6 Aims of the Project
A primary event in the destruction of cartilage in arthritic diseases is the loss of aggrecan from the 
extracellular matrix of articular cartilage. During aggrecan breakdown important cleavage sites are 
utilised which reside within the interglobular domain (IGD) of the aggrecan core protein. The 
Asn^-Phe342 bond is cleaved by members of the MMP family, whereas the second of the two 
cleavage sites, the Glu373-Ala374 bond (also known as the IGD aggrecanase site) is cleaved by 
members of the ADAMTS family. Both ADAMTS-4 and -5 have been identified, cloned, and shown 
to readily cleave aggrecan at the IGD aggrecanase site (Tortorella et al., 1999, Abbaszade et al., 
1999, and Sandy et al., 2000). ADAMTS-1 has also been shown to be able to cleave at the IGD 
aggrecanase site in vitro (Kuno et al., 2000, and Rodriguez-Manzaneque et al., 2002), but only at 
supraphysiological concentrations and therefore its role in vivo has yet to be confirmed (Sandy and 
Verscharen 2001). ADAMTS-4 and -5 also cleave at a number of other sites along the length of 
the aggrecan core protein (Tortorella et al., 2000a). ‘IGD aggrecanase activity’ has been shown to 
be membrane associated (Hascall et al., 1999) but it has also been detected in media samples 
from chondrocytes embedded in agarose showing it to be soluble (Hughes et al., 1997).
The model system used for these investigations is that of chondrocytes embedded in 
agarose. This system was pioneered by Aydelotte et al., 1988 and allows analysis of the 
metabolism and catabolism of chondrocytes and their extracellular matrix.
TIMP-3 has several properties distinct from those of other TIMPs, which include its ability to 
bind tightly to the extracellular matrix (Pavloff et al., 1992 and Yu et al., 2000). The amino-terminal 
domain of TIMP-3 has been shown to inhibit the catalytic activity of both ADAMTS-4 and -5 
(Kashiwagi etal., 2001).
Therefore the aims of this project are:
□ Investigate the aggrecan content of the extracellular matrix secreted in the model system of 
chondrocytes embedded in agarose.
□ Determine the effects of exposure of the aggrecan present in the extracellular matrix of 
chondrocyte-agarose cultures to catabolic stimuli (IL-1 a).
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□ Examine the secretion, sequestration and activation of the aggrecanases (ADAMTS-4 and 
-5) in this culture system using a series of mono- and polyclonal antibodies recognising 
various domains of the enzymes.
□ Scrutinize the effect of TIMP-3 on the ADAMTS-4 and -5 present in the culture system.
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Chapter 2: General Materials and Methods 
2.1. Materials
• Pronase from Streptomyces griseus was obtained from Boehringer Manheim.
• Collagenase type II prepared from Clostridium Histolyticum was obtained from Worthington, 
Lakewood, NJ, US.
• Dulbecco’s Modified Eagles Medium (DMEM) without sodium pyruvate with 450mg/ml 
glucose with pyridoxine was obtained from Invitrogen, Frankfurt, Germany.
• Gentamicin (1000x stock) was obtained from Invitrogen, Frankfurt, Germany.
• Foetal Calf Serum (FCS) was obtained from Invitrogen, Frankfurt, Germany.
• Phosphitan™C was obtained from Showa Denko, Tokyo, Japan.
• 40pm Nylon Cell Strainers were obtained from BD Falcon, BD-Biosciences - Discovery 
Labware, Bedford, MA, US.
• Seaplaque Agarose was obtained from Fisher, Loughborough, UK.
• All general chemical reagents used to make up the dimethylmethylene blue (DMMB) 
solution was obtained from Sigma-Aldrich, Poole, Dorset, UK.
• Chondroitin sulphate C from shark cartilage was obtained from Sigma-Aldrich, Poole, 
Dorset, UK.
• Mutiwell plates were obtained from Elkay Laboratory Products UK Ltd., Basingstoke, UK.
• Labsystem Multiscan MS spectrophotometer was used.
• Lactate Assay Kit was obtained from Sigma-Aldrich, Poole, Dorset, UK. Beckman.
• Ultracentrifuge tubes were obtained from Beckman, London Road, Bucks, UK.
• Recombinant human ADAMTS-4 was a kind gift donated by Dr. Carl Flannery, Wyeth, 
Boston, US.
• Recombinant human MMP-13 was a kind gift from Dr. Peter Mitchell formerly at Pfiser, New 
York US, now at Eli Lilly, Indiana, US.
• Chondroitinase ABC was obtained from Sigma-Aldrich, Poole, Dorset, UK.
• Keratanase was obtained from Seikagaku /  AMS Biotechnology, Abindon, UK.
• Keratanase II was obtained from Seikagaku /  AMS Biotechnology, Abindon, UK.
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• Gradient 4-12% Tris Glycine gels were obtained from Invitrogen, Frankfurt, Germany.
• Nitrocellulose membrane was obtained from Schleicher and Schuell Bioscience, Dassel 
Germany.
• Alkaline phosphatase linked goat anti-mouse secondary antibody was obtained from 
Promega, Madison, US.
• BC-3, BC-14, BC-13 and BC-4 monoclonal antibodies were all developed and characterised 
by members of this laboratory (Hughes et a!., 1995, Hughes et ai, 1992 and for reviews see 
Caterson et a!., 1995 and Caterson et at., 2000).
• Heparin immobilised on 4% beaded agarose (activation epichlorohydrin) was obtained from 
Sigma-Aldrich, Poole, Dorset, UK.
• Imidodiacetic acid immobilised on cross-linked 4% beaded agarose (activation epoxy) were 
obtained from Sigma-Aldrich, Poole, Dorset, UK.
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2.2 Methods
2.2.1 Isolation of Porcine Articular Cartilage Chondrocytes
Porcine articular cartilage was obtained from 2-6 month old pig hock joints, which had been 
slaughtered at Ensors abattoir at Cinderford in the Forest of Dean. Hocks were obtained within 4-6 
hours of slaughter. Chondrocytes were isolated using methods described by Hughes et al, 1998. 
The hocks were firstly cleaned and skinned prior to dissection of the metacarpophalangeal joint 
and removal of cartilage tissue slices under asceptic conditions. The chondrocytes were isolated 
from their surrounding matrix firstly by digesting the cartilage slices in 0.1% (w/v) pronase in 
DMEM containing 50pg/ml gentamicin and 5% (v/v) Foetal Calf Serum (FCS) (7.5ml / g cartilage 
wet weight) for 3-4 hours at 37°C with constant agitation. Following removal of the pronase solution 
the tissue was further incubated at 37°C overnight with 0.04% (w/v) collagenase in DMEM 
containing 50pg/ml gentamicin and 5% (v/v) FCS (7.5ml / g cartilage wet weight) with constant 
agitation to free the cells from the collagen network.
The cells were filtered through a 40pm Nylon (Falcon) filter. The chondrocytes were 
pelleted by centrifugation at 1500rpm for 10 minutes, and then resuspended in 50ml of DMEM; this 
was repeated twice to wash the chondrocytes free of enzymes. The chondrocytes were 
resuspended in a known volume of DMEM a quantity of which was then taken and further diluted 
before being counted using a bright light haemocytometer.
The total cell number was calculated according to the equation:
Number of cells = Average cell number x 104 x Total volume x Dilution
The chondrocytes were then resuspended at 12 x 106cells / ml in DMEM with 50pg/ml gentamicin.
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2.2.2 Preparation of Chondrocyte-Agarose Cultures
A 2% (w/v) solution of Seaplaque Agarose in DMEM containing 50pg/ml gentamicin was prepared 
and dissolved by heating before diluting to 1% (w/v) with DMEM containing 50pg/ml gentamicin. 
This 1 % (w/v) agarose solution was plated at 2ml per 60mm plate and allowed to set at 4°C for 20- 
25 minutes before warming through at 37°C for 10-15 minutes to form a plug. Chondrocytes at 12 x 
106 / ml were diluted 1:2 with 2% (w/v) agarose, resulting in a 1% (w/v) agarose solution containing 
6 x 106 chondrocytes / ml, 1ml of this solution was overlaid onto the agarose plug and again 
allowed to set at 4°C for 10-15 minutes. Preculture medium of DMEM with 50pg/ml gentamicin, 
10% (v/v) Foetal Calf Serum (FCS) and 25pg/ml Phosphitan™C (a stable form of ascorbate) was 
added at 4ml/plate and the cultures were maintained at 37°C in a humidified atmosphere of 5% 
C02, the medium was changed every 4-5 days. The chondrocytes were precultured for 14 or 21 
days and then washed 3 x 20 minutes in serum free DMEM containing 50pg/ml gentamicin. The 
experimental conditions vary and are therefore described in the appropriate sections.
2.2.3 Extraction of Proteoglycans from Agarose Plugs
Matrix molecules, including proteoglycans, present in the agarose plugs were extracted by addition 
of 10ml guanidine extraction buffer (4M guanidine HCI, 50mM sodium acetate pH 5.8-6.8, 0.1 M 6- 
amino-hexanoic acid, 5mM benzamidine HCI, 10mM ethylene diaminetetra acetic acid (EDTA) 
(tetrasodium salt), 1mM phenyl methyl sulphonyl fluoride (PMSF) to each 3ml plug for 48 hours at 
4°C with constant agitation (as described in Roughley and White 1980). The mixture was dialysed 
exhaustively against MilliQ™ water before being spun at 15,000rpm for 30 minutes to remove the 
remaining agarose and the supernatant stored at -20°C until required. The remaining agarose 
plugs were subjected to alkaline (3-elimination to extract any remaining GAGs by addition of 5ml 
1M sodium hydroxide to each 3ml agarose plug and incubation at room temperature for 24 hours 
with constant agitation (adapted from Anderson et al, 1964). This mixture was then dialysed 
exhaustively against MilliQ™ water. The samples were spun at 15,000rpm for 30 minutes to 
remove the remaining agarose and the supernatant stored at -20°C until required.
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2.2.4 Analysis of Glycosaminoglycan Concentration using the Dimethylmethylene 
Blue Assay (DMMB)
Proteoglycan content of medium, guanidine extracts and (3-eliminations from chondrocyte-agarose 
cultures was measured as sulphated GAG using the DMMB assay (Farndale et ai, 1986). In this 
assay, DMMB binds to the sulphate groups on glycosaminoglycans forming a dye-GAG complex. 
Formation of this complex produces a shift in the colour absorbance from blue to pink.
Standards ranging from 0-40pg/ml shark chondroitin sulphate C, and appropriately diluted 
unknown samples were added to a 96 well multiwell plate. 200pl of DMMB solution (32mg 1,9 
DMMB, 20ml ethanol, 59ml 1M sodium hydroxide, 7ml 98% (v/v) formic acid and made up to 2L 
with MilliQ™ water) was added to the samples and the absorbance read immediately at 525nm on 
a Labsystem Multiscan MS Spectrophotometer. All standards were measured in triplicate and all 
samples were measured in duplicate.
2.2.5 Analysis of Lactate Concentration
Lactate assay was carried out using the Sigma lactate assay kit as a measure of metabolic activity 
and hence an indicator of cell viability during the preculture and experimental periods. The principal 
behind this kit is that lactic acid is converted to pyruvate and hydrogen peroxide by lactate oxidase. 
In the presence of hydrogen peroxide, peroxidase catalyses the oxidative condensation of 
chromogen precursors to produce a coloured dye with an absorption maximum of 540nm. The 
increase in absorbance is directly proportional to lactate concentration in the sample.
In a multiwell plate 5pl of lactate standards of 400, 300, 200, 100, 50 and 25pg/ml were 
placed in individual wells. 5pl of culture medium, diluted 1:10 with water, was also placed in 
individual wells. To each well was added 250pl of lactate reagent and incubated at room 
temperature for 5-10 minutes. The colour change was then read using the Labsystem multiscan 
MS spectrophotometer at 540nm. All standards were measured in triplicate and all samples were 
measured in duplicate.
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2.2.6 Extraction and Purification of Aggrecan from Porcine Articular Cartilage
Articular cartilage was harvested from the metacarpophalangeal joints of 2-6 month old pigs as 
described in Section 2.2.1. Cartilage was finely diced prior to addition of guanidine extraction buffer 
(see Section 2.2.3) (10ml per gram cartilage wet weight) and incubation for 48 hours at 4°C with 
constant agitation. The extracted cartilage debris was removed, by centrifugation at 15,000rpm for 
10 minutes, and discarded. The liquid supernatant was dialysed exhaustively against MilliQ™ 
water. The volume of liquid following dialysis was noted and a 1/10 volume of 10x sodium acetate 
buffer was added (500mM sodium acetate pH 7.5). Sufficient dry weights of the following 
proteinase inhibitors were added to give final concentrations of 0.1 M 6-amino-hexanoic acid, 5mM 
benzamidine HCI, 10mM EDTA (tetrasodium salt) and 1mM PMSF. The density of the extract was 
adjusted to 1.5g/ml by addition of caesium chloride and aggrecan purified by ultracentrifugation in 
a Beckman L-60 Ultracentrifuge at 37,000rpm for 70 hours at 4°C. The extract was fractionated 
into 4 equal pools designated A1-A4, the lowest fraction A1 containing the purified aggrecan 
having a density >1.57g/ml and the highest A4 having a density of <1.4g/ml. The A1 fraction was 
adjusted to 4M guanidine HCI by the addition of sufficient solid guanidine HCI. The density was 
then adjusted to 1.5g/ml by the addition of caesium chloride solid and spun at 37,000rpm for 70 
hours at 4°C in a Beckman L-60 Ultracentrifuge. The tubes were then fractionated into 4 equal 
portions designated A1D1-A1D4, the lowest fraction A1D1 having a density >1.57g/ml and the 
highest A1D4 having a density of <1.35g/ml. The A1D1 fraction was dialysed exhaustively against 
MilliQ™ water and analysed for sulphated GAG content by the DMMB assay as described in 
Section 2.2.4.
67
2.2.7 Digestion of A1D1 by Recombinant Human ADAMTS-4 and MMP-13 in Order to 
Generate Neoepitope Bearing Aggrecan Fragments
Sample of A1D1 (100pg GAG equivalents) were digested either with recombinant human 
ADAMTS-4 (1pg), to generate a positive control of aggrecan fragments bearing the amino- and 
carboxy-terminal neoepitopes 374ARGSV... and ...NITEGE373, respectively, or recombinant human 
MMP-13 (1pg activated by 100mM 4-aminophenylmercuric acetate [APMA]), in order to generate a 
positive control of aggrecan fragments bearing the amino- and carboxy-terminal neoepitopes 
342FFGV... and ...DIPEN341, respectively, buffered by addition of a 1/10 volume of 10x digestion 
buffer (200mM tris HCI pH 7.5 containing 1M sodium chloride and 100mM calcium chloride) 
overnight at 37°C with constant agitation.
2.2.8 Western Blot Analysis of Aggrecan Fragments
Media, guanidine extracts and positive control samples equivalent to 40-1 OOpg of sulphated GAG 
were adjusted to 0.1 M tris acetate pH 6.5 by the addition of 1M tris acetate pH 6.5 prior to 
deglycosylation by addition of Chondroitinase ABC (0.001 U per 10pg GAG), Keratanase (0.001 U 
per 10pg GAG) and Keratanase II (0.00001 U per 10pg GAG) and incubation at 37°C for 4-5 hours 
(as described in Hughes et al., 1995). The samples were then dialysed exhaustively against 
MilliQ™ water and lyophilised on a speedvac. The samples were reconstituted, in Laemmli sample 
buffer (62.5mM tris HCI, pH 6.8 containing 4% (w/v) Sodium Dodecyl Sulphate (SDS), 20% (v/v) 
glycerol and 0.01% (w/v) bromophenol blue) (Laemmli 1970) containing 10% (v/v) p- 
mercaptoethanol and electrophoresed under reducing conditions on 4-12% Tris Glycine gels in 
running buffer (25mM trizma, 192mM glycine and 0.1% (w/v) SDS). The gels were then transferred 
onto Nitrocellulose membrane (0.22p) in transfer buffer (25mM trizma pH 8.1-8.4 containing 
192mM glycine and 20% (v/v) methanol) at 100V for 60 minutes. Following their electrophoretic 
transfer the membranes were subjected to Western blot analysis. Membranes were blocked in 5% 
(w/v) Bovine Serum Albumen (BSA) in Tris Saline Azide (TSA - 50mM tris, 200mM sodium chloride 
pH 7.4 containing 0.02% (w/v) sodium azide) for a minimum of 1 hour at room temperature with 
rocking. The membranes were washed 3 x 1 0  minutes in TSA and incubated in the appropriate
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primary antibodies diluted 1:100 in 1% (w/v) BSA in TSA overnight at room temperature with 
rocking.
Media samples were probed with monoclonal antibodies BC-3 (which specifically 
recognises aggrecan metabolites bearing the amino-terminal aggrecanase generated interglobular 
domain neoepitope sequence 374ARGSV...) and BC-14 (which specifically recognises aggrecan 
metabolites bearing the amino-terminal MMP-generated interglobular domain neoepitope 
sequence ^FFGV...).
Metabolites from guanidine extracts of agarose plugs were probed with monoclonal 
antibodies BC-13 (which specifically recognises aggrecan metabolites bearing the carboxy- 
terminal aggrecanase generated interglobular domain neoepitope sequence ...NITEGE373) and BC- 
4 (which specifically recognises aggrecan metabolites bearing the carboxy-terminal MMP- 
generated interglobular domain neoepitope sequence ...DIPEN341).
The membranes were washed 3 x 1 0  minutes in TSA then incubated for 1 hour at room 
temperature with rocking in alkaline phosphatase conjugated goat anti-mouse secondary antibody 
diluted 1:7500 in 1% (w/v) BSA in TSA. The membranes were washed 3x10 minutes in TSA and 
developed in nitro blue tetrazolium (NBT - 50mg/ml in dimethylformamide) and 5-bromo-4-chloro-3- 
indoyl phosphate (BCIP -- 50mg/ml in dimethylamide), 66pl NBT and 33pl BCIP per 10ml alkaline 
phosphatase (AP) buffer (100mM tris, 100mM sodium chloride, pH 9.55 containing 5mM 
magnesium chloride) (from Hughes etal., 1998).
2.2.9 Detergent Extraction of Agarose Plugs
Each 3ml agarose plug was extracted in 4ml detergent extraction buffer (50mM Tris HCI, 100mM 
sodium chloride, pH 7 with 0.5% (v/v) nonidet P-40) for 24 hours at 4°C on a roller (as described by 
Gao et al., 2002). The mixture was spun at 15,000rpm for 30 minutes at 4°C and the supernatant 
removed and stored at -80°C for later analysis. The remaining agarose was discarded.
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2.2.10 Partial Purification of Media Samples from Chondrocyte-Agarose Cultures
• Semi-Purification of Culture Medium using Heparin Affinity Binding
Aliquots (100pl) of heparin-sepharose gel suspension were placed in individual eppendorfs 
and washed 5 x 500pl with 100mM tris HCI pH 7.5 containing 50mM sodium chloride and 
0.05% (v/v) brij (here named equlibriation buffer). Each bead aliquot was incubated with a 
500pl aliquot of culture medium, harvested from the agarose culture experiments, on a 
mixer at 4°C for 30-35 minutes. Following this the supernatant was removed and stored on 
ice prior to further purification (see below). The beads were washed, to remove non-bound 
material, 5 x 100pl with equlibriation buffer and the first wash was combined with the 
column supernatant and stored on ice prior to further purification (see below). The beads 
were then eluted in 100pl of 0.8M sodium chloride, 100mM tris HCI, pH 7.5 with 0.05% (v/v) 
brij (here named elution buffer). Samples were stored at -80°C for later analysis.
• Semi-Purification of Heparin-Sepharose Non-bound Fractions Using Zinc Chelation
Aliquots (200pl) of imidodiacetic acid gel suspension were placed in individual eppendorfs 
and washed 5 x 200pl with MilliQ™ water before chelation using 2 x 100pl of 1 mg/ml zinc 
chloride for 5 minutes each time. The beads were washed 2 x 50pl in 0.5M sodium 
chloride, 20mM tris HCI pH 7.5 (buffer 1) then 2 x 500pl in 0.5M sodium chloride, 20mM tris 
HCI pH 7.5 with 5mM calcium chloride (start buffer). The beads were incubated with 500pl 
of the supernatant from the Heparin-Sepharose column combined with 100pl of the first 
column wash from the heparin column and 60pl of 5M sodium chloride, 200mM tris HCI 
pH7.5 with 50mM calcium chloride for 5-10 minutes on ice. The column supernatant was 
removed and stored at -80°C, the beads were then washed 5 x 100pl in start buffer before 
eluting with 5 x 100pl of 0.5M sodium chloride, 20mM tris HCI pH 7.5 containing 1mM 
calcium chloride and 35mM imidazole. All eluents were stored at -80°C until required.
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Chapter 3: Composition of Extracellular Matrix Secreted by 
Chondrocyte-Agarose Cultures
3.1 Introduction
In order to investigate the sequestration and activity of ADAMTS-4 and -5 a model system of 
chondrocytes embedded in agarose was utilised. This system involves preculture of chondrocytes 
in agarose with foetal calf serum and Phosphitan™C (a stable ascorbate analogue) to allow 
secretion of an extracellular matrix. In this chapter partial characterisation of this newly synthesized 
matrix is described using previously characterised monoclonal antibodies (M’Abs) which recognise 
carbohydrate moieties present on proteoglycans of the articular cartilage extracellular matrix (see 
Figure 3.1).
Chondroitin-4-sulphate ‘stubs’ are recognised on deglycosylated aggrecan, decorin and 
biglycan by M’Ab 2B6 (Caterson et al., 1985). Chondroitin-6-sulphate ‘stubs’ are recognised on 
deglycosylated aggrecan by M’Ab 3B3+ (Caterson et al., 1995). The (+) indicates deglycosylation 
with Chondroitinase ABC. A mimotope (a biochemical structure that mimics the epitope recognised 
by a given antibody) (Geysen et al., 1988), containing a saturated glucuronic acid residue at the 
non-reducing terminal (Caterson et al., 1990), that occurs in chondroitin sulphate chains of 
proteoglycans isolated from osteoarthritic cartilage is recognised in non-deglycosylated aggrecan 
by the M’Ab 3B3(-) (Visco et al., 1993). The (-) indicates that no predigestion has been carried out. 
Proteoglycans containing the 3B3(-) mimotope at the non-reducing terminal of chondroitin sulphate 
glycosaminoglycans occur at low frequency in proteoglycans isolated from normal cartilage. 
However, its expression is much more prevalent in proteoglycans isolated from osteoarthritic 
cartilage (Carney et al., 1992, Slater et al., 1995, and Caterson et al., 1991). Keratan sulphate 
chains on aggrecan, fibromodulin and lumican are recognised by M’Ab 5D4 (Caterson et al., 1983). 
Thus the similarities and differences between the matrix synthesised by chondrocytes in agarose 
and a native articular cartilage extracellular matrix may be determined.
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Figure 3.1 Diagrammatic representation of the structure of aggrecan showing its’ glycosaminoglycan chains 
and the specific monoclonal antibodies which recognise epitopes within the chains and on the ‘stubs’ 
resulting from digestion of the glycosaminoglycan chains with Chondroitinase ABC.
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3.2 Materials
• Horse serum was obtained from Vector Laboratories Inc, Burlingame, CA, US.
• Horse anti-mouse antibody-horse radish peroxidase conjugate was obtained from Vector 
Laboratories Inc, Burlingame, CA, US.
• Peroxidase substrate solution was obtained from Vector Laboratories Inc, Burlingame, CA, 
US.
• Avidin Biotin Complex (ABC)-Peroxidase elite kit was obtained from Vector Laboratories 
Inc, Burlingame, CA, US.
• Phosphate Buffered Saline (PBS) tablets from Oxoid, Basingstoke, UK, were dissolved 1 
per 100ml MilliQ™ water to give 10mM phosphate, 2.7mM potassium chloride, 137mM 
sodium chloride pH 7.4.
• Monoclonal Antibodies (M’Abs) 2B6, 3B3 and 5D4 were all produced and characterised by 
members of this laboratory (Caterson et al., 1983, 1985, 1990, 1991 and 1995).
• All other reagents were of analytical grade.
3.3 Methods
3.3.1 Preparation of Chondrocyte-Agarose Cultures
Chondrocyte agarose cultures were prepared and precultured for 14 days as described in Chapter 
2 Section 2.2.1 and 2.2.2. Following this preculture period the plates were washed 3 x 20 minutes 
in serum free DMEM with 50pg/ml gentamicin before culture in serum free DMEM with 50pg/ml 
gentamicin and 25pg/ml Phosphitan™C for 96 hours.
Following the 96 hour culture period the medium was removed and stored frozen. The agarose 
was sliced and wrapped in foil before being snap frozen in liquid nitrogen and stored at -20°C.
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3.3.2 Histological Analysis
Cryosections of the agarose pieces (30pm in thickness) were cut using an automated Bright 
Cryostat and mounted on amino propyl triethoxysilane (APES) coated slides. These slides were 
prefixed in -20°C methanol then air dried face up at room temperature for 2-3 hours to facilitate 
adhesion. The slides were then wrapped in foil and stored at -20°C until required.
Slides were equilibrated to room temperature and sections were fixed in freshly prepared 
4% (w/v) paraformaldehyde in Phosphate Buffered Saline (PBS) for 10 minutes at room 
temperature before being washed (3 x 10 minutes) in PBS containing 0.01% tween-20 (PBS-T). 
The sections were flooded with the appropriate buffer (see Table 3.1) and allowed to equilibrate for 
10 minutes. The sections were incubated at 37°C for 2 hours in the necessary enzyme(s); for 2B6 
and 3B3+ Chondroitinase ABC, Keratanase and Keratanase II digestion, for 5D4 Chondroitinase 
ABC digestion only and for 3B3- no digestion (Chondroitinase 0.5 Units/ml, Keratanase 0.5 
Units/ml and Keratanase II 0.005 Units/ml) (see Table 3.1).
The sections were washed ( 3 x 5  minutes) in PBS-T and any non-specific binding was 
blocked by incubating sections in 5% (v/v) normal horse serum in PBS-T for 20 minutes at room 
temperature. Primary M’Abs 2B6, 3B3 and 5D4 were diluted in 2% (v/v) horse serum in PBS-T to 
1:1600, 1:1000 and 1:1500, respectively (see Table 3.1). M’Abs were incubated on the slides for 1 
hour at room temperature. Following 3x10  minute washes in PBS-T sections were incubated with 
biotinylated anti-mouse secondary antibody diluted 1:200 in 1% (v/v) horse serum in PBS-T for 1 
hour at room temperature. The sections were washed (3 x 10 minutes) before incubation in 
Vector’s Avidin Biotin Complex (ABC) reagent for 1 hour at room temperature. Sections were 
washed (3 x 10 minutes) in PBS-T before applying Vector’s 3, 3’-Diaminobenzidine (DAB) 
substrate solution for 5 minutes to develop the coloured product. The reaction was stopped by 
washing the sections in water before counterstaining to show the nuclei with Mayer’s 
Haematoxylin. Sections were again washed in water then dehydrated through alcohols, cleared in 
xylene and mounted under coverslips in p-xylene-bis (N-pyridinium bromide) (DPX mountant).
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Table 3.1 Monoclonal antibodies used for immunohistochemistry, their pre-treatments, dilutions and the 
epitope they recognise.
M o n o c lo n a l
A n tib o d y
P r e -d ig e c t io n  e n z y m e s  &
BUFFERS
M o n o c lo n a l  
A n t ib o d y  D ilutio n
E p ito p e
R e c o g n is e d
3B3(-) None 1:1000 1 hour RT
Native
chondroitin
sulphate
3B3(+)
Chondroitinase ABC, 
Keratanase and Keratanase II 
in 100mM tris acetate pH 6.5 
with 5mM 1,10 phenanthroline
1:1000 1 hour RT chondroitin-6- 
sulphate ‘stubs’
2B6 1:1600 1 hour RT chondroitin-4- 
sulphate ‘stubs’
5D4
Chondroitinase ABC in 100mM 
tris acetate pH7.8 with 5mM 1,10 
phenanthroline
1:1500 1 hour RT keratan sulphate
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3.4 Results
Cryosections of chondrocyte-agarose cultures precultured with Foetal Calf Serum (FCS) and 
Phosphitan™C for 14 days to establish an extracellular matrix were immunostained with a variety 
of GAG recognising M’Abs to assess the composition and morphology of the proteoglycans 
secreted by the chondrocytes. The antibodies used and the epitopes they recognise on the GAG 
chains are listed in Table 3.2.
All four of the monoclonal antibodies utilised resulted in strong immunopositive staining 
pericellularly with paler more diffuse staining within the interterritorial matrix. This indicates a dense 
proteoglycan containing extracellular matrix to have been secreted by the chondrocytes suspended 
in agarose during the preculture period. For all four M’Abs control sections were stained in the 
absence of primary antibody or with preimmunised mouse serum and in all four cases these 
controls were blank indicating no detectable non-specific binding (Figures 3.2 -  3.5 A and B). The 
immunopositive staining seen with M’Abs 2B6 and 5D4 (Figures 3.2C and 3.5C, respectively) 
indicate that the secreted matrix contains proteoglycan, since 2B6 recognises chondroitin-4- 
sulphate ‘stubs’ present on deglycosylated proteoglycans such as aggrecan, decorin and biglycan 
(Caterson et al., 1985) and 5D4 recognises epitopes within the keratan sulphate chains of 
aggrecan, fibromodulin and lumican (Caterson et al., 1983). The dark immunopositive staining 
seen with M’Abs 2B6 and 3B3+ (Figures 3.2C and 3.3C, respectively) indicates that the majority of 
the proteoglycan present is in the form of aggrecan since 2B6 recognises chondroitin-4-sulphate 
stubs’, and 3B3+ recognises chondroitin-6-sulphate ‘stubs’, present on deglycosylated aggrecan 
(Caterson et al., 1985, and 1995, respectively). Interestingly, immunopositive staining was 
detected for 3B3- (Figure 3.4C). The presence of 3B3- immunopositive staining in these sections 
indicates epitopes to be present in the chondroitin sulphate chains of aggrecan which are 
characteristic of newly synthesised aggrecan or cartilage undergoing tissue remodelling (Visco et 
al., 1993, Carney eta!., 1992, Slater et al., 1995, and Caterson et al., 1991).
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Table 3.2 Monoclonal antibodies used in the immunohistochemical analysis of the proteoglycans present in 
agarose plugs from the chondrocyte-agarose cultures and the epitopes they recognise within the GAG 
chains and on the ‘stubs’ resulting from digestion of the glycosaminoglycan chains with Chondroitinase ABC.
Mo no clo nal
Antibody
Epito pe  Recog nised
2B6 Chondroitin-4-sulphate ‘stubs’ on aggrecan, decorin & biglycan
3B3(-) Chondroitin-sulphate characteristic of newly synthesised aggrecan
3B3(+) Chondroitin-6-sulphate ‘stubs’ on aggrecan
5D4 Keratan sulphate on aggrecan, fibromodulin & lumican
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(A) No primary 
control
100um
(B) Preimmunised mouse 
serum antibody control
«
* 100um
(C) 2B6 M’Ab
Figure 3.2 Immunohistochemical analysis of chondroitin-4-sulphate stubs present 
in deglycosylated cryosections of chondrocyte-agarose cultures (A) No primary 
antibody control section, (B) Preimmunised mouse serum antibody control section 
and (C) 2B6 stained section
(A) No primary 
control
100um
100um
(B) Preimmunised mouse 
serum antibody control
—
m
*
(C) 3B3+ M’Ab
Figure 3.3 Immunohistochemical analysis of chondroitin-6-sulphate stubs present 
in deglycosylated cryosections of chondrocyte-agarose cultures (A) No primary 
antibody control section, (B) Preimmunised mouse serum antibody control section 
and (C) 3B3+ stained section
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(A) No primary 
control
100um
(B) Preimmunised mouse 
serum antibody control
%
*
*
(C) 3B3- M’Ab
Figure 3.4 Immunohistochemical analysis of chondroitin sulphate stubs on newly 
synthesised aggrecan present in cryosections of chondrocyte-agarose cultures 
(A) No primary antibody control section, (B) Preimmunised mouse serum antibody 
control section and (C) 3B3- stained section
80
h— - — I 
IQOpm
(A) No primary antibody 
control
(B) Preimmunised mouse 
serum antibody control
100pm
(C) 5D4 M’Ab
Figure 3.5 Immunohistochemical analysis of keratan sulphate chains present in 
cryosections of Chondroitinase ABC digested chondrocyte-agarose cultures (A) 
No primary antibody control section, (B) Preimmunised mouse serum antibody 
control section and (C) 5D4 stained section
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3.5 Discussion
Staining of agarose sections with various M’Abs to epitopes within glycosaminoglycan chains and 
on the ‘stubs’ resulting from digestion of the GAG chains with Chondroitinase ABC indicate the 
establishment of an extracellular matrix containing proteoglycans, including aggrecan, to have 
been secreted around the chondrocytes embedded in agarose (Figures 3.2C, 3.3C and 3.5C). This 
matrix is most dense in the pericellular region with a sparser matrix penetrating further out into the 
agarose. This is similar to the matrix described by Ayedelotte and Kuettner in the culture system of 
bovine chondrocytes embedded in agarose (Ayedelotte and Kuettner 1988). Some of the aggrecan 
monomers present contain epitopes characteristic of newly synthesised aggrecan recognised by 
M’Ab 3B3- (Figure 3.4C). This pre-established extracellular matrix will be utilized as a model 
system to investigate the enzymes involved in the catabolism of aggrecan especially ADAMTS-4 
and -5.
3.6 Summary
. A matrix rich in aggrecan was secreted by chondrocytes embedded in agarose during the 
preculture period in the presence of serum
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Chapter 4: Investigation of the Effects of IL-1a on the Aggrecan Present 
in the Extracellular Matrix Secreted by Chondrocyte-Agarose Cultures
4.1 Introduction
The extracellular matrix of chondrocyte-agarose cultures described in Chapter 3 will be utilized as 
a model system to investigate the enzymes involved in extracellular matrix catabolism of aggrecan. 
In order to determine the effect of cytokines on this pre-established matrix, the chondrocyte- 
agarose cultures were treated with interleukin-1 a (IL-1a) following 21 days of preculture (an 
adaptation of the investigation carried out by Aydelotte and Kuettner 1988). In cartilage IL-1 a 
retards synthesis and secretion of matrix macromolecules and can induce matrix proteases such 
as ADAMTS-4 and -5 (Arner et al., 1999) and MMPs (Cawston et al., 1999). IL-1 a signalling is 
extremely rapid and within a few minutes of binding to the cell IL-1 a can induce several 
biochemical processes (Dinarello 1996). High levels of IL-1 in human joint effusions have been 
proposed to be responsible for the cartilage degeneration seen in inflammatory joint disease 
(Tortorella et al., 1999). IL-1 a was used as the catabolic agent as it is known to mimic the 
degradative process involved in the catabolism of articular cartilage in diseases such as 
osteoarthritis and rheumatoid arthritis. The effect of this cytokine treatment on the chondrocyte- 
agarose matrix will be analysed using the DMMB assay to determine the proportion of the 
sulphated GAG in the matrix released to the medium following cytokine treatment. The composition 
of this released sulphated GAG will be analysed by Western blotting using M’Abs which recognise 
neoepitopes generated by cleavage within the interglobular domain (IGD) of the core protein of 
aggrecan (see Figure 4.1).
During aggrecan catabolism cleavage sites are utilised within the IGD of the core protein. 
The Asn341 - Phe342 bond is cleaved by a number of members of the MMP family (Fosang et al., 
1991, 1992, 1993, 1994, 1996 and 1998, Lark et al., 1995, Stracke et al., 2000, and Little et al., 
1999) and results in the amino- and carboxy-terminal neoepitopes ^FFGV... and ...DIPEN341, 
respectively. The ^FFGV... neoepitope is recognised by M’Ab BC-14 and the ...DIPEN341 
neoepitope is recognised by M’Ab BC-4 (see Figure 4.1). The Glu373 -Ala374 bond can be cleaved 
by ADAMTS-4 and -5 (see Chapter 1 Section 1.5.2) and results in the amino- and carboxy-terminal
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neoepitopes 374ARGSV... and ...NITEGE373, respectively. The 374ARGSV... neoepitope is 
recognised by M’Ab BC-3 and the ...NITEGE373 neoepitope is recognised by M’Ab BC-13 (see 
Figure 4.1). Thus the effect of IL-1 a on the rate of proteoglycan release from the matrix may be 
determined, using the DMMB assay, as well as which enzymes are responsible for matrix 
catabolism in this culture system by Western blot analysis with specific neoepitope antibodies 
(Figure 4.1).
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Chondroitin
Sulphate
...KEEE1714 — ,7, 'GLGS... 
Aggrecanase Cleavage
Native
I ink Protein
IGD
G1
Chondroitin 
Sulphate Stubs
Deglycosylated Aggrecanase Cleavage Aggrecanase Cleavage
...NITEGE575 -  JARGSV... ...OELE1480 -  1481GRGT...
MMP Cleavage 4
...DIPEN 41 -  ^ FF G V ... BC.13
Aggrecanase Cleavage
...TAQE1818 - 1820AGEG...BC-3
BC-14
Figure 4.1 Diagram of aggrecan structure showing GAG chains, cleavage sites, neoepitopes and specific 
monoclonal antibodies (M’Abs)
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4.2 Materials
• lnterleukin-1 (IL-1)a human recombinant was obtained from Tebu-Bio Ltd., Peterborough, 
UK.
• All other reagents are listed in Chapter 2 Section 2.1.
4.3 Methods
4.3.1 Treatment of Chondrocyte-Agarose Cultures with lnterleukin-1 (IL-1)a
Porcine articular chondrocytes were isolated, embedded in agarose and precultured as described 
in Chapter 2 Section 2.2.1 and 2.2.2. Following the 21 day preculture period the plates were 
washed 3 x 20 minutes in serum free DMEM with 50pg/ml gentamicin before experimental 
conditions were set up as follows: (A) Control culture in serum free DMEM with 50pg/ml gentamicin 
and 25pg/ml Phosphitan™C or (B) Serum free medium (DMEM with 50pg/ml gentamicin and 
25pg/ml Phosphitan™C) containing 10ng/ml IL-1 a, for 24 to 120 hours. Each treatment and culture 
period was carried out on triplicate plates in triplicate experiments giving a total n of 9. Following 
the culture period the medium was removed and stored along with the agarose plugs at -80°C for 
further analysis.
4.3.2 Analysis of Experimental Medium Collected At Time Intervals Following 
Treatment in Serum Free Medium
The metabolic activity of the chondrocytes during the experimental period was analysed using the 
Lactate assay as described in Chapter 2 Section 2.2.5. Proteoglycans present in the agarose plugs 
were extracted as described in Chapter 2 Section 2.2.3. The concentration of sulphated GAG 
released to the culture medium, and present in the guanidine extracts and alkaline (3-eliminations 
was analysed using the DMMB assay described in Chapter 2 Section 2.2.4.
Western blot analysis was carried out on media and guanidine extracts as described in 
Chapter 2 Section 2.2.8. Positive controls for these analyses were prepared as described in 
Chapter 2 Sections 2.2.6 and 2.2.7.
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4.4 Results
4.4.1 Analysis of Lactate and Sulphated GAG Released to Culture Medium at Time 
Intervals Following Treatment in Serum Free Medium
Media samples were analysed using the Lactate assay kit. The results of this analysis show 
treatment with IL-1a to have no effect on the metabolic activity of the chondrocytes present in the 
culture system (results not shown).
The amount of sulphated GAG released to the medium during the treatment time was 
determined using the Dimethyl Methylene Blue (DMMB) assay. The agarose plugs were extracted 
with 4M guanidine HCI at the end of each treatment time, in order to release intact proteoglycan, 
followed by alkaline p-elimination to release any remaining GAG chains (the alkaline p-elimination 
causes release of the GAG chains from the proteoglycan core protein and subsequent removal 
from the agarose matrix). GAG content was determined in both the guanidine extracted and p- 
eliminated agarose plug samples. The total sulphated GAG per culture was then calculated as the 
sum of the GAG concentrations measured in the medium, guanidine extracted and (3-eliminated 
plug samples. The raw data results of all of these analyses are shown in Table 4.1. In addition the 
percentage of the total sulphated GAG present released into the media was calculated as pg GAG 
in medium / total GAG per culture plate x 100. The total GAG per plate was decreased in cultures 
treated with IL-1a compared to control cultures (Table 4.1). An Anderson-Darling test for normality 
showed the differences between the total GAG present in control and IL-1a treated cultures to be 
normally distributed (p-value 0.782). Comparison of the total GAG present per plate in control and 
IL-1 oc treated cultures using a paired t-test gave a p-value of 0.001. Therefore, the increased 
concentration of GAG per plate detected in control cultures compared to those treated with IL-1 a 
was statistically significant. This may be due to known ability of IL-1 a to decrease proteoglycan 
synthesis.
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Table 4.1 Tabulated results of three separate experiments showing the mean GAG (pg) released into the 
culture medium and from guanidine extracted and alkaline p-eliminated agarose plugs of triplicate control 
and IL-1 a (10ng/ml) treated cultures collected over a 120 hour time period. From these mean results the 
total GAG (pg) per plate was calculated and thus the percentage of the total GAG released to the culture 
medium during each treatment and treatment time (%).
Treatment and 
Time
GAG (pg/plate) Percentage of 
total GAG 
Released to 
medium (%)
Media Guanidine
Extract
Alkaline
^-Elimination
Total
Control 24 hrs 46.78 28.52 114.60 189.9 24.6
IL-1 24 HRS 227.92 1.64 54.79 284.4 80.1
Control 48 hrs 124.04 171.30 150.91 446.3 27.8
1—
H
IL-1 48 HRS 256.16 11.33 66.14 333.6 76.8
ZUls
Control 72 hrs 145.72 199.02 110.80 455.5 31.9
OCUJQ.
IL-1 72 HRS 242.10 0.00 18.61 260.7 92.9
XUJ Control 96 hrs 148.76 207.15 79.70 435.6 34.2
IL-1 96 HRS 345.10 0.00 9.35 354.5 97.3
Control 120 hrs 268.26 234.89 37.40 540.6 49.6
IL-1 120 HRS 463.4 0.00 4.4 467.8 99.1
Control 24 hrs 43.95 90.9 266.1 400.95 10.96
IL-1 24 HRS 196.70 2.4 84.2 283.3 69.43
Control 48 hrs 47.15 98.4 268.8 414.35 11.38
CM
H
IL-1 48 HRS 278.75 10.1 69.95 358.8 77.68
ZUJ
S
Control 72 hrs 77.45 145.1 276.9 499.45 15.51
CCUJ0.
IL-1 72 HRS 451.90 7.4 96.5 555.8 81.31
XUJ Control 96 hrs 113.10 229.5 320.5 663.1 17.06
IL-1 96 HRS 570.60 0.0 61.15 631.75 90.32
Control 120 hrs 126.45 371.1 296.7 794.25 15.92
IL-1 120 HRS 490.40 0.0 57.9 548.3 89.44
Control 24 hrs 48.90 90.4 178.23 317.53 15.4
IL-1 24 HRS 155.28 5.6 45.61 206.49 75.2
Control 48 hrs 85.00 100.2 237.69 422.89 20.1
CO
1-
IL-1 48 HRS 228.32 11.3 55.37 294.99 77.4
zUJs
Control 72 hrs 121.70 156.3 224.89 502.89 24.2
OCUJQ.
IL-1 72 HRS 256.16 7.1 53.38 316.64 80.9
XUJ Control 96 hrs 129.38 230.6 130.10 490.08 26.4
IL-1 96 HRS 253.24 4.2 39.79 297.23 85.2
Control 120 hrs 191.86 356.2 89.35 637.41 30.1
IL-1 120 HRS 288.60 0.0 26.47 315.07 91.6
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The yield of intact proteoglycan extracted from the agarose plugs by guanidine extraction 
was relatively low in comparison with the amount of isolated GAG chains extracted by 3- 
elimination (see Table 4.1). This may indicate a tight association between aggrecan present in the 
agarose plugs and other matrix molecules with treatment of agarose plugs by ^-elimination being 
sufficient to release the GAG chains from the matrix.
An Anderson-Darling test for normality showed the differences between the GAG released 
to the medium in control and IL-1 a treated cultures to be normally distributed (p-value 0.553). A 
paired t-test comparing the amount of sulphated GAG released to the medium of control and IL-1 
treated cultures gave a p-value of <0.00001 showing the increased GAG release seen in the IL-1 
treated cultures compared to controls to be statistically significant (see Figure 4.2).
An Anderson-Darling test for normality gave p-values of 0.362 and 0.511 for GAG released 
to the medium of control and IL-1 treated cultures, respectively, indicating the data to be normally 
distributed. A p-value of 0.493 was obtained from a one way Analysis of Variance (ANOVA) for 
comparison of the GAG released to the medium of control cultures at the different treatment time 
points. This indicates no statistical difference in the GAG released to the medium of control 
cultures between the treatment times. A p-value of 0.005 was obtained from a one way ANOVA for 
comparison of the GAG released to the medium of IL-1 a treated cultures at the treatment times 
tested. This indicates a statistically significant difference in the percentage of the total GAG 
released to the medium at the different treatment points in IL-1 a treated cultures. Since treatment 
time in the presence of IL-1 a significantly affects the proportion of the total sulphated GAG 
released to the medium, treatment time must be considered an important factor when analysing 
GAG release in IL-1 a treated chondrocyte-agarose cultures.
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a Individual 95% Confidence Intervals for Percentage of Total GAG Released to Medium in
Control vs IL-1 a (10ng/ml) Treated Cultures:
T reatment Mean Percentage of Total GAG Released in Treatment Time (%)
Control 23.7
IL-1 a 84.3
Control (-*-) 
IL-1 a
20 40 60 80 100
Mean and Spread of Total GAG Released in Treatment Time (%)
b Individual 95% Confidence Intervals for Percentage of Total GAG Released to Medium in 
Control Cultures at Different Treatment Times:
Treatment Time 
(hours)
Mean Percentage GAG Released in Control Cultures in 
Treatment Time (%)
24 16.99
48 19.76
72 23.87
96 25.89
120 31.87
24hr (------------ *------------- )
48hr (-------------*-------------- )
72hr (------------- *------------- )
96hr (-------------- *------------- )
120hr---------------- (-------------- *-------------)
12 24 36
Mean and Spread of Total GAG Released in 
Control Cultures in Treatment Time (%)
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C Individual 95% Confidence Intervals for Percentage of Total GAG Released to Medium in IL-1 a
(10ng/ml) Treated Cultures in Different Treatment Times:
Treatment Time 
(hours)
Mean Percentage GAG Released in IL-1 a Treated Cultures in 
Treatment Time (%)
24 74.91
48 77.29
72 85.04
96 90.94
120 93.38
24hr(--------*---------)
48hr (-------*-------- )
72hr (-------- *-------- )
96hr (-------- *-------- )
120hr ( -------*-------- )
70 80 90 100
Mean and Spread of Percentage of Total GAG Released to Medium in 
IL-1 a Treated Cultures in Treatment Time (%)
Figure 4.2 (a) Shows the mean, and the spread either side of the mean, percentage of the total GAG per 
plate released to the medium in cultures treated in the absence (control) and presence of IL-1 a (10ng/ml) at 
all time points (b) Shows the mean and the spread either side of the mean, percentage of the total GAG per 
plate released to the medium in control cultures at the different time points tested, and (c) Shows the mean, 
and the spread either side of the mean, percentage of the total GAG per plate released to the medium in IL- 
1a (10ng/ml) treated cultures at the different time points tested.
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The mean percentage of the total GAG per culture plate released to the medium during the 
treatment time was expressed as a histogram and is shown in Figure 4.3.
In control cultures only 20 - 30% of the total sulphated GAG present in each plate was 
released into the medium following 120 hours of treatment (see Figure 4.3, and Table 4.1 for raw 
data). In contrast, the release of sulphated GAG to the medium in the cultures exposed to IL-1 a 
occurred rapidly with over 70% of the total GAG being lost to the medium in the first 24 hours. This 
percentage release increased further to 80 - 90% of the total sulphated GAG present being 
released into the medium by 120 hours of treatment (Figure 4.3 and Table 4.1 for raw data).
Sulphated GAG concentration, measured by the DMMB assay, is routinely taken to reflect 
GAG chains on aggrecan; yet, other matrix proteoglycans containing GAG chains such as biglycan 
and decorin may also be present in the samples analysed and contribute to GAG measured using 
the assay. However, the majority of the proteoglycan present in the matrix secreted by 
chondrocytes embedded in agarose was shown to be composed of aggrecan in Chapter 3, the 
contribution of sulphated GAG from other proteoglycans is assumed to contribute minimally to the 
concentrations of GAG measured using the DMMB assay.
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Figure 4.3 Histogram of the mean values for the percentage of the total sulphated GAG released to the 
experimental medium of control and IL-1 a (10ng/ml) treated cultures in the treatment time. Errors shown are 
standard error. Triplicate plates were treated in three experiments giving a total n of 9.
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4.4.2 Analysis of Aggrecan Catabolites by Western Blotting
In order to determine the composition of the aggrecan metabolites in the medium a series of 
Western blots were carried out, under reducing conditions, using previously characterised M’Abs 
which specifically recognise neoepitopes resulting from catalytic cleavage within the aggrecan core 
protein.
Western blot analysis was carried out using M’Abs BC-14 (342FFGV...) and BC-4 
(...DIPEN341) to detect MMP-generated aggrecan catabolites in the deglycosylated media samples 
and guanidine extracts of agarose plugs, (see Figures 4.4 and 4.5), respectively. These results 
showed no MMP-generated aggrecan metabolites to be present in either the control or IL-1 a 
treated cultures at any of the tested treatment times. Thus it may be concluded that no MMP 
activity against aggrecan within the IGD is detectable in this culture system under the conditions 
used.
However, Western blot analysis of deglycosylated media samples showed increased levels 
of aggrecan catabolites bearing the 374ARGSV... neoepitope (recognised by M’Ab BC-3) in the IL- 
1a treated cultures compared to the untreated controls (see Figure 4.6). This indicates that 
treatment of these cultures with IL-1 a has resulted in increased ‘IGD aggrecanase activity’ as 
defined by the presence of aggrecan fragments bearing the 374ARGSV... neoepitope. This 
correlates with the increased release of sulphated GAG to the medium seen in the IL-1 a treated 
cultures compared to controls (see Figure 4.3 and Table 4.1), and indicates that the sulphated 
GAG release seen in these cultures is the result of increased ‘aggrecanase activity’ within the IGD 
of the aggrecan core protein. The aggrecan catabolites detected using BC-3 in the IL-1 a treated 
cultures are high molecular weight products in the range of >250 - 150kD. In the shorter treatment 
times (24 - 48 hours) the higher molecular weight catabolites predominate. With increasing 
treatment time in the IL-1 a cultures the intensity of the lower molecular weight catabolites (~150kD) 
increases as the intensity of the higher molecular weight metabolites (>250kD) decreases. This 
data indicates that the aggrecan catabolites, initially resulting from cleavage within the IGD alone, 
are further degraded at additional sites carboxy-terminal to the IGD to form smaller molecular 
weight species over time in the presence of IL-1 a.
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Western blot analysis showed G1 aggrecan catabolites bearing the ...NITEGE373 
neoepitope (as detected by M’Ab BC-13) to be present in guanidine extracts of agarose plugs at 
time zero, and in both control and IL-1 a treated cultures at all time points investigated (see Figure 
4.7). The presence of aggrecanase-generated aggrecan metabolites in untreated cultures at time 
zero was confirmed by positive immunostaining by Western blot analyses of pre-culture medium 
with M’Ab BC-3 (data not shown). The presence of both BC-13 and BC-3 immunopositive 
aggrecan metabolites in untreated cultures at time zero indicated aggrecanases to be involved in 
the matrix turnover which occurs during the preculture period in the presence of serum.
Following 96 hours of treatment increased levels of immunopositive staining were detected 
(using M’Ab BC-13) in guanidine extracts of agarose plugs from IL-1 a treated cultures compared to 
controls (see Figure 4.7). Following 120 hours of treatment both the control and IL-1 a treated 
cultures show increased levels of immunopositive staining compared to the levels detected at 
earlier time points, excluding 96 hours. This data indicates BC-13 staining does not correspond 
with the BC-3 staining seen in Figure 4.6 i.e. BC-13 positive catabolites do not increase in the IL- 
1a treated cultures at all time points. The variability detected in staining of Western blots may 
reflect the poor extractability of proteoglycans using guanidine HCI, as discussed earlier and 
shown in Table 4.1. In addition, this may be due to loss of the ...NITEGE373 neoepitope through 
trimming by MMPs (Van-Meurs et al., 1999, and Little et at., 2002b). However since no BC-4 
staining was detected (see Figure 4.5) it is unlikely that this trimming was due to MMPs in this 
culture system. Alternatively, cleavage of the aggrecan core protein at the Glu373 - Ala374 bond 
within the IGD may result in loss of both aggrecan catabolites to the medium due to the ‘looser’ 
nature of the matrix produced by this culture system compared to the matrix present in cartilage 
explant cultures. Thus both the carboxy-terminal portion bearing the 374ARGSV... neoepitope 
detected by BC-3 and the amino-terminal portion bearing the ...NITEGE373 neoepitope detected by 
BC-13 could be present in the medium from these cultures. This was confirmed by immunopositive 
staining on Western blots of deglycosylated media samples probed with M’Ab BC-13 (data not 
shown).
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Figure 4.4 Western blot analysis of MMP-generated aggrecan metabolites containing the IGD neoepitope 
^FFGV... detected with M’Ab BC-14. Western blot analysis of media samples from cultures treated in the 
absence (control) or presence of IL-1 a (10ng/ml) for 24 - 120 hours (20pg GAG equivalent per lane). The 
positive control was MMP-13 digested A1D1 (20pg GAG equivalent).
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Figure 4.5 Western blot analysis of MMP-generated aggrecan metabolites containing the IGD neoepitope 
.DIPEN341 detected with M’Ab BC-4. Western blot analysis of guanidine extracts of agarose plugs of 
cultures at time zero and following treatment in the absence (control) or presence of IL-1a (10ng/ml) for 24 - 
120 hours (20pg GAG per lane). The positive control is MMP-13 digested A1D1 (20pg GAG equivalent).
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Figure 4.6 Western blot analyses of aggrecanase-generated aggrecan metabolites containing the IGD 
neoepitope 374ARGSV... detected with M’Ab BC-3. Western blot analysis of media samples from cultures 
treated in the absence (control) or presence of IL-1 a (10ng/ml) for 2 4 -  120 hours (20pg GAG equivalent per
lane).
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Figure 4.7 Western blot analysis of aggrecanase-generated aggrecan metabolites containing the IGD
neoepitope ...NITEGE373 detected with M’Ab BC-13. Western blot analysis of guanidine extracts of agarose 
plugs of cultures at time zero and following treatment in the absence (control) or presence of IL-1a (10ng/ml) 
1 for 24-120 hours (20pg GAG equivalent per lane).
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4.5 Discussion
Agarose cultures were precultured for 21 days to generate an extracellular matrix then washed and 
treated in serum free medium in the absence (control) or presence of IL-1 a for 24 - 120 hours. 
During this treatment time aggrecan (as determined by the release of sulphated GAG) was 
released from the extracellular matrix into the culture medium. In control cultures the proportion of 
the total GAG present in each plate released to the medium increased with treatment time from 
<20% release at 24 hours to >30% release following 120 hours serum free treatment (see Figure 
4.2). In contrast, the addition of IL-1 a to these cultures resulted in the percentage of the total GAG 
released per plate to the medium to be >80% over the same culture period (see Figure 4.2). These 
results are similar to those previously reported for cartilage explants exposed to the same 
treatment. For example Little et al., reported release of >80% of the total GAG present from 
explant cultures treated in the presence of IL-1 for 7 days (Little et al., 2002b). Sandy et al., 
reported release to the medium of only 36% of the total GAG present from explant cultures treated 
in serum free medium for 15 days (Sandy et al., 1991a). The addition of IL-1 a increased this to 
65% of the total GAG being released to the medium over the same culture period (Sandy et al., 
1991a). The differences in the culture period required for release of >50% of the total GAG present 
to the culture medium may be due to the fact that the study by Little et al., used bovine nasal 
cartilage (Little et al., 2002b) whereas in the study carried out by Sandy et al., bovine articular 
cartilage was used (Sandy eta!., 1991a).
Western blot analyses were carried out in order to determine whether fragments released
resulted from cleavage of aggrecan at the two sites within the IGD namely the ...DIPEN341-
“ FFGV... bond and the ...NITEGE373-374ARGSV... bond (Fosang et al., 1995, and Maniglia et al.,
1991, respectively). The absence of immunopositive staining on Western blots of deglycosylated
media samples and guanidine extracts probed with M’Abs BC-14 and BC-4, to detect the MMP-
generated amino- and carboxy-terminal neoepitopes ^FFGV... and ...DIPEN341 respectively,
indicated that there was no MMP activity within the IGD of aggrecan detectable in this culture
system (see Figures 4.4 and 4.5). This is in contrast to previous reports which have detected
MMP-generated aggrecan metabolites in articular cartilage explant cultures treated in serum free
medium for 5 days (Fosang et al., 2000). In these explant cultures no increase was detected in the
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levels of MMP activity against the interglobular domain of aggrecan between cultures treated in the 
absence or presence of IL-1 a for 1-5 days. Therefore the MMP activity against the interglobular 
domain is unlikely to be involved in aggrecan degradation in response to IL-1 a. Little et al., showed 
increased MMP activity against the interglobular domain of aggrecan following treatment of nasal 
cartilage explant cultures in the presence of IL-1 for 21 days (Little et al., 2002b). However, activity 
at the ‘aggrecanase site’ within the IGD of aggrecan was detected in the explant cultures following 
only 7 days of culture in the presence of IL-1, whereas MMP activity against the IGD of aggrecan 
was not detected until 21 days of treatment. In addition MMP activity against the IGD of aggrecan 
was detected at a later time point than MMP activity against type II collagen. Therefore it would 
appear that activity of MMPs against the IGD of aggrecan occurs only in very late stage cartilage 
degradation. In the system used here the treatment period of 120 hours may be insufficient to see 
any effect of IL-1 a on the activity of MMPs for aggrecan. In addition, any background levels of 
MMP turnover of aggrecan in this culture system appear to be below detection limits.
In contrast, BC-3 and BC-13 positive staining were detected in preculture medium (data not 
shown) and agarose plugs at time zero (see Figure 4.7), and were further enhanced in IL-1 a 
treated cultures, strongly indicating aggrecanases to be active during the preculture period and 
treatment regime. The base level of ‘aggrecanase activity’ detected in the agarose cultures prior to 
treatment in serum free conditions is significantly increased in the cultures exposed to IL-1 a (see 
Figure 4.6). Immunopositive staining with M’Ab BC-3 indicates that the release of sulphated GAG 
to the medium, detected by the DMMB assay, was the result of ‘aggrecanase activity’ within the 
IGD of the aggrecan core protein. This corresponds with numerous previously published results, 
which detected increased aggrecanase-generated aggrecan catabolites in the medium of explant 
cultures treated with IL-1 (Gendron et al., 2003, Hughes et al., 1995, and Arner et al., 1998).
This agarose culture system provides a means of rapidly (24 hours compared to 1 week) 
evaluating the effects of IL-1 a exposure on chondrocyte / cartilage metabolism and thus may be 
useful for “high throughput” evaluation of drugs (therapeutic agents) on inhibiting this process.
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4.6 Summary
2 In this chapter the effect of exposure of the aggrecan present in the extracellular matrix of 
chondrocyte-agarose cultures to the catabolic stimulant IL-1 a, was investigated.
2 Aggrecan turnover during the preculture period, in the presence of serum, was shown to be 
due to ‘aggrecanase activity’ within the IGD of the aggrecan core protein (detected using M’Ab 
BC-13).
2 Treatment of chondrocyte-agarose cultures with IL-1 a resulted in increased ‘aggrecanase 
activity’ (detected using M’Ab BC-3) and release of sulphated GAG to the culture medium 
compared to the levels detected in untreated control cultures.
a Thus again the matrix produced by chondrocytes embedded in agarose has been shown to 
mimic the extracellular matrix of articular cartilage and is therefore a useful model system to 
investigate the enzymes involved in degradation of the aggrecan present in this matrix. In this 
chapter these enzymes were shown to be aggrecanases i.e. ADAMTS-4, -5 and -1 (see 
Sections 1.3.5 and 1.5.2).
L
100
Chapter 5: Investigation of ADAMTS-4 and -5 Isoforms Present in 
Chondrocyte-Agarose Cultures
5.1 Introduction
The extracellular matrix produced by the model culture system of chondrocytes embedded in 
agarose was investigated in Chapter 3 and shown to have similarities to the matrix of articular 
cartilage in its proteoglycan composition. In Chapter 4 the effect of exposure of this matrix to the 
catabolic stimulant IL-1 a was investigated. The aggrecan present was degraded by aggrecanases 
and resulted in the release of aggrecan metabolites some of which bear the interglobular domain 
neoepitope 374ARGSV... and were highly sulphated (as measured by the DMMB assay).
As the aggrecanases are now known to include the enzymes ADAMTS-4 and -5 (see Figure 
5.1), reviewed in the Introduction of this thesis (Chapter 1 Section 1.3.5 and 1.5.2), and are thought 
to be key players in the degradation of aggrecan in diseases such as osteoarthritis and rheumatoid 
arthritis, their presence and contribution to the degradation of aggrecan in the culture system of 
chondrocytes embedded in agarose was investigated.
Little is known of the mechanisms of action of ADAMTS-4 and -5 in cartilaginous extracellular 
matrices. In order to investigate the synthesis and secretion of these enzymes, commercially 
available polyclonal antibodies raised against the propeptide and spacer domains of ADAMTS-4 
and -5 were purchased, and a new linear epitope monoclonal antibody (M’Ab) Anti-TS-4N which 
recognises amino acids within the sequence 213FASLSRFV220 present at the amino-terminal end of 
the metalloproteinase domain of ADAMTS-4 (see Figure 5.1), was produced in our laboratory. This 
sequence is thought to form the amino-terminus of the protein in Furin-cleaved ADAMTS-4 (Molloy 
etal., 1992, and Tortorella et al., 1999). Purified furin can cleave the proform of ADAMTS-4 in vitro 
within the consensus sequence 206RPRRAKR212 (Gao et al., 2002). Furthermore, recombinant 
mutants of pro-ADAMTS-4 indicated cleavage to occur at three sites within this sequence
2°6 r p r r 209, 209RAKR212 and 211KR212 (Wang et 2Q04).
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Figure 5.1 Proposed structures of the proforms of ADAMTS-4 and -5  with the Furin cleavage sites indicated 
by the red arrows. The regions recognised by the commercially available polyclonal antibodies are shown. 
Anti-ADAMTS-4 prodomain and Anti-ADAMTS-4 Spacer domain recognise ADAMTS-4, and Anti-ADAMTS-5 
prodomain and Anti-ADAMTS-5 Spacer domain recognise ADAMTS-5. Also indicated is the newly 
characterised monoclonal antibody Anti-TS-4N which specifically recognises the sequence 
213FASLSRFV220 at the amino terminus of the metalloproteinase domain of ADAMTS-4.
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5.2 Materials
• Monoclonal antibody Anti-TS-4N was produced by Dr. Clare Hughes and Dr. Chris Little 
using methods described previously (Hughes et al., 1995).
• Polyclonal antibodies Anti-ADAMTS-4 Prodomain (RP2-ADAMTS-4), Anti-ADAMTS-4 
Spacer domain (RP1-ADAMTS-4), Anti-ADAMTS-5 Prodomain (RP2-ADAMTS-5) and Anti- 
ADAMTS-5 Spacer domain (RP1-ADAMTS-5) were all obtained from Triple Point Biologies 
Inc., Forest Grove, OR, US.
• Horseradish peroxidase linked goat anti-mouse secondary antibody was obtained from 
Amersham, Buckinghamshire, UK.
• Horseradish peroxidase linked goat anti-rabbit secondary antibody was obtained from 
Amersham, Buckinghamshire, UK.
• Blocking agent was obtained from Amersham, Buckinghamshire, UK.
• Enhanced Chemiluminescence (ECL) Western blotting Detection reagent was obtained 
from Amersham, Buckinghamshire, UK.
• Hyperfilm ECL was obtained from Amersham, Buckinghamshire, UK.
• Recombinant human ADAMTS-4 and -5  were a kind gift from Dr. Carl Flannery, Wyeth, 
Boston, US.
• All other reagents were of laboratory grade and are listed in Chapter 2 Section 2.1 and 
Chapter 4 Section 4.2.
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5 ,3  Methods
5.3.1 Specificity of Monoclonal Antibody Anti-TS-4N for Recombinant Human 
ADAMTS-4 by Western Blotting and Chemiluminescence
• Optimisation of Western Blotting using Monoclonal Antibody Anti-TS-4N
Samples (0.5-0.125pg protein per lane) of recombinant human ADAMTS-4 were prepared 
in Laemmli sample buffer (Laemmli 1970) containing 10% (v/v) p-mercaptoethanol and 
electrophoresed under reducing conditions on 10% SDS-PAGE slab gels in running buffer 
The gels were then transferred onto Nitrocellulose membrane (0.22pm) in transfer buffer at 
100V for 60 minutes. Following their electrophoretic transfer the membranes were 
subjected to Western blot analysis. Membranes were blocked in 5% (w/v) Amersham 
blocking agent in PBS-T (10mM phosphate, 2.7mM potassium chloride, 137mM sodium 
chloride pH 7.4 with 0.1% (v/v) tween 20) overnight with constant rocking. The Western 
blots were washed 2 x 5  minutes, 1 x 1 5  minutes and 2 x 5  minutes in PBS-T then 
incubated in monoclonal antibody (M’Ab) Anti-TS-4N diluted 1:100, 1:200 or 1:500 in 1% 
(w/v) blocking agent in PBS-T for 1 hour at room temperature with constant rocking. The 
blots were washed, 2 x 5  minutes, 1 x 15 minutes and 2 x 5  minutes, in PBS-T then 
incubated in horse-radish peroxidase linked goat anti-mouse secondary antibody diluted 
1:1000 in 1% (w/v) blocking agent in PBS-T and incubated on the blots for 1 hour at room 
temperature with rocking. The blots were washed, 2 x 5  minutes, 1x15  minutes and 2 x 5  
minutes, in PBS-T before incubation in Amersham ECL developer solution (50:50 solution A 
and solution B) for 1 minute. The excess liquid was carefully blotted from the membranes 
with tissue before the membranes were placed between two sheets of clear plastic in a light 
proof cassette. The Hyperfilm ECL films were exposed for 1-11/2 hours before development 
in an automated developer (Gevamatic 60 from AGFA Gevaert).
Specificity of Monoclonal Antibody Anti-TS-4N for Recombinant Human 
ADAMTS-4
Recombinant human ADAMTS-4 (1pg) was incubated at 37°C for 20 hours to allow 
autocatalysis to occur (Flannery et al., 2002). Samples (0.5pg protein per lane) were 
prepared in Laemmli sample buffer containing 10% (v/v) p-mercaptoethanol and 
electrophoresed in duplicate on 10% SDS-PAGE gels in running buffer. The gels were then 
transferred onto Nitrocellulose membrane (0.22pm) in transfer buffer at 100V for 60 
minutes. Following their electrophoretic transfer the membranes were subjected to Western 
blot analysis. Membranes were blocked in 5% (w/v) Amersham blocking agent in PBS-T 
overnight with constant rocking.
Concurrently immunising peptide, sequence 213FASLSRFV220 (50pg), was dot 
blotted onto a piece of Nitrocellulose membrane (0.22pm) and allowed to air dry for 20-30 
minutes at room temperature. Optimally diluted Anti-TS-4N (1:200) in 1% (w/v) blocking 
agent in PBS-T was incubated overnight at 4°C on Nitrocellulose membrane, either blank or 
dot blotted with immunising peptide.
Western blots were washed, 2 x 5  minutes, 1 x 1 5  minutes and 2 x 5  minutes, in 
PBS-T then incubated for 1 hour at room temperature with rocking in the Anti-TS-4N 
solutions removed from the dot blotted membranes. The blots were washed, 2 x 5  minutes, 
1 x 15 minutes and 2 x 5  minutes, in PBS-T, then incubated in horse-radish peroxidase 
linked goat anti-mouse secondary antibody diluted 1:1000 in 1% blocking agent in PBS-T 
for 1 hour at room temperature with rocking. The blots were washed, 2 x 5  minutes, 1x15  
minutes and 2 x 5  minutes, in PBS-T, before incubation in ECL Developer solution (50:50 
solution A and solution B) for 1 minute. The excess liquid was carefully blotted from the 
membranes with tissue before being placed between two sheets of clear plastic in a light 
proof cassette. The ECL films were exposed for 1-11/2 hours before development in an 
automated developer (Gevamatic 60 from AGFA Gevaert).
5,3i  Characterisation of Monoclonal Antibody Anti-TS-4N and the Commercially 
Obtained Polyclonal Antibodies Recognising Protein Domains in Recombinant 
Human ADAMTS-4 and -5
Recombinant human ADAMTS-4 (1pg) was incubated at 37°C for 20 hours to allow autocatalysis 
to occur (Flannery et al., 2002). Samples (1pg protein per lane) of recombinant human ADAMTS-4 
tautocatatysed) and recombinant human ADAMTS-5 were prepared in Laemmli sample buffer 
(Laemmli 1970) containing 10% (v/v) p-mercaptoethanol and electrophoresed under reducing 
condtions on 10% SDS-PAGE slab gels in running buffer. The gels were then transferred onto 
Nitrocellulose membrane (0.22pm) in transfer buffer at 100V for 60 minutes. Following their 
electrophoretic transfer the membranes were subjected to Western blot analysis. Membranes were 
blocked in 5% (w/v) Amersham blocking agent in PBS-T for a minimum of 1 hour with constant 
rocking. The Western blots were washed 2 x 5  minutes, 1x15 minutes and 2 x 5  minutes in PBS-T 
then incubated in optimally diluted monoclonal Anti-TS-4N (1:200) or polyclonal Anti-ADAMTS-4 
Prodomain, Anti-ADAMTS-4 Spacer, Anti-ADAMTS-5 Prodomain and Anti-ADAMTS-5 Spacer (all 
1:1000) overnight at room temperature with constant rocking. The blots were washed, 2 x 5  
minutes, 1 x 15 minutes and 2 x 5  minutes, in PBS-T then incubated in either horse-radish 
peroxidase linked goat anti-mouse secondary antibody, for the Western blots probed with the M’Ab 
(Anti-TS-4N), or horse-radish peroxidase linked goat anti rabbit secondary antibody, for the 
Western blots with the polyclonal antibodies (Anti-ADAMTS-4 Prodomain, Anti-ADAMTS-4 Spacer, 
Anti-ADAMTS-5 Prodomain or Anti-ADAMTS-5 Spacer). Both secondary antibodies were diluted 
1:1000 in 1% (w/v) blocking agent in PBS-T and incubated on the blots for 1 hour at room 
temperature with rocking. The blots were washed, 2 x 5  minutes, 1x15 minutes and 2 x 5  minutes, 
in PBS-T, before incubation in Amersham ECL developer solution (50:50 solution A and solution B) 
fa 1 minute. The excess liquid was carefully blotted from the membranes with tissue before the 
membranes were placed between two sheets of clear plastic in a light proof cassette. The 
Hyperfilm ECL films were exposed for 1-1V2 hours before development in an automated developer 
(Gevamatic 60 from AGFA Gevaert).
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5,3 .3  Silver Stain of Recombinant Human ADAMTS-5
Recombinant human ADAMTS-5 (1pg protein) was prepared in Laemmli sample buffer (Laemmli 
1970) containing 10% (v/v) p-mercaptoethanol and electrophoresed under reducing conditions on 
10% SDS-PAGE slab gels in running buffer. The gel was prefixed in 30% (v/v) ethanol and 10% 
(v/v) acetic acid in MilliQ™ water overnight with rocking. The gel was rinsed 2 x 10  minutes in 10% 
(v/v) ethanol in MilliQ™ water, then 3 x 10 minutes in MilliQ™ water before soaking in 5pg/ml 
dithiothreitol (DTT) for 30 minutes. The DTT solution was poured off and without rinsing 0.1% (w/v) 
silver nitrate solution was added for 30 minutes. The gel was rinsed once with a small volume of 
MilliQ™ water, then twice with 100ml developer (50pl 37% (v/v) formaldehyde in 100ml 3% (w/v) 
sodium carbonate, anhydrous) until the desired level of staining was obtained. Staining was 
stopped by addition of exactly 5ml of 2.3M citric acid to the developer and incubation for 10 
minutes with rocking. The gel was washed thoroughly with several changes of MilliQ™ water.
5.3*4 Western Blot Analysis of ADAMTS-4 and ADAMTS-5 Isoforms Present in Media 
Samples and Detergent Extracts of Agarose Plugs
Heparin and zinc chelator column eluents or detergent extracts of agarose plugs (prepared in 
Chapter 4 Section 4.3.1 and Chapter 2 Sections 2.2.9 and 2.2.10) (all 50pl per lane) along with 
recombinant human ADAMTS-4 and -5  (0.5pg per lane) were prepared in Laemmli sample buffer 
containing 10% (v/v) p-mercaptoethanol and electrophoresed in duplicate on 10% SDS-PAGE gels 
in running buffer. The gels were then transferred onto Nitrocellulose membrane (0.22pm) in 
transfer buffer at 100V for 60 minutes. Following their electrophoretic transfer the membranes were 
subjected to Western blot analysis as described in Chapter 5 Section 5.3.2.
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5^ 5 Analysis of ‘Aggrecanase Activity’ of Heparin and Zinc Chelator Bound Media 
Samples from IL-1 a Treated Cultures Against the IGD of Purified Aggrecan (A1D1)
Purified aggrecan (A1D1) was prepared as described in Chapter 2 Section 2.2.6. To aliquots of 
A1D1 (100pg GAG equivalent) was added 300pl Heparin-Sepharose or Zinc Chelator column 
eluents (see Section 5.3.6) with 1/10 volume 10x buffer (20mM tris, 100mM sodium chloride, 
10mM calcium chloride, pH 7.5 with 2.5% (v/v) triton) in the absence or presence of M’Ab Anti-TS- 
4N(500mI) or control M’Ab 70.6 Anti-Decorin (500pl). The digestions were incubated at 37°C for 24 
hours before precipitation of the chondroitin sulphate bearing aggrecan fragments using 
cetylpyridinium chloride (CPC).
To the digestion mixtures was added a 1/10-volume 10x sodium sulphate buffer (0.5M 
sodwm sulphate). Cetylpyridinium chloride (CPC) solution (10% [w/v] in MilliQ™ water) was added 
drop wise at room temperature until a precipitate formed. The precipitate was spun down at room 
temperature at 2000 x g for 5 minutes and the supernatant discarded. The pellets were washed 
twice in 0.05% (w/v) CPC solution (4ml) to remove any sodium ions then resuspended in 0.5ml 
80% (v/v) propan-1-ol in water. To the mixtures was added 100pl saturated sodium acetate 
solution (1g/8ml in MilliQ™ water), 1 drop acetic acid and 3ml cold ethanol and they were left to 
precipitate overnight at 4°C. The precipitate was spun down at 2000 x g for 5 minutes, the 
supernatant discarded and the pellets dried under a vacuum. The pellets were resuspended in 
0.1M tris acetate pH 6.5 and deglycosylated, dialysed and lyophilised on a speedvac as described 
in Chapter 2 Section 2.8. Following this the samples were reconstituted, in Laemmli sample buffer 
(Laemmli 1970) containing 10% (v/v) p-mercaptoethanol and electrophoresed under reducing 
conditions on 4-12% Tris Glycine gels, transferred and subjected to Western blot analysis with 
M’Ab BC-3 as described in Chapter 2 Section 2.2.8.
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5.4 Results
5,4.1 Optimisation of Western Blot Analysis of Human Recombinant ADAMTS-4 
using Monoclonal Antibody Anti-TS-4N
In order to investigate the possible isoforms of ADAMTS-4 present in various culture systems a 
monoclonal antibody (M’Ab) which recognises amino acids within the sequence 213FASLSRFV220 
present at the amino-terminal end of the metalloproteinase domain of ADAMTS-4, was produced. 
This sequence is thought to form the amino-terminus of the protein in Furin-activated ADAMTS-4 
(Molloy eta!., 1992, Gao et al., 2002, Wang et al., 2004, and Tortorella et al., 1999). A number of 
hybridoma clones were obtained from immunisation of one mouse with the ovalbumen-conjugated 
peptide (213FASLSRFV220), a clone designated Anti-TS-4N reacted strongly in an Enzyme Linked 
Immunosorbant Assay (ELISA) with the immunising peptide, but showed no reactivity with 
unrelated peptide conjugates nor with the carrier protein (results not shown).
In order to determine the optimal quantities of recombinant human ADAMTS-4 used for 
peptide inhibition analysis of the new M’Ab Anti-TS-4N a series of Western blots of samples of 
human recombinant ADAMTS-4 (0.5-0.125pg protein per lane) were probed with a variety of 
dilutions (1:100-1:500) of the antibody.
The results show that detection of 0.5pg human recombinant ADAMTS-4 was achieved at 
all antibody dilutions used. The detection of 0.25pg of protein was attainable with a 1:200 antibody 
dilution, whilst 0.125pg was detected using a 1:100 antibody dilution. For much of the subsequent 
analysis an antibody dilution of 1:100-1:200 was used, dependent on the time of antibody 
incubation.
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:^ ure 5.2 Optimisation of Western blot analysis of recombinant human ADAMTS-4 with monoclonal 
antibody Anti-TS-4N. Samples of recombinant human ADAMTS-4 (0.5, 0.25 and 0.125pg protein) were 
Ejected to Western blot analysis using monoclonal antibody Anti-TS-4N (A) Diluted 1:100, (B) Diluted 
200 and (C) Diluted 1:500.
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512 Specificity of Monoclonal Antibody Anti-TS-4N for Recombinant Human 
lDAMTS-4 Using Peptide Inhibition Analysis
1 order to confirm the specificity of the monoclonal antibody Anti-TS-4N for ADAMTS-4 in Western 
$ analysis a peptide inhibition was carried out. The optimal antibody dilution was determined as 
100 for immunolocalisation of 0.125pg autocatalysed human recombinant ADAMTS-4 using 
Western blotting and ECL as the detection method (see Figure 5.2). Hence a 1:100 dilution of Anti- 
'S-4N was pre-incubated with nitrocellulose membranes, dot blotted with or without 
TASISRFV220 ovalbumen conjugated peptide (50pg protein) and subsequently blocked to 
jfwent non-specific binding, prior to incubation with membranes containing 0.125pg of human 
ttombinant ADAMTS-4. The results shown in Figure 5.3 demonstrate in the absence of pre- 
asorption of the antibody with peptide conjugate, Anti-TS-4N immunostains 4 bands of 75, 55, 45 
3nd40kD (Figure 5.3A). However, in the presence of competing antigen no staining was observed 
Fgure5.3B). This inhibition was specifically caused by the immunising peptide and was not due to 
#TS-4N sticking to the membrane of the dot blot, since membrane used as a control, blocked 
j^notpre-absorbed with peptide, did not affect Anti-TS-4N binding (Figure 5.3A). In conclusion, 
ttbandsseen by Western blot analysis with Anti-TS-4N are all isoforms of ADAMTS-4 containing 
i*linear sequence 213FASLSRFV220 at the amino-terminal end of their metalloproteinase domain, 
a^bsorption of Anti-TS-4N with the immunising peptide conjugate results in the loss of this 
staining (Figure 5.3B).
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gure 5.3 Specificity of M’Ab Anti-TS-4N for recombinant human ADAMTS-4 using peptide inhibition 
inalysis. Samples of autocatalysed recombinant human ADAMTS-4 (0.125pg protein per lane) were 
objected to Western blot analysis using M’Ab Anti-TS-4N. Anti-TS-4N (diluted 1:100) was preincubated on 
A) BSA blocked membrane and (B) Membrane dot blotted with ovalbumen-conjugated immunising peptide 
FASLSRFV220) prior to BSA blocking.
112
5,iJ Characterisation of ADAMTS-4 and -5  Mono- and Polyclonal Antibodies Using 
Hjcombinant Human ADAMTS-4 and -5 Protein Preparations
SOTples of recombinant human ADAMTS-4 and -5  (0.5pg protein per lane), which had been 
globed to undergo autocatalysis, were electrophoresed under reducing conditions on 10% SDS- 
PAGEslab gels and subjected to Western blot analysis using the mono- and polyclonal antibodies 
feCognising various domains of ADAMTS-4 and -5. The results of these analyses are shown in 
Figure 5.4.
The polyclonal antibody raised against the amino-terminal prodomain of ADAMTS-4 did not 
Med any bands of ADAMTS-4 protein indicating that none of the recombinant human protein is 
released with its prodomain intact (Figure 5.4A). The newly characterised M’Ab, Anti-TS-4N, which 
recognises the amino-terminus of the metalloproteinase domain of ADAMTS-4 detected a series of 
lads of ADAMTS-4 protein at -75, 55 and 45kD (Figure 5.4B). The predicted molecular weight of 
Fuin-ectivated human ADAMTS-4 is 67.9kD, therefore it is assumed that the 75kD isoform 
represents the mature Furin-activated form of ADAMTS-4 and the smaller isoforms result from 
2Utoc8talysis of the enzyme within its carboxy-terminal domains (Flannery etal., 2002). Indeed, the 
55and45kD isoforms have been previously described and shown to result from carboxy-terminal 
miction of the protein (Flannery et ai, 2002). However, interestingly, the polyclonal antibody 
reisti against a peptide sequence in the carboxy-terminal spacer domain of ADAMTS-4 
recognised the same three isoforms of ADAMTS-4 protein as Anti-TS-4N (Figure 5.4C). As 
epfed there was no immunoreactivity seen with any of these three antibodies against the 
recombinant human ADAMTS-5.
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:pe 5.4 Western blot analyses of recombinant human ADAMTS-4 (TS-4) and ADAMTS-5 (TS-5) (0.5pg 
:Ttein per lane). Western blots were probed with antibodies to (A) The amino-terminal prodomain of 
0AMTS4 (aTS-4 Pro), (B) The amino-terminus of the metalloproteinase domain of ADAMTS-4 (aTS-4N),
- The carboxy-terminal spacer domain of ADAMTS-4 (aTS-4 Spacer), (D) The amino-terminal prodomain 
ADAMTS-5 (aTS-5 Pro), (E) The spacer domain of ADAMTS-5 (aTS-5 Spacer) and (F) Silver stain for 
M protein.
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The polyclonal antibody raised against the amino-terminal prodomain of ADAMTS-5 
detected a series of bands in the recombinant ADAMTS-5 protein preparation at 105, 90, 3 0 , 2 7 , 
20 and 15kD (Figure 5.4D). The predicted molecular weight of the zymogen form of human 
ADAMTS-5 is 101.7kD, this strongly suggests that the isoforms detected at 105 and 90kD may 
represent an intact zymogen form of the enzyme. The difference between the 105 and 90kD 
isoforms may be the result of variable glycosylation of the enzyme. The smaller ADAMTS-5 
isoforms detected are assumed to be the result of extracellular removal of the prodomain by 
enzyme autocatalysis or another enzyme present in the culture system. The small isoforms are not 
detected by the polyclonal antibody to the spacer domain of ADAMTS-5 (Figure 5.4E).
The polyclonal antibody raised against the spacer domain of ADAMTS-5 detected a single 
band in the recombinant ADAMTS-5 protein preparation at ~90kD (Figure 5.4E). This band 
corresponds with the 90kD band detected by the polyclonal antibody raised against the amino- 
terminal prodomain of ADAMTS-5 thus this isoform may be the intact zymogen form of the 
enzyme. Interestingly, the polyclonal antibody to the spacer domain did not detect the 105kD 
isoform of ADAMTS-5 detected by the antibody to the prodomain of the enzyme (Figures 5.4E and 
D, respectively). This may indicate masking of the spacer domain epitope in this isoform.
The predicted molecular weight of Furin-activated human ADAMTS-5 is 73.6kD, therefore 
intriguingly, the antibodies raised against ADAMTS-5 did not detect an isoform corresponding to 
the Furin-activated form in the samples of recombinant protein. As expected there was no 
immunoreactivity seen with either of these two antibodies against the recombinant ADAMTS-4.
Silver staining for total protein present in the preparation of human recombinant ADAMTS-5 
detected bands at 105, 75, 45kD and between 20-35kD (Figure 5.4F). The 75 and 45kD isoforms 
of ADAMTS-5 were not detected by either of the antibodies raised against ADAMTS-5. The 75kD 
isoform detected may be the active Furin processed form of the enzyme (predicted human 
molecular weight 73.6kD).
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5.4 .4  Western Blot Analysis of Detergent Extracted Agarose Plugs at Time Zero
In order to establish whether ADAMTS-4 and -5 are sequestered in the extracellular matrix of the 
model culture system detergent extraction of the agarose plugs was carried out at time zero prior 
to treatment in serum free conditions. The detergent extracts may also contain intracellular and 
membrane-bound / associated proteins. The extracts were electrophoresed under reducing 
conditions on 10% SDS-PAGE slab gels and subjected to Western blot analysis using the series of 
commercially available polyclonal antibodies (characterised in Section 5.4.3) and the M’Ab Anti- 
TS-4N (characterised in Sections 5.4.1, 5.4.2 and 5.4.3). The results are shown in Figure 5.5. 
Interestingly these analyses show multiple isoforms of ADAMTS-4 and -5 to be present. The 
molecular weight of the ADAMTS-4 and -5 isoforms detected in detergent extracts of agarose 
plugs from chondrocyte-agarose cultures differ from those described in Section 5.4.3 for the 
recombinant enzymes. This may be due to species variation as the predicted molecular weights 
and recombinant protein preparations used were human and the chondrocyte-agarose cultures 
used porcine articular chondrocytes.
The ADAMTS-4 and -5 isoforms extracted from agarose plugs were potentially intracellular 
or membrane-bound / associated, or had been sequestered in the extracellular matrix in the 
agarose plugs during the 21 day preculture period in the presence of serum.
All of the antibodies raised against the domain-sequences in ADAMTS-4 detected an 
immunopositive band at 100kD (Figure 5.5 A-C). The 100kD bands detected by the anti-ADAMTS- 
4 antibodies may represent the intact zymogen form of the enzyme (human predicted molecular 
weight 90.2kD). Alternatively, it may represent a variety of cassette forms of the enzyme 
associated with other intracellular molecules or extracellular matrix components. The three anti- 
ADAMTS-4 antibodies also detect bands at 75 and 55kD as well as a broad band at ~60kD 
(Figures 5.5 A-C). The 75 and 60kD bands detected by M’Ab, Anti-TS-4N, (Figure 5.5B) and the 
polyclonal antibody to the spacer domain of ADAMTS-4 (Figure 5.5C) may represent intact Furin- 
activated forms of ADAMTS-4 (human predicted molecular weight 67.9kD). The polyclonal 
antibody to the prodomain of ADAMTS-4 also detected an immunopositive band at 250kD, which 
may correspond to ADAMTS-4 associated with extracellular matrix components such as fibronectin 
(Hashimoto et al., 2004) or intracellular molecules.
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Figure 5.5 Western blot analyses of ADAMTS-4 and -5  present in detergent extracts of agarose plugs (30pl 
per lane) at time zero following 21 days preculture. Western blots were probed with antibodies to (A) The 
amino-terminal prodomain of ADAMTS-4 (Anti-TS-4 Pro), (B) The amino-terminus of the metalloproteinase 
domain of ADAMTS-4 (Anti-TS-4N), (C) The carboxy-terminal spacer domain of ADAMTS-4 (Anti-TS-4 
Spacer), (D) The amino-terminal prodomain of ADAMTS-5 (Anti-TS-5 Pro) and (E) The spacer domain of 
ADAMTS-5 (Anti-TS-5 Spacer).
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The polyclonal antibodies raised against sequences in ADAMTS-5 both detect bands at 75 and 
60kD (Figures 5.5D and E). Either of the isoforms detected by the antibody to the spacer domain of 
ADAMTS-5 (Figure 5.5E) may correspond to the Furin processed active form of the enzyme 
(predicted human molecular weight 73.6kD). The 60 and 75kD bands detected by the antibody to 
the prodomain may be smaller carboxy-terminally truncated isoforms of ADAMTS-5 perhaps 
associated with other extracellular matrix or membrane components, or intracellular molecules. 
The antibody to the prodomain of ADAMTS-5 also detects high molecular weight bands at 100 and 
240kD (Figure 5.5D). The 100kD isoform may represent the intact zymogen form of ADAMTS-5 
(predicted human molecular weight 101.7kD). However, the antibody to the spacer domain of 
ADAMTS-5 does not detect this band (Figure 5.5E), possibly due to masking of the epitope. The 
105kD isoform of recombinant human ADAMTS-5 was also not detected by the polyclonal antibody 
to the spacer domain of the protein presumably due to epitope masking (Section 5.4.3, Figure 
5.4E). Alternatively, both the 100 and 240kD bands detected by the antibody to the prodomain of 
ADAMTS-5 may be smaller truncated isoforms of the enzyme complexed with other extracellular 
matrix or membrane components, or residual cleaved prodomain associated with intracellular 
molecules (e.g. Golgi components) that were extracted by the detergent.
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5,4.5 Western Blot Analysis of ADAMTS-4 and -5 Isoforms Present in Detergent 
Extracts of Agarose Plugs Following Treatment in the Presence or Absence of IL1-a
To determine the effects of culture in serum free conditions, with or without stimulation by IL-1a, on 
the isoforms of ADAMTS-4 and -5 seen in detergent extracts of agarose plugs the extracts were 
analysed by Western blotting using a panel of antibodies recognising different domains of the 
enzymes after each time point of the experimental period (see Chapter 4 Section 4.3.1).
Western blot analyses of detergent extracts of agarose plugs from control and IL-1 a treated 
cultures showed a similar banding pattern to that present in the extracts of cultures taken at time 
zero (Figures 5.6 and 5.5, respectively). No discernable differences were detectable between the 
time points tested, therefore the results presented in this thesis are only those from cultures treated 
in the presence or absence of IL-1 a for 96 hours (Figure 5.6).
No differences were detectable between control and IL-a treated cultures in the higher 
molecular weight isoforms present (Figure 5.6). All of the antibodies raised against sequences in 
ADAMTS-4 detected bands at 100, 75 and 55kD as well as a broad band ~60kD (Figures 5.6 A-C). 
The polyclonal antibody to the prodomain of ADAMTS-4 also identified an immunopositive band at 
250kD (Figure 5.6A). The polyclonal antibodies raised against sequences in ADAMTS-5 both 
detected bands at 75 and 60kD (Figures 5.6 D and E). The antibody to the prodomain of ADAMTS- 
5 also detected high molecular weight bands at 240 and 100kD (Figure 5.6D). All of these bands 
are discussed in detail in Section 5.4.4.
The antibody raised against the prodomain of ADAMTS-5 detected a 32kD band in 
detergent extracts of agarose plugs from control cultures, which was absent from extracts of 
agarose plugs from cultures treated with IL-1 a (Figure 5.6D). The antibody raised against the 
spacer domain of ADAMTS-5 detected a 32kD band in detergent extracts of agarose plugs from IL- 
1a treated cultures which was absent from extracts of agarose plugs from control cultures (Figure 
5.6E). These smaller isoforms of ADAMTS-5 may result from catalysis of the enzyme.
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Figure 5.6 Western blot analyses of ADAMTS-4 and -5 isoforms present in detergent extracts of agarose 
plugs (30pl per lane) of chondrocyte-agarose cultures treated in serum free medium in the absence (control) 
or presence of IL-1 a (10ng/ml) for 96 hours. Western blots were probed with antibodies to (A) The amino- 
terminal prodomain of ADAMTS-4 (aTS-4 Pro), (B) The amino-terminus of the metalloproteinase domain of 
ADAMTS-4 (aTS-4N), (C) The carboxy-terminal spacer domain of ADAMTS-4 (aTS-4 Spacer), (D) The 
amino-terminal prodomain of ADAMTS-5 (aTS-5 Pro) and (E) The spacer domain of ADAMTS-5 (aTS-5 
Spacer).
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5.4 .6  Western Blot Analysis of ADAMTS-4 and -5 Isoforms Present in the Culture 
Medium from Control and IL-1 a Treated Chondrocyte-Agarose Cultures
Media was harvested and partially purified via passage over a Heparin-Sepharose column where 
the non-bound fraction from the Heparin-Sepharose column was then subsequently passed over a 
Zinc Chelator column. The heparin and zinc-binding fractions were fractionated by SDS-PAGE 
under reducing conditions and subjected to Western blot analysis with the panel of ADAMTS-4 and 
•5 antibodies (characterised in Sections 5.4.1, 5.4.2 and 5.4.3, and illustrated in Figure 5.1). The 
resulting Western blots showed multiple isoforms of ADAMTS-4 and -5  to be present in the 
medium from both control and IL-1a treated cultures (see Figures 5.7 and 5.8 A-E).
Binding of ADAMTS-4 and -5 isoforms to the heparin column was presumably instigated 
through the GAG binding regions of the enzymes such as the thrombospondin type I repeats, 
cysteine-rich and spacer domains (Flannery et a!., 2002). In contrast, binding to the Zinc-Chelator 
column was mediated via the metalloproteinase domains of the enzymes.
The molecular weight of the ADAMTS-4 and -5 isoforms detected in media samples from 
chondrocyte-agarose cultures differ from those described in Section 5.4.3 for the recombinant 
enzymes. This may be due to species variation as the predicted molecular weights and 
recombinant protein preparations used were human and the chondrocyte-agarose cultures used 
porcine articular chondrocytes.
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• Zinc Chelator Bound Media Fractions
Media Samples Partially Purified via Passage over Heparin-Sepharose and Bound by 
a Zinc Chelator Column
The zinc chelator bound isoforms of ADAMTS-4 and -5  detected showed no differences between 
the time points tested, therefore the data is shown for cultures treated in the presence or absence 
of IL-1 a for 96 hours (Figure 5.7) as this is representative of the results obtained for all time points. 
Staining revealed a complex pattern of bands using the polyclonal antibodies to the prodomains of 
ADAMTS-4 and -5 (Figures 5.7 A and D, respectively), with more simplistic patterns appearing with 
the M’Ab Anti-TS-4N and the polyclonal antibodies to the spacer domains of ADAMTS-4 and -5 
(Figures 5.7 B, C and E, respectively).
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Figure 5.7 Western blot analyses of ADAMTS-4 and -5 isoforms present in media fractions bound to Zinc 
Chelator column and eluted in 35mM imidazole (50jnl per lane) from 21 day chondrocyte-agarose cultures 
treated in serum free medium in the absence (control) or presence of IL-1 a (10ng/ml) for 96 hours. Western 
blots were probed with antibodies to (A) The amino-terminal prodomain of ADAMTS-4 (aTS-4 Pro), (B) The 
amino-terminus of the metalloproteinase domain of ADAMTS-4 (aTS-4N), (C) The carboxy-terminal spacer 
domain of ADAMTS-4 (aTS-4 Spacer), (D) The amino-terminal prodomain of ADAMTS-5 (aTS-5 Pro) and 
(E)The spacer domain of ADAMTS-5 (aTS-5 Spacer).
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A predominant ~70kD zinc chelator bound isoform of ADAMTS-4 was detected by all of the 
antibodies raised against different domains of the enzyme in control and IL-1 a treated cultures 
(Figures 5.7 A, B and C). Immunostaining with all three antibodies strongly suggests multiple forms 
of the enzyme are represented within the relatively broadly stained band. The band may contain a 
proportion of Furin-cleaved ADAMTS-4 (predicted human molecular weight 67.9kD), as well as 
cassette forms of prodomain, and carboxy or metalloproteinase domains or combinations there of, 
alone or associated with other matrix molecules which have been released into the culture medium 
during the treatment period.
The polyclonal antibody to the prodomain of ADAMTS-4 detected numerous high molecular 
weight zinc bound bands between 250 and 100kD in medium from control and IL-1 a treated 
cultures (Figure 5.7A). The 100kD band detected by the polyclonal antibody to the prodomain of 
ADAMTS-4 may represent the intact zymogen form of the enzyme released to the medium 
(predicted human molecular weight 90.2kD). However, this isoform was not detected by antibodies 
to the metalloproteinase or spacer domains of ADAMTS-4 (Figures 5.7 B and C, respectively). 
Therefore the 100 and 250kD isoforms of ADAMTS-4 detected by the antibody to the prodomain 
may represent truncated forms of the enzyme associated with other matrix proteins e.g. fibronectin 
(Hashimoto et a!., 2004).
Both antibodies to the pro- and metalloproteinase domains of ADAMTS-4 detected a zinc 
chelator bound band of 55kD in medium from control and IL-1a treated cultures (Figures 5.7 A and 
B). The polyclonal antibody to the prodomain of ADAMTS-4 detected a ~30kD band in zinc 
chelator bound samples of medium from control cultures which was absent from IL-1 a treated 
cultures (Figure 5.7B). These smaller isoforms of ADAMTS-4 may result from enzyme catalysis.
The predominant ~70kD zinc chelator bound isoform of ADAMTS-5 is detected by both the 
antibodies to the pro- and spacer domains of the enzyme in media samples from control and IL-1 a 
treated cultures (Figures 5.7 D and E). The ~70kD isoform may in part represent the Furin-cleaved 
form of the enzyme (predicted human molecular weight 73.6kD).
The polyclonal antibody to the prodomain of ADAMTS-5 detected high molecular weight 
n^cchelator bound bands, at 250 and 100kD, in media from control and IL-1 a treated cultures at 
all time points tested (Figures 5.7D and E). The 100kD isoform of ADAMTS-5 may correspond to
124
the zymogen form of the enzyme (predicted human molecular weight 101.7kD), however the 
antibody raised against the spacer domain of ADAMTS-5 does not detect this isoform. Therefore 
both the 100 and 250kD isoforms of ADAMTS-5 detected by the antibody to the prodomain of the 
enzyme may correspond to smaller isoforms complexed with other matrix proteins e.g. fibronectin 
(Hashimoto et al., 2004).
The polyclonal antibody to the prodomain of ADAMTS-5 detected low molecular weight zinc 
chelator bound bands, at 55 and 30kD (Figure 5.7D). The 55kD ADAMTS-5 isoform was detected 
in media from control and IL-1 a treated cultures at all time points tested. In contrast, the 30kD 
isoform was detected in media samples from control cultures, but was absent from IL-1 a treated 
cultures (Figure 5.7D). Both of these low molecular weight isoforms may result from enzyme 
catalysis.
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• Heparin-Sepharose Bound Media Fractions
Media Samples Partially Purified via Passage over Heparin-Sepharose
Western blot analysis of the heparin bound fractions reveals a less complex pattern of 
immunopositive bands than those seen in zinc bound media fractions with antibodies recognising 
domains of ADAMTS-4 and -5, perhaps representing non-matrix associated populations of 
enzymes. Interestingly, the predominant heparin bound isoforms of ADAMTS-4 and -5  co-migrate 
at 37kD (Figures 5.8 A - E) with an additional 55kD isoform of ADAMTS-4 detected by the antibody 
to the spacer domain of the protein (Figure 5.8C). The heparin bound 37kD isoforms of ADAMTS-4 
and-5 were detected in increased amounts in IL-1 a treated cultures compared to controls and in 
addition, the intensity of the heparin bound 37kD isoforms of ADAMTS-4 and -5  also increased 
with increasing treatment time. These low molecular weight isoforms may result from enzyme 
catalysis during the catabolism of aggrecan. Alternatively, the co-migrating 37kD isoforms of 
ADAMTS-4 and -5 may result from alternatively spliced forms of the enzymes. The 37kD co- 
migrating isoforms detected by the antibodies to the prodomains of ADAMTS-4 and -5 will be 
inactive due to them possessing a prodomain (Figures 5.8 A and D). The 37kD co-migrating 
isoforms detected by the antibodies to the spacer domains of ADAMTS-4 and -5 are likely to be 
inactive, if they result from enzyme catalysis, as they are too small to contain both the 
metalloproteinase and spacer domains (Figures 5.8 C and E). The 37kD band detected by Anti-TS- 
4N is likely to contain a mixed population of ADAMTS-4 isoforms, including the inactive 37kD 
isoform which is also detected by the antibody to the prodomain of ADAMTS-4, and a Furin 
cleaved catalytically active form of the enzyme (Figure 5.8B).
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Figure 5.8 Western blot analyses of ADAMTS-4 and -5 isoforms present in media fractions bound to a 
Heparin-Sepharose column and eluted in 0.8M sodium chloride (50pl per lane) from 21 day chondrocyte- 
agarose cultures treated in serum free medium in the absence (control) or presence of IL-1a (10ng/ml) (1) 
Control 24 hours, (2) IL-1 a 24 hours, (3) Control 48 hours, (4) IL-1 a 48 hours, (5) Control 72 hours, (6) IL-1 a 
72 hours, (7) Control 96 hours, (8) IL-1a 96 hours, (9) Control 120 hours and (10) IL-1a 120 hours. Western 
blots were probed with antibodies to (A) The amino-terminal prodomain of ADAMTS-4 (Anti-TS-4 Pro), (B) 
The amino-terminus of the metalloproteinase domain of ADAMTS-4 (Ant-TS-4N), (C) The carboxy-terminal 
spacer domain of ADAMTS-4 (Anti-TS-Spacer), (D) The amino-terminal prodomain of ADAMTS-5 ( Anti-TS-5 
Pro) and (E) The spacer domain of ADAMTS-5 (Anti-TS-5 Spacer).
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5.4.7 Presence of ‘IGD Aggrecanase Activity’ in Heparin and Zinc Chelator Bound 
Media Fractions using Exogenous A1D1 as a Substrate
The ‘IGD aggrecanase activity’ of the heparin and zinc chelator bound fractions of medium from 
cultures treated with and without IL-1 a for 96 hours was assessed against purified aggrecan 
(A1D1) using M’Ab BC-3 to detect cleavage at the Glu373-Ala374 bond within the interglobular 
domain of the aggrecan core protein (the ‘IGD aggrecanase site’). No BC-3 positive aggrecanase- 
generated aggrecan fragments were detected in the A1D1 preparation prior to digestion (Figures 
5.9 A and E). No ‘IGD aggrecanase activity’ was detected against the IGD of the aggrecan core 
protein in heparin bound media fractions from control cultures (Figure 5.9B). However, the heparin 
bound media fractions from IL-1 a treated cultures were shown to possess ‘aggrecanase activity’ 
against the IGD of the aggrecan core protein detected using M’Ab BC-3 (Figure 5.9 C and F). The 
IGD aggrecanase activity’ of the zinc chelator bound fractions was extremely variable between 
digests (data not shown). The intensity of ‘IGD aggrecanase activity’ present in the IL-1 a treated 
heparin bound media fractions (i.e. that detected as BC-3 positive staining) was markedly reduced 
by preincubation with M’Ab Anti-TS-4N (Figure 5.9D), but was not significantly decreased by 
preincubation with a control M’Ab (70.6 Anti-Decorin) (Figure 5.9G). This result suggests that 
isoforms of ADAMTS-4 were responsible for the ‘IGD aggrecanase activity’ present in these 
heparin bound media fractions.
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Figure 5.9 Western blot analysis of samples of purified aggrecan (A1D1) digested with heparin bound media 
fractions from cultures treated in the absence (control) and presence of IL-1 a  (10ng/ml) for 96 hours (A) and 
(E) Undigested aggrecan (A1D1), (B) A1D1 digested with heparin column eluent from control cultures, (C) 
and (F) A1D1 digested with heparin column eluent from IL-1 a  treated cultures, (D) A1D1 digested with 
heparin column eluent from IL-1 a  treated cultures following preincubation with MAb Anti-TS-4N and (G) 
A1D1 digested with heparin column eluent from IL-1 a  treated cultures following preincubation with control 
MAb (70.6 Anti-Decorin). Western blots were probed with M’Ab BC-3 detecting the aggrecanase-generated 
interglobular domain neoepitope 374ARGSV... Samples were deglycosylated prior to electrophoretic 
separation.
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5.5 Discussion
In the presence of IL-1 a the aggrecan present in the matrix secreted by chondrocytes 
embedded in agarose is degraded by aggrecanases, two of which have been identified as 
ADAMTS-4 and -5. In order to investigate the secretion, sequestration and activation of ADAMTS- 
4 We report a new monoclonal antibody (M’Ab) Anti-TS-4N, which has been generated against 
amino acids within the sequence 213FASLSRFV220 located at the amino-terminus of the 
metalloproteinase domain of ADAMTS-4. This sequence is thought to form the amino-terminus of 
the protein in Furin cleaved ADAMTS-4 (Molloy et al., 1992, and Tortorella et al., 1999). Purified 
Furin can cleave pro-ADAMTS-4 in vitro within the consensus sequence 206RPRRAKR212 (Gao et 
al., 2002). Furthermore recombinant mutants of pro-ADAMTS-4 indicated cleavage to occur at 
three sites within this sequence 206RPRR209, 209RAKR212 and 211KR212 (Wang et al., 2004). In 
addition, commercially available polyclonal antibodies raised against the pro- and spacer domains 
of ADAMTS-4 and -5, were purchased. The specificity of Anti-TS-4N was determined by Western 
blot analysis with or without immunising peptide (see Figure 5.3).
Anti-TS-4N specifically recognised several isoforms of autocatalysed recombinant human 
ADAMTS-4 at 75, 55, 45 and 40kD (Figure 5.3A). The 55 and 40kD isoforms of ADAMTS-4 have 
been previously described and determined to be the result of carboxy-terminal truncation (Flannery 
et al., 2002). However, the polyclonal antibody to the carboxy-terminal spacer domain also 
recognised these isoforms of ADAMTS-4 (Figure 5.4C). This suggests the presence of mixed 
populations of co-migrating isoforms of ADAMTS-4 where some isoforms have undergone 
carboxy-terminal truncation, as described by Flannery et al., 2002, and others amino-terminal 
truncation, resulting in isoforms of similar molecular weights.
Both of the antibodies raised against ADAMTS-5 recognised a 90kD isoform of the 
recombinant protein (Figures 5.4 D and E) which may represent the intact zymogen form of the 
enzyme (predicted molecular weight 101.7kD). The isolated prodomain of ADAMTS-5, along with 
other carboxy-terminally truncated isoforms of the enzyme, were detected by the polyclonal 
antibody to the prodomain as a series of small bands between 15-30kD (Figure 5.4D). As expected 
the small isoforms were not detected by the polyclonal antibody to the spacer domain of ADAMTS-
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Interestingly, the antibody to the spacer domain of ADAMTS-5 did not detect an
5 (Figure 5 .4 E).
tn the Furin cleaved form (predicted molecular weight 73.6kD) (Figure
isoform corresponding to
iix/er staining for total protein present in the preparation of human recombinant 
5.4E). However, snver
MTS 5 detected bands at 105, 75 and 45kD as well as between 20-35kD (Figure 5.4F). The
is Dredicted to be the Furin cleaved isoform of the enzyme (predicted 75kD isoform deiecieu K
lar weight 73 6kD). Interestingly, the 45kD isoform was also not detected by the antibody to 
h spacer domain of ADAMTS-5 which may be due to masking of the epitope (Figure 5.4E).
The molecular weight of the ADAMTS-4 and -5 isoforms detected in media samples and 
detergent extracts of agarose plugs from chondrocyte-agarose cultures differ from those described 
in Section 5.4.3 for the recombinant enzymes. This may be due to species variation as the 
predicted molecular weights and recombinant protein preparations used were human and the 
chondrocyte-agarose cultures used porcine articular chondrocytes.
Isoforms of ADAMTS-4 and -5 detected in detergent extracts of agarose plugs may be 
sequestered in the extracellular matrix, membrane-bound or associated, or located intracellulariy. 
Western blots, using antibodies to ADAMTS-4 and -5, of detergent extracts from control and IL-1 a 
treated cultures, as well as a time zero matrix, all showed isoforms of ADAMTS-4 and -5 with 
apparent equal staining intensity (Figures 5.5 and 5.6). A 100kD isoform of ADAMTS-4 was 
detected in detergent extracts of agarose plugs by all of the antibodies raised against sequences in 
different domains of the protein (Figures 5.5 A-C and 5.6 A-C) and could represent the zymogen 
form of the enzyme (predicted human molecular weight 90.2kD) (Figure 5.10A). A 110kD isoform 
of ADAMTS-4 was described by Pratta et al., which was detected, using a polyclonal antibody to 
the peptide sequence 394VMAH397 within the metalloproteinase domain of the enzyme, in cell 
lysates from bovine monolayers and predicted to correspond to the intact zymogen form of 
ADAMTS-4 (Pratta et al., 2003). All three antibodies raised against ADAMTS-4 also detected 
bands at 75 and 55kD as well as a broad band at ~60kD (Figures 5.5 A-C and 5.6 A-C). The 75 
nd 60kD bands detected may represent the intact Furin processed active form of ADAMTS-4 
cted human molecular weight 67.9kD) (Figure 5.10C). However, since these bands were also 
sd by the polyclonal antibody to the amino-terminal prodomain of the enzyme (Figures 5.5A 
) this may indicate a truncated protein containing the prodomain associated with other
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(Fiqure 5.10B). A 55kD isoform of ADAMTS-4 was described by Pratta et al., 
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003) and was predicted to result from carboxy-terminal truncation (Flannery et al., 2002, and Gao 
I 2004) However, since the 55kD isoform was detected by the antibody to the spacer domain 
f ADAMTS-4 (Figures 5.5C and 5.6C) this may indicate the presence of isoforms of the enzyme 
which have either undergone carboxy- or amino-terminal truncation resulting in isoforms of similar 
size (Figures 5.10 E and D, respectively). In conclusion staining of these bands with all three 
antibodies suggests the presence of mixed populations of co-migrating isoforms of the enzyme.
A 100kD isoform of ADAMTS-5 was detected by the antibody to the prodomain of the 
protein in detergent extracts of agarose plugs as well as in zinc chelator bound samples of media 
from control and IL-1a treated cultures (Figures 5.5D, 5.6D and 5.7D). This 100kD ADAMTS-5 
isoform may be the zymogen form of the enzyme (predicted human molecular weight 101.7kD) 
(Figure 5.11 A), however as no staining was seen with the antibody to the spacer domain (Figures 
5.5E, 5.6E and 5.7E) it is more likely to be a smaller truncated form complexed with other matrix 
components such as fibronectin (Hashimoto et al., 2004) (Figure 5.11B).
The polyclonal antibodies raised against sequences in ADAMTS-5 both detect bands at 75 
and 60kD in detergent extracts of agarose plugs as well as in zinc chelator bound samples of 
media from control and IL-1 a treated cultures (Figures 5.5 D and E, 5.6 D and E, and 5.7 D and E). 
Either, or both, of the isoforms detected by the antibody to the spacer domain of ADAMTS-5 may 
correspond to the Furin processed active form of the enzyme (predicted human molecular weight 
73.6kD) (Figure 5.11C). The antibody to the spacer domain of ADAMTS-5 also detected a small 
isoform (32kD) of the enzyme in detergent extracts of agarose plugs from cultures treated with IL- 
1a which was absent from control cultures (Figure 5.6E), indicating catalysis of ADAMTS-5 to 
ccur following treatment with IL-1 a in serum free conditions.
Predominantly, high molecular weight isoforms of ADAMTS-4 and -5 failed to bind to the 
Heparin S
epharose column and were bound by the Zinc Chelator column, whereas lower
ular weight isoforms were bound by the Heparin-Sepharose column. Interestingly, many of
the rriol I
6 ar weight zinc bound isoforms of the enzymes, which failed to bind to the
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nosses the thrombospondin type I repeats, cysteine-rich and / or spacer domains 
heparin column, P
g a g  fand therefore heparin) binding. This suggests some form of structural 
thought to mediate u m  *
preventing the GAG binding regions of ADAMTS-4 and -5 from interacting with the
Sepharose column. This structural interference is absent from the smaller molecular 
ht ADAMTS-4 and -5 isoforms allowing them to bind to the heparin column.
The zinc chelator bound isoforms of ADAMTS-4 and -5  detected showed no differences 
b tween the time points tested (Figure 5.7). All of the antibodies to ADAMTS-4 detected a 
dominant ~70kD isoform in media from control and IL-1 a treated cultures (Figures 5.7 A-C), 
which could be the Furin-activated form of the enzyme (predicted human molecular weight 67.9kD) 
(Figure 5 10C). The presence of immunopositive bands of the same molecular weight detected by 
the antibody to the prodomain suggests the presence of mixed populations co-migrating active and
inactive isoforms of ADAMTS-4.
Both antibodies to the pro- and metalloproteinase domains of ADAMTS-4 detected a zinc
chelator bound band of 55kD in medium from control and IL-1 a treated cultures (Figures 5.7 A and 
B). Flannery et al., 2002 described a 55kD isoform of ADAMTS-4 which resulted from autocatalytic 
truncation of the enzyme through loss of the carboxy-terminal spacer domain, which may explain 
the lack of reactivity of the 55kD isoform of ADAMTS-4 with the polyclonal antibody raised against 
the spacer domain of the enzyme (Figure 5.7C). An alternative strategy for production of the 55kD 
isoform of ADAMTS-4 has recently been described by Gao et al., (Gao et al., 2004). GPI-anchored 
MT4-MMP binds to Furin-activated ADAMTS-4 (human predicted molecular weight 67.9kD) and 
cleaves at the Lys694-Phe695 bond within the cysteine-rich domain resulting in a ~55kD isoform 
(Figure 5.1 OE) with an increased ability to cleave aggrecan at the ‘aggrecanase site’ compared to 
the 67.9kD isoform (Gao et al., 2004).
The predominant ~70kD zinc chelator bound isoform of ADAMTS-5 was detected by both 
the antibodies to the pro- and spacer domains of the enzyme in media samples from control and 
IL 1a treated cultures (Figures 5.7 D and E). Immunostaining detected by the antibody to the 
spacer domain of ADAMTS-5 suggests that a proportion of this band may represent furin activated 
enzyme (predicted human molecular weight 73.6kD) (Figure 5.11C).
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The polyclonal antibody to the prodomain of ADAMTS-5 detected low molecular weight zinc 
bound bands, at 55 and 30kD (Figure 5.7D). Both of these low molecular weight isoforms
m  result from enzyme catalysis (Figure 5.11G).
The predominant heparin bound isoforms of ADAMTS-4 and -5  all co-migrated at 37kD
_ Q * with an additional 55kD isoform of ADAMTS-4 being detected by the antibody to 
(F ig ures  o . o  m - c ;  w u
h spacer domain of the protein (Figure 5.8C). The 55kD isoform is likely to result from amino- 
terminal truncation of ADAMTS-4 (Figure 5.10D). In detergent extracts of agarose plugs a 55kD 
immunopositive band was detected by all three antibodies to ADAMTS-4 (Figures 5.6 A-C and 5.7 
A C) indicating mixed populations of co-migrating isoforms some of which had undergone amino- 
terminal truncation and others carboxy-terminal truncation (Figures 5.10 D and E, respectively) as 
d escrib ed  by (Flannery et al., 2002, and Gao et al., 2004). In zinc chelator bound media fractions 
55kD isoforms were detected by antibodies to the pro- and metalloproteinase domains of 
ADAMTS-4 (Figures 5.8 A and B). This indicates the mixed population of co-migrating 55kD 
isoforms of ADAMTS-4 detected in detergent extracts of agarose plugs to also be present in the 
experimental culture medium. These were partially separated by Heparin-Sepharose with amino- 
terminally truncated isoforms (Figure 5.10D) binding to the heparin and the carboxy-terminally 
truncated isoforms (Figure 5.10E) binding to the zinc chelator column. This may be due to the 
ability of the carboxy-terminal regions of ADAMTS-4 to interact with sulphated GAGs including 
heparin (Flannery et al., 2002).
The intensity of immunopositive staining of the heparin bound 37kD isoforms of ADAMTS-4 
and-5 increases significantly over the treatment time and in IL-1 a treated cultures compared to 
controls (Figures 5.8A-E). This is similar to previously published results indicating treatment with 
IL-1p to increase the prevalence of lower molecular weight isoforms of ADAMTS-4 in cell lysates 
from bovine chondrocyte monolayers (Pratta et al., 2003). The co-migrating 37kD isoforms of 
ADAMTS-4 and -5 may result from enzyme catalysis either by autocatalysis due to a lack of 
suitable substrate or activation of soluble forms of the enzymes. Agarose cultures treated in the 
presence of IL-1 a release over 70% of the sulphated GAG present to the medium in 24 hours (see 
Chapter 4). Therefore following 24 hours of treatment in the presence of IL-1 a 70% of the 
bstrate for ADAMTS-4 and -5  has been lost to the medium, consequently by 48 hours of
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n the presence of IL-1a the enzymes themselves may be undergoing autocatalysis.
. fnr ceneration of 55 and 40kD isoforms of ADAMTS-4 was recently described
Then again. a ^
* i ,cic n r ru rs  at the cell surface via membrane bound M T 4 -M M P  (Gao et al., 2 0 0 4 ). In jn which catalysis occur* a
e occurs at the Lys694-Phe695 bond within the cysteine-rich domain resulting in athis model cieavay
5kD isoform and at the Thr^-Phe502 bond within the thrombospondin-1 like domain resulting in 
40kD isoform. The 40kD isoform described using human peptide sequence by Gao et al., 2004
h ve a molecular weight of ~37kD in porcine chondrocytes (Figure 5.10 F and G). A similar may na*o
mechanism of cleavage may be proposed for ADAMTS-5 (Figure 5.11G and H). Alternatively, the 
37kD isoforms of ADAMTS-4 and -5  may result from alternative splicing or proteolytic activation of 
the enzyme. Since these 37kD isoforms of ADAMTS-4 and -5  are increased in IL-1u treated 
cultures compared to controls they may play a role in the increased ‘IGD aggrecanase activity’ 
detected in these cultures (see Chapter 4).
The heparin bound media fractions from cultures treated with IL-1 a for 96 hours possess 
activity against the Glu373-Ala374 bond (‘aggrecanase site’) within the interglobular domain of the 
core protein of purified aggrecan (A1D1) (Figures 5.9 C and F). This ‘IGD aggrecanase activity' 
was decreased by preincubation with monoclonal antibody Anti-TS-4N. This indicates the ‘IGD 
aggrecanase activity’ of the heparin bound media fractions to be mainly due to ADAMTS-4 
isoforms containing the sequence 213FASLSRFV220. Therefore a proportion of the 37kD heparin 
bound isoforms of ADAMTS-4 detected by Anti-TS-4N possess ‘IGD aggrecanase activity’. 
Previously published data indicated ADAMTS-4 to be the key player in IL-1 induced ‘IGD 
aggrecanase activity'. Immunodepletion of ADAMTS-4 from the medium of IL-1 stimulated bovine 
articular cartilage explants led to a 75% reduction in ‘IGD aggrecanase activity’ against purified 
exogenous aggrecan as detected using a BC-3 ELISA. In contrast, immunodepletion with an 
ADAMTS-5 antibody decreased the detected ‘IGD aggrecanase activity’ by only 15% (Tortorella et 
a/., 2001). Furthermore it has recently been reported that carboxy-terminal truncation enhances the 
IQD aggrecanase activity’ of ADAMTS-4 (Gao et al., 2002, and Kashiwagi et al., 2004), thus 
^plying a role for the carboxy-terminally truncated 37kD isoforms of ADAMTS-4 and, possibly - 5, 
nthe increased ‘IGD aggrecanase activity’ seen in the presence of IL-1 a (Chapter 4).
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Figure 5.10 Potential ADAM TS-4 isoforms (A) Full length zymogen form of ADAMTS-4 (human predicted 
molecular weight 90.2kD) detected by all antibodies to ADAMTS-4 (B) Isolated prodomain of ADAMTS-4  
(approximate molecular weight ~16kD) detected by antibody to the prodomain of ADAMTS-4 (Anti-ADAMTS- 
4 Prodomain). (C) Furin-activated intact ADAMTS-4 (human predicted molecular weight 67 9kD) detected by 
antibodies to the metaiioproteinase and spacer domains of ADAMTS-4 (Anti-TS-4N and Anti-ADAMTS-4 
Spacer Domain, respectively) (D) Amino-terminally truncated ADAMTS-4 isoform detected by the antibody 
to the spacer domain of ADAM TS-4 (Anti-ADAMTS-4 Spacer Domain) (E) Fuhn cleaved ADAMTS-4 isoform 
cleaved within the cysteine-rich domain by MT4-MMP at the Lys^-Phe®*5 bond (Gao et al 2004) and 
detected by the antibody to the metaiioproteinase domain of ADAMTS-4 (Anti-TS-4N) (F) Fuhn cleaved 
ADAMTS-4 isoform cleaved within the thrombospondin-1 like domain by MT4-MMP at the Thr^ ’-Phe5"  bond 
(Gaoeta/., 2004) and detected by the antibody to the metaiioproteinase domain (Anti-TS-4N (G) ADAMTS- 
4 isoform resulting from cleavage by MT4-MMP at the T h r^ ’ -Phe5*2 site within the thrombospondm-1 type 
domain and detected by the antibody to the spacer domain of ADAMTS-4 (Anti-ADAMTS-4 Spacer domain)
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Figure 5.11 Potential ADAMTS-5 isoforms (A) Full length zymogen form of ADAMTS-5 (human predicted 
molecular weight 101.7kD) detected by both antibodies to ADAMTS-5 (B) Isolated prodomain of ADAMTS-5 
(approximate molecular weight -25kD ) detected by antibody to the prodomain of ADAMTS-5 (Anti-ADAMTS- 
5 Prodomain). (C) Furin cleaved intact ADAMTS-5 (human predicted molecular weight 73 6kD) detected by 
the antibody to the spacer domain of ADAMTS-5 (Anti-ADAMTS-5 Spacer Domain) (D) Carboxy-terminally 
truncated Furin cleaved ADAMTS-5 isoform detected by the antibody to the spacer domain of ADAMTS-5 
(Anti-ADAMTS-5 Spacer Domain) (E) ADAMTS-5 isoform detected by the antibody to the prodomain of the 
enzyme (Anti-ADAMTS-5 Prodomain) (F) Amino-terminally truncated ADAMTS-5 isoform detected by the 
antibody to the antibody to the spacer domain of the enzyme (Anti-ADAMTS-5 Spacer domain) (G) Carboxy 
terminally truncated non Furin cleaved ADAMTS-5 isoform detected by the antibody to the prodomain of 
MTS 5 (Anti-ADAMTS-5 Prodomain). (H) ADAMTS-5 isoform detected by the antibody to the spacer 
domain of the enzyme (Anti-ADAMTS-5 Spacer domain)
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,6 Summary
We report the characterisation of a new M’Ab Anti-TS-4N which specifically recognises amino 
acids within the sequence 213FASLSRFV220 located at the amino-terminus of Furin cleaved
ADAMTS-4.
Multiple isoforms of ADAMTS-4 and -5 were detected in detergent extracts of agarose plugs 
from chondrocyte-agarose cultures treated in the absence or presence of IL-1 a and at time 
zero prior to treatment in serum free conditions, which may represent enzyme isoforms which 
were membrane bound / associated, located intracellularly or sequestered in the extracellular 
matrix. These included potential zymogen, Furin cleaved and truncated enzyme isoforms. 
Several high molecular weight isoforms of ADAMTS-4 and -5 were detected in fractions of 
media samples bound to a Zinc Chelator column. These included potential zymogen, Furin 
cleaved and truncated enzyme isoforms.
No differences were detected between control and IL-1 a treated cultures in the ADAMTS-4 and 
-5 isoforms present in detergent extracts of agarose plugs and zinc chelator bound media 
fractions.
In media fractions bound by a Heparin-Sepharose column a series of low molecular weight co- 
migrating 37kD isoforms of ADAMTS-4 and -5 were detected in apparently increased amounts 
with increasing treatment time and in IL-1 a treated cultures compared to controls.
Heparin bound media fractions from IL-1 a treated cultures, but not controls, possess IGD 
aggrecanase activity’ against exogenous purified aggrecan.
The ‘IGD aggrecanase activity’ of heparin bound media fractions from IL-1 a treated cultures
was ablated by addition of M’Ab Anti-TS-4N. Therefore indicating the ‘IGD aggrecanase
activity’ of heparin bound media fractions to reside in a low molecular weight, 37kD, isoform of 
ADAMTS-4.
Chapter 6: Analysis of Tissue Inhibitor of MetalloProteinase-3 (TIMP-3)
5,1 introduction
Th family of Tissue Inhibitors of MetalloProteinases (TIMPS) currently comprises 4 members in
t i m p  1 2 -3 and -4 These are homologous in sequence and have similar secondaryhumans: i i M r - i ,
d tertiary structures. Mammalian TIMPs are two-domain molecules, having amino-terminal 
domains of -125 amino acids and smaller carboxy-terminal domains of -65 residues. Each domain
is stabilised by three disulphide bonds (Williamson et al., 1990).
TIMP-3 has several properties distinct from those of other TIMPs, which include its ability to 
bind tightly to the extracellular matrix via interaction of its amino-terminal domain with polyanionic 
c o m p o n e n ts  of the extracellular matrix (Pavloff et al., 1992, and Yu et al., 2000). The ammo- 
terminal domain of TIMP-3 has been shown to inhibit the catalytic activity of both ADAMTS-4 and -  
5(Kashiwagi et al., 2001). This interaction is not unique to TIMP-3 as TIMPs-1, -2 and -4 also bind 
to ADAMTS-4, but with much lower affinity than TIMP-3 (Hashimoto et al., 2001). The amino- 
terminal portion of TIMP-3 has been proposed to interact with ADAMTS-4 and -5  via their 
metaiioproteinase domains and is postulated to be their natural inhibitor.
ADAMTS-4 and -5 isoforms were detected sequestered in the matrix in chondrocyte 
agarose cultures (Chapter 5 Sections 5.4.4 and 5.4.5), as well as released to the culture medium 
(Section 5.4.6), in the absence (control) and presence of IL-1 a. Many of these isoforms were 
detected in control cultures and sequestered in the agarose plugs prior to treatment in serum free 
conditions. In order to determine whether these isoforms of ADAMTS-4 and -5 were inactive or 
were being inactivated by the presence of their proposed natural inhibitor, TIMP-3, a polyclonal 
antibody raised against the carboxy-terminal domain of TIMP-3 (RP2T3) was purchased.
Kashiwagi et al., have recently developed a purification method for ADAMTS-4 and -5 using 
a recombinant protein comprising the amino-terminal portion of TIMP-3 (N-TIMP-3) to bind the 
enzymes allowing them to be co-purified by binding of the Tag on the N-TIMP-3 to a nickel agarose
column (Kashiwagi et al., 2004 ). This purification system was used to examine the isoforms of 
ADAMTS-4 anrl r-o present in media samples and detergent extracts of agarose plugs from 
ndrocyte-agarose cultures which were able to bind the amino-terminal domain of TIMP-3.
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Th se isoforms of A D A M T S -4  and -5 were analysed using the mono- and polyclonal antibodies to
. f a d A M T S -4  and -5 described in Chapter 5 (illustrated in Figure 5.1). domains ui “
In addition, the ‘IGD aggrecanase activity’ present in the medium of chondrocyte-agarose 
cultures was analysed against purified porcine aggrecan (A1D1) in the presence and absence of 
full length human recombinant TIMP-3 and the recombinant protein comprising the amino-terminal 
portion of human TIMP-3 (N-TIMP-3).
144
6.2 Materials
• Polyclonal antibody RP2T3 raised against the carboxy terminal region of TIMP-3 was 
obtained from Triple Point Biologies Inc., Forest Grove, OR, US.
• Human recombinant TIMP-3 was obtained from Triple Point Biologies Inc., Forest Grove, 
OR, US.
• Alkaline Phosphatase linked goat anti-rabbit secondary antibody was obtained from Sigma- 
Aldrich, Poole, Dorset, UK.
• N-TIMP-3 was a kind gift from Dr. Masahide Kashiwagi and Professor Hideaki Nagase, 
Impehal College, The Kennedy Institute of Rheumatology, London, UK.
• Nickel-Agarose was obtained from Sigma-Aldrich, Poole, Dorset, UK.
• All other reagents were of laboratory grade and are listed in Chapter 2 Section 2.1 and 
Chapter 4 Section 4.2.
6.3 Methods
6.3.1 Western blot analysis of TIMP-3
Experimental media samples or detergent extracts of agarose plugs (prepared in Chapter 4 
Section 4.3.1 and Chapter 2 Sections 2.2.9 and 2.2.10) (all 50pl per lane) and samples of 
recombinant human TIMP-3 (0.5pg protein per lane) were prepared in Laemmli sample buffer 
(Laemmli 1970) with (reducing conditions) or without (non-reducing conditions) 10% (v/v) 3- 
mercaptoethanol, and electrophoresed on 12% SDS-PAGE slab gels in running buffer. The gels 
were then transferred onto Nitrocellulose membrane (0.22p) in transfer buffer at 100V for 60 
minutes. Following their electrophoretic transfer the membranes were subjected to Western blot 
analysis. Membranes were blocked in 5% (w/v) Bovine Serum Albumen (BSA) in Tris Saline Azide 
(TSA) for a minimum of 1 hour at room temperature with rocking. The membranes were washed 3 
x 10 minutes in Phosphate Buffered Saline with 0.1% Tween 20 (PBS-T) and incubated with 
antibody RP2T3 (a polyclonal antibody to the carboxy terminal region of TIMP-3) diluted 1:1000 in 
1% (w/v) BSA in TSA overnight at room temperature with rocking. The blots were washed 3 x 1 0  
minutes in PBS-T and incubated in alkaline phosphatase linked goat anti-rabbit secondary
145
antibody diluted 1:1000 in 1% (w/v) BSA in TSA for 1 hour at room temperature with rocking. The 
membranes were washed 3 x 1 0  minutes in PBS-T and developed in Nitro Blue Tetrazolium (NBT- 
50mg/ml in dimethylformamide) and 5-Bromo-4-Chloro-3-lndoyl Phosphate (BCIP-50mg/ml in 
dimethylamide), 66pl NBT and 33pl BCIP per 10ml Alkaline Phosphatase (AP) buffer (100mM tris, 
100mM sodium chloride, 5mM magnesium chloride pH 9.55) (adapted from Hughes etal., 1998).
6.3.2 Purification of ADAMTS-4 and -5 Isoforms using N-TIMP-3 and a Nickel- 
Agarose Column
Aliquots of media and detergent extracts of agarose plugs (500pl), from cultures treated in the 
absence (control) or presence of IL-1 a for 96 hours, were added to 100nM human recombinant N- 
T1MP-3 and mixed. The mixture was then dialysed against a 100x volume of wash buffer (50mM 
tr»s HCI pH 7.5 with 100mM sodium chloride and 10mM calcium chloride) overnight at 4°C. An 
aliquot of Nickel-Agarose beads (30pl) were washed 2 x 0.5ml wash buffer. The dialysed solution 
was mixed with the washed Nickel-Agarose beads by inversion at 4°C for 2 hours. The beads were 
washed 2 x 1ml wash buffer and eluted in 30pl elution buffer (50mM tris HCI pH7.5 with 6M urea 
and500mM sodium chloride). The elutions were stored at -80°C until required.
6.3.5 Inhibition of ‘Aggrecanase Activity’ of Heparin and Zinc Chelator Bound Media 
Samples from IL-1 a Treated Cultures, Against the IGD of Purified Aggrecan (A1D1), 
by Preincubation with N-TIMP-3 and Recombinant Human TIMP-3
Purified aggrecan (A1D1) was prepared as described in Chapter 2 Section 2.2.6. To aliquots of 
A1D1 (100|ig GAG equivalent) was added 300pl heparin or zinc chelator bound fractions (see 
Section 5.4.6) with 1/10 volume 10x buffer (20mM tris, 100mM sodium chloride, 10mM calcium 
chloride, pH 7.5 with 2.5% (v/v) triton) in the absence or presence of human recombinant TIMP-3 
(Ipg protein) or the recombinant protein comprising the amino-terminal region of human TIMP-3 
(N-TIMP-3) (100nM). The mixtures were incubated at 37°C for 24 hours before isolation of the 
sulphated GAG bearing aggrecan fragments using cetylpyridinium chloride (CPC) precipitation as 
described in Chapter 5 (Section 5.3.5).
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The samples were reconstituted, in Laemmli sample buffer (Laemmli 1970) containing 10% 
v/v) 3-mercaptoethanol and electrophoresed under reducing conditions on 4-12% Tris Glycine 
gels, electrophoretically transferred and subjected to Western blot analysis with M’Ab BC-3 as 
jescribed in Chapter 2 Section 2.2.8.
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6.4 Results
6.4.1 Western Blot Analysis of TIMP-3 Present in Chondrocytes-Agarose Cultures
n order to determine the effects of culture in serum free conditions and stimulation by IL-1 a on the 
TlMP-3 protein secreted by porcine chondrocytes embedded in agarose, and precultured for 21 
lays, detergent extracts of the agarose plugs and experimental media samples were analysed by 
.Vestern blotting using a polyclonal antibody raised against the carboxy-terminal region of TIMP-3.
Samples of recombinant human TIMP-3 (0.5pg protein per lane), detergent extracts of 
agarose plugs at time zero prior, to treatment in serum free conditions, as well as experimental 
"iedia samples and detergent extracts of agarose plugs from cultures treated with or without IL-1 a 
‘or 24 - 120 hours (all at 50pl per lane) were electrophoresed, under reducing and non-reducing 
oonditions, on 12% SDS-PAGE slab gels, electrophoretically transferred and subjected to Western 
riot analysis using a polyclonal antibody raised against the carboxy-terminal region of TIMP-3. The 
oanding pattern was the same for all time points tested, therefore data is shown for 96 hours 
,reatment time as representative (Figures 6.1 and 6.2).
The antibody to the carboxy-terminal region of the protein detects recombinant human 
TIMP-3 as a doublet at 24 and 27kD under reducing conditions and a single broad band at ~25kD 
jnder non-reducing conditions (Figures 6.2A and 6.1 A, respectively). The predicted molecular 
weight of human TIMP-3 is 21.7kD, however previous analysis by SDS-PAGE has detected bands 
of the glycosylated protein at 30 and 23kD (Triple Point Biologies data sheet). The recombinant 
Human TIMP-3 bands detected are quite diffuse presumably due to variable glycosylation of the 
orotein.
The predominant bands detected in the detergent extracts of agarose cultures were also a 
doublet at 24 and 27kD under reducing conditions (Figures 6.2 B and C). Under non-reducing 
conditions a single broad band at ~25kD is detected (Figures 6.1 B and C). These TIMP-3 bands 
were detected in equal intensity in detergent extracts of agarose plugs from control and IL-1 a 
treated cultures at all treatment times tested (data for 96 hours shown in Figures 6.1C and 6.2C), 
as well as at time zero, prior to treatment in serum free conditions (Figures 6.1 B and 6.2B).
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Figure 6.1 Western blot analysis of samples electrophoresed under non-reducing conditions of (A) 
Recombinant human TIMP-3 (0.5pg protein/lane), (B) Detergent extracts of agarose plugs from cultures at 
time zero, (C) Detergent extracts of agarose plugs and (D) Media samples from agarose cultures following 
treatment in the absence (control) or presence of IL-1 a  (10ng/ml) for 96 hours (all at 50pl/lane).
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:igure 6.2 Western blot analysis of samples electrophoresed under reducing conditions of (A) Recombinant 
uman TIMP-3 (0.5pg protein/lane), (B) Detergent extracts of agarose plugs from cultures at time zero, (C) 
t^ergent extracts of agarose plugs and (D) Media samples from agarose cultures following treatment in the 
j»ence (control) or presence of IL-1a (10ng/ml) for 96 hours (all at 50pl/lane).
The predominant TIMP-3 bands detected in media samples from agarose cultures were a 
joubtet at 24 and 27kD under reducing conditions (Figure 6.2D). Interestingly, the higher molecular 
weight glycosylated form of TIMP-3 is detected in increased intensity in media samples from IL-1 a 
seated cultures whereas in the control cultures the lower molecular weight deglycosylated form of 
IMP-3 predominates. The same doublet of TIMP-3 bands was detected, at 24 and 27kD, in media 
samples under non-reducing conditions and here the lower molecular weight non-glycosylated 
ym of the molecule is detected in increased amounts in control cultures compared to IL-1 a 
seated cultures, however, the higher molecular weight glycosylated form does not predominate in 
IL-1 a treated cultures (Figure 6.1 D).
Staining of detergent extracts of agarose plugs and media samples also revealed a 
somplex pattern of higher molecular weight bands indicating TIMP-3 to be associated with various 
matrix molecules, which may include isoforms of ADAMTS-4 and -5.
In the detergent extracts of agarose plugs under reducing conditions higher molecular 
weight immunopositive bands were detected in detergent extracts of agarose plugs at 37, 40, 55 
and 75kD with a large diffuse band at ~100kD (Figures 6.2 B and C). Linder non-reducing 
Additions bands were detected at 45, 75, 100 and 110kD as well as a broad band at ~55kD 
Figures 6.1 B and C). These bands were detected in equal intensity in extracts of agarose plugs 
om cultures treated in the absence (control) or presence of IL-1 a for all time points analysed 
data for 96 hours is shown in Figures 6.1C and 6.2C), as well as at time zero prior to treatment in 
serum free conditions (Figure 6.1B and 6.2B).
The TIMP-3 immunopositive band(s) visualised in the detergent extracts of agarose plugs 
st~25kD were detected in apparently increased intensity under reducing conditions compared to 
'ion-reducing conditions (Figures 6.2 B and C, and Figures 6.1 B and C, respectively). This 
indicates that some TIMP-3 interactions may be dissociated under reducing conditions which are 
still viable under non-reducing conditions.
Interestingly, the 100kD diffuse TIMP-3 immunopositive band detected in detergent extracts 
Agarose plugs was significantly reduced in intensity under non-reducing conditions (Figures 6.1 
3and C) compared to under reducing conditions (Figures 6.2 B and C). This may indicate TIMP-3 
associated with a very large molecule unable to pass into the SDS-PAGE gel under non-reducing
conditions. The molecular weight of this complex may be massively greater than 100kD as this was 
the highest molecular weight marker visible of 12% SDS-PAGE slab gels.
In media samples under reducing conditions immunopositive bands were detected at 55 
and 90kD as well as a diffuse band at ~100kD (Figure 6.2C). Under non-reducing conditions 
immunopositive bands were detected at 50 and 75kD with a doublet at 100kD (Figure 6.1 C). These 
bands were detected in equal intensity in experimental media samples from control and IL-1 a 
treated chondrocyte-agarose cultures for all treatment times tested (data shown at 96 hours in 
Figures 6.2C and 6.1 C).
The 50, 75 and 90kD TIMP-3 immunopositive bands detected in media samples under non- 
reducing conditions were present at markedly decreased intensity under reducing conditions. The 
25kD TIMP-3 immunopositive bands detected in media samples were markedly increased under 
reducing conditions compared to non-reducing conditions. This suggests that under non-reducing 
conditions TIMP-3 is associated with other molecules resulting in 50, 75 and 90kD immunopositive 
bands which are dissociated under reducing conditions resulting in detection of apparently 
increased amounts of free (~25kD) TIMP-3.
As described above, in detergent extracts of agarose plugs, the diffuse 100kD TIMP-3 
immunopositive band detected in media samples was markedly decreased in intensity under non­
reducing (Figure 6.1 D) conditions compared to under reducing conditions (Figure 6.2D). This may 
indicate TIMP-3 associated with a very large molecule unable to pass into the SDS-PAGE gel 
under non-reducing conditions. The molecular weight of this complex may be massively greater 
than 100kD as this was the highest molecular weight marker visible on 12% SDS-PAGE gels.
5.4.2 Isoforms of ADAMTS-4 and -5  which are Bound by a Recombinant Protein 
Comprising the Amino-Terminal Region of Human TIMP-3 (N-TIMP-3)
lour model chondrocyte-agarose culture system TIMP-3 was detected both sequestered in the 
Tatixand released to the experimental medium. In order to determine whether the TIMP-3 is 
ieracting with isoforms of ADAMTS-4 and -5 identified in the chondrocyte-agarose culture system 
see Chapter 5) a recombinant protein comprising the amino terminal region of human TIMP-3 
abeledwith a His Tag (N-TIMP-3) was used to capture the enzymes. The recombinant TIMP-3 
]roiein was incubated with samples of experimental media or detergent extracts, from cultures 
e^atsd with and without IL-1 a for 96 hours. The N-TIMP-3 and any associated proteins were then 
'etrieved using a Nickel-Agarose column which will bind the His Tag motif of the recombinant 
ttlein. The column was eluted and samples of the bound and non-bound fractions were 
sWrophoresed under reducing conditions on 10% SDS-PAGE slab gels and subjected to 
Western blot analysis using the M’Ab raised against the amino-terminus of the metaiioproteinase 
xmain of ADAMTS-4, Anti-TS-4N (characterised in Chapter 5 Sections 5.4.2 and 5.4.3), as well 
spolyclonal antibodies to the pro- and spacer domains of ADAMTS-4 and -5 (characterised in 
Chapter 5 Section 5.4.3). The results shown in Figure 6.3 demonstrate interactions between N- 
TMP-3 and isoforms of both ADAMTS-4 and -5. The isoforms of ADAMTS-4 and -5 available to 
fldtothe recombinant N-TIMP-3 were those not associated with endogenous TIMP-3 shown to 
3epresent in this culture system (Section 6.4.1). N-TIMP-3 may also compete for binding with 
atw TIMP-3.
In the non-bound supernatant from the Nickel-Agarose column the mono- and polyclonal 
f^oodies to the pro-, metaiioproteinase and spacer domains of ADAMTS-4 and the polyclonal 
n^fibody to the prodomain of ADAMTS-5 detected co-migrating enzyme isoforms at 37kD, which 
W present in increased intensity where the starting material for the column was experimental 
^samples and detergent extracts of agarose plugs from plates cultured in the presence of IL- 
ocompared to where untreated control cultures were used (Figures 6.3 Ai, Bi, Ci and Di).
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W  6.3 Samples of bound and non-bound fractions from Nickel-Agarose column electrophoresed under 
during conditions on 10% SDS-PAGE slab gels and analysed by Western blotting using mono- and 
c^lonal antibodies to various domains of ADAMTS-4 and -5. (i) Non-bound supernatant, and (ii) Bound 
eluent from Nickel-Agarose column of (1) Detergent extracts of agarose plugs treated in serum free 
editions for 96 hours, (2) Detergent extracts of agarose plugs treated in the presence of IL-1 a for 96 hours, 
Media samples from agarose cultures treated in serum free conditions for 96 hours, (4) Media samples 
a^garose cultures treated in the presence of IL-1 a for 96 hours. Western blots were probed with (A) 
■Wonal antibody to the amino-terminal prodomain of ADAMTS-4 (Anti-TS-4 Pro), (B) Monoclonal antibody 
amino-term in us of the metaiioproteinase domain of ADAMTS-4 (Anti-TS-4N), (C) Polyclonal antibody 
carboxy-terminal spacer domain of ADAMTS-4 (Anti-TS-4 Spacer), (D) Polyclonal antibody to the 
n^o-terminal prodomain of ADAMTS-5 (Anti-TS-5 Pro) and (E) Polyclonal antibody to the spacer domain 
A^MTS-5 (Anti-TS-5 Spacer).
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Several additional immunopositive bands corresponding to different isoforms of ADAMTS-4 
and -5 were also detected in the non-bound supernatant from the Nickel-Agarose column 
indicating multiple isoforms of the enzymes to be present in media samples and detergent extracts 
of agarose plugs which were not bound by the N-TIMP-3 (Figures 6.3 Ai, Bi, Ci, Di and Ei) either 
because they lack the necessary binding region for N-TIMP-3 or because they are already strongly 
associated with endogenous TIMP-3.
In the non-bound supernatant from the Nickel-Agarose column the antibodies to the pro- 
and metaiioproteinase domains of ADAMTS-4 detected bands at 75, 60 and 55kD, which were of 
equal intensity in all treatments tested (Figures 6.3Ai Lanes 1-4 and 6.3Bi Lanes 1-4). A single 
immunopositive band was also detected by both antibodies at 70kD in the bound fraction from the 
Nickel-Agarose column using detergent extracts of agarose plugs as the starting preparation 
(Figures 6.3Aii Lanes 1 and 2, and 6.3Bii Lanes 1 and 2), in both control and IL-1 a treated 
cultures. In the media samples, the 70kD fragment was not detected by the antibody to the spacer 
domain of ADAMTS-4 (Figure 6.3Aii Lanes 3 and 4) and was detectable with Anti-TS-4N at 
reduced intensity compared to the levels detected in the detergent extracts of agarose plugs 
(Figures 6.3Bii Lanes 3 and 4, and 6.3Bii Lanes 1 and 2, respectively). Additional 30 and 20kD 
isoforms of ADAMTS-4 were detected with equal intensity in the non-bound supernatant from the 
Nickel-Agarose column where the starting material was detergent extracts of agarose plugs (Figure 
6.3Bi).
Only weak staining was observed with the antibody to the spacer domain of ADAMTS-4. A 
70kD band was detectable in the non-bound fractions which was of equal intensity in all treatments 
tested (Figure 6.3Ci Lanes 1-4). No ADAMTS-4 isoforms were detectable using the antibody to the 
spacer domain of the protein in the bound fraction from the Nickel-Agarose column (Figure 6.3Cii 
Lanes 1-4).
In the non-bound supernatant from the Nickel-Agarose column the polyclonal antibody to 
the amino-terminal prodomain of ADAMTS-5 detected bands at 100, 75, 60, 55 and 30kD, which 
were of equal intensity in all treatments tested (Figure 6.3Di Lanes 1-4). In the bound fraction from 
the Nickel-Agarose column isoforms of ADAMTS-5 were detected with equal intensity at 240 and 
lOOkD using the antibody to the prodomain of the protein (Figure 6.3Dii Lanes 1-4). An additional
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isoform of ADAMTS-5 was detected at 70kD, which was present in increased intensity in the 
detergent extracts of agarose plugs compared to equivalent samples of experimental media 
(Figures 6.3Eii Lanes 1 and 2, and 6.3Eii Lanes 3 and 4, respectively).
The intensity of staining detected with the polyclonal antibody to the spacer domain of 
ADAMTS-5 was very faint with bands detectable in the non-bound fractions at 70 and 55kD which 
were of equal intensity in all treatments tested (Figure 6.3Ei Lanes 1-4). A single ADAMTS-5 
isoform was detected at 60kD, with equal intensity, in the bound fractions from the Nickel-Agarose 
column (Figure 6.3Eii).
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6.4.3 Inhibition of ‘Aggrecanase Activity’ of Heparin and Zinc Chelator Bound Media 
Samples from IL-1 a Treated Cultures, Against the IGD of Purified Aggrecan (A1D1), 
by Preincubation with Recombinant Human N-TIMP-3 and TIMP-3
The heparin and zinc chelator bound media fractions from chondrocyte-agarose cultures treated 
with IL-1 a for 96 hours were assayed for ‘aggrecanase activity’ against the Glu373-Ala374 bond 
within the interglobular domain of aggrecan (detected using M’Ab BC-3) using purified porcine 
aggrecan (A1D1) as a substrate, in the presence and absence of a recombinant protein comprising 
the amino-terminal region of human TIMP-3 (N-TIMP-3) or recombinant human TIMP-3.
The starting preparation of purified A1D1 did not contain any BC-3 positive aggrecan 
catabolites (Figures 6.4 A and E). However, A1D1 digested with heparin bound or zinc chelator 
bound media fractions contained BC-3 positive bands ranging in molecular weight from 30 to 
>250kD (Figures 6.4 B and F, respectively). This indicates that both the heparin and zinc chelator 
column eluents contain ‘aggrecanase activity’ directed against the Glu373-Ala374 bond within the 
interglobular domain of aggrecan. This ‘IGD aggrecanase activity’ appears to be greater in the 
heparin bound media fractions than in the zinc chelator bound media fractions (Figures 6.4 B and 
F, respectively). However the activity in the zinc chelator bound fractions varied between digests 
(data not shown).
Preincubation with N-TIMP-3 or recombinant human TIMP-3 decreased the ‘aggrecanase 
activity’ in digests from both the heparin and zinc chelator bound media fractions (Figures 6.4 C 
and D, and 6.4 G and H, respectively). In conclusion this data indicates that the detectable 
aggrecanase activity’ against the Glu373-Ala374 bond within the interglobular domain of aggrecan 
present in these eluents is inhibited by the amino-terminal domain of TIMP-3.
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Figure 6.4 Western blot analysis using M ’Ab BC-3 of samples of purified A1D1 digested with either heparin 
or zinc chelator bound media fractions from chondrocyte-agarose cultures treated with IL-1 a  (10ng/ml) for 96 
tours (A) and (E) Purified undigested aggrecan (A1D1), (B) A1D1 digested with Heparin-Sepharose column 
eluent, (C) A1D1 digested with Heparin-Sepharose column eluent in the presence of N-TIMP-3 (100nM), (D) 
A1D1 digested with Heparin-Sepharose column eluent in the presence of human recombinant TIMP-3 (1 j-tg), 
(F) A1D1 digested with Zinc Chelator column eluent, (G) A1D1 digested with Zinc Chelator column eluent in 
the presence of N-TIMP-3 (100nM), (H) A1D1 digested with Zinc Chelator column eluent in the presence of 
toman recombinant TIMP-3 (1fig). Samples were deglycosylated prior to electrophoretic separation.
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6.5 Discussion
The presence of TIMP-3 in the medium and sequestered in the matrix of the model chondrocyte- 
agarose culture system was assessed using a polyclonal antibody raised against the carboxy- 
terminal region of the protein. Immunopositive bands were detected at 24 and 27kD (under both 
reducing and non-reducing conditions) in media samples and detergent extracts of agarose plugs 
(Figure 6.1 B, C and D, and 6.2B, C and D). The bands detected under non-reducing conditions 
were Tree’ TIMP-3 i.e. TIMP-3 not associated with any other molecule. Interestingly, the higher 
molecular weight glycosylated form of TIMP-3 was detected in increased intensity under reducing 
conditions in media samples from cultures treated in the presence of IL-1 a, whereas in the 
untreated control cultures the lower molecular weight deglycosylated form of TIMP-3 
predominated. The reason for this variation in the glycosylation of TIMP-3 is unknown. In addition 
to the “free’ TIMP-3, immunopositive bands corresponding to TIMP-3 associated with other matrix 
molecules were detected under both reducing and non-reducing conditions (Figures 6.1 and 6.2). 
These molecules may include ADAMTS-4 and -5. The ability of TIMP-3 to bind to components of 
the extracellular matrix is unique among TIMP family members (Pavloff et al., 1992, and Yu et al., 
2000). Under reducing conditions the high molecular weight bands were decreased in intensity 
compared to under non-reducing conditions. The low molecular weight bands ~25kD were 
increased in intensity under reducing conditions compared to under non-reducing conditions. This 
indicates that in this culture system TIMP-3 forms high molecular weight complexes which are only 
dissociated under reducing conditions.
The above data shows TIMP-3 to be both sequestered in the matrix and released to the
medium of chondrocyte-agarose cultures. The amino-terminal region of TIMP-3 has been shown
previously to be involved in the inhibition of ADAMTS-4 and -5 (Kashiwagi et al., 2001). Therefore
in order to determine whether TIMP-3 is able to interact with the isoforms of ADAMTS-4 and -5
detected in these cultures (described in Chapter 5 Sections 5.4.4, 5.4.5 and 5.4.6) a recombinant
protein comprising the amino-terminal region of TIMP-3 labelled with a His Tag was used (N-TIMP-
3). The N-TIMP-3 and any associated proteins were bound to Nickel-Agarose then eluted. The
bound and non-bound fractions from the Nickel-Agarose column were analysed by Western
blotting using the mono- and polyclonal antibodies to domains of ADAMTS-4 and -5 (characterised
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in Chapter 5 illustrated in Figure 5.1). The results demonstrate an interaction between N-TIMP-3 
and isoforms of ADAMTS-4 and -5 (Figure 6.3).
The polyclonal antibodies to the spacer domains of ADAMTS-4 and -5 both detected only 
very faint immunopositive bands in both the bound and non-bound fractions from the Nickel- 
Agarose column (Figure 6.3 C and E). This may indicate that N-TIMP-3 stearically hinders binding 
of the antibodies to the spacer regions of ADAMTS-4 and -5, and may itself interact with the 
enzymes through their spacer domains. No data is available indicating the region(s) of ADAMTS-4 
and -5 which interact with the amino-terminal region of TIMP-3, however it has been suggested to 
occur through the metaiioproteinase domains of the enzymes.
In the non-bound supernatant from the Nickel-Agarose column the antibodies to domains of 
ADAMTS-4 and the antibody to the prodomain of ADAMTS-5 detected isoforms of the enzymes 
which co-migrate at 37kD. These 37kD isoforms are detected in increased intensity where the 
starting material bound to N-TIMP-3 was media samples or detergent extracts of agarose plugs 
from cultures treated with IL-1 a compared to from untreated control cultures. Therefore these 37kD 
co-migrating isoforms most likely correspond to those detected in the heparin bound media 
samples described in Chapter 5 Section 5.4.6 and resulting from enzyme catalysis or alternative 
splicing. These 37kD co-migrating isoforms have been proposed to be the active form of the 
enzymes since they were detected in increased amounts in heparin bound media samples from IL- 
1a treated cultures compared to untreated controls (Chapter 5). Interestingly, no 37kD isoforms of 
ADAMTS-4 or -5 were detected in the detergent extracts of agarose plugs prior to incubation with 
N-TIMP-3 (Chapter 5 Sections 5.4.4 and 5.4.5). The significance of this observation is at present 
unknown.
Several additional immunopositive bands corresponding to ADAMTS-4 and -5 were 
detected in the non-bound supernatant from the Nickel-Agarose column indicating multiple 
isoforms of the enzymes to be present which are not bound by exogenous N-TIMP-3 (Figures 6.3 
Ai, Bi, Ci, Di and Ei). These isoforms of ADAMTS-4 and -5 may lack the domains required for 
interaction with N-TIMP-3 or may already be associated with endogenous TIMP-3 previously 
shown to be present in this culture system (Section 6.4.1).
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In the bound fractions from the Nickel-Agarose column the major immunopositive band was 
detected at 70kD by the antibodies to the pro- and metalloproteinase domains of ADAMTS-4 and 
antibodies to the pro- and spacer domains of ADAMTS-5 (Figures 6.3 Ai, Bi, Di and Ei). The 70kD 
isoform detected by the antibody to the prodomain of ADAMTS-4 was detected only in the bound 
fraction from Nickel-Agarose columns where the starting preparation had been detergent extracts 
of agarose plugs (Figure 6.3Aii). The 70kD isoforms detected by the antibodies to the 
metalloproteinase domain of ADAMTS-4 and the pro- and spacer domains of ADAMTS-5 were 
detected in increased intensity in the bound fraction from Nickel-Agarose columns where the 
starting material was detergent extracts of agarose plugs compared to those where the starting 
material was media samples (Figures 6.3 Bii, Dii and Eii). The 70kD isoforms of ADAMTS-4 and -5 
may correspond to the 70kD zinc chelator bound isoforms of ADAMTS-4 and -5 described in 
Chapter 5 Section 5.4.6. The 70kD band detected by the antibodies to the metalloproteinase 
domain of ADAMTS-4 and the spacer domain of ADAMTS-5 may represent the Furin-activated 
forms of the enzymes (predicted human molecular weights 67.9 and 73.6kD, respectively). The 
presence of 70kD immunopositive bands detected by the antibodies to the amino-terminal 
prodomains of ADAMTS-4 and -5 indicates the presence of co-migrating ‘active’ and ‘inactive’ 
isoforms of ADAMTS-4 and -5. Additional immunopositive bands were detected by the antibody to 
the prodomain of ADAMTS-5 at 100 and 240kD (Figure 6.3Dii), these may correspond to the 
isoforms of ADAMTS-5 detected at 100 and 240kD in both detergent extracts of agarose plugs and 
zinc chelator bound fractions of media samples in Chapter 5 Sections 5.4.4, 5.4.5 and 5.4.6. The 
lOOkD isoform may be the zymogen form of ADAMTS-5 (predicted human molecular weight 
101.7kD), however, since it was not detected by the antibody to the spacer domain of the enzyme 
these may be smaller carboxy-terminally truncated isoforms of ADAMTS-5 associated with other 
matrix molecules such as fibronectin.
This data is in contrast to results already published using N-TIMP-3 and a Nickel-Agarose 
column as a purification method (Kashiwagi et ai, 2004). In the previous study isoforms of 
ADAMTS-4 were isolated from guanidine HCI extracts of porcine articular cartilage explants 
cultured with IL-1a for 3 days. The isoforms were detected with an antibody to the 
metalloproteinase domain of ADAMTS-4 at 46, 40 and 37kD. In the present study none of the co-
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g^rating 37kD isoforms of ADAMTS-4 detected were bound by N-TIMP-3. This may be due to the 
jfferent methods used to extract ADAMTS-4 from the extracellular matrix. ADAMTS-4 isoforms 
associated with endogenous TIMP-3 may be dissociated by guanidine HCI extraction, allowing the 
flAMTS-4 isoforms to interact with the exogenous N-TIMP-3, whereas the methods employed in 
die present study use detergent to extract the enzyme isoforms and may not dissociate them from 
any endogenous TIMP-3.
Media fractions, partially purified via passage over a Heparin-Sepharose column, followed 
jyaZinc Chelator column, were assayed for ‘IGD aggrecanase activity’ against the Glu373-Ala374 
jond within the IGD of aggrecan, using purified porcine aggrecan (A1D1) as a substrate. Digests 
were preincubated in the presence or absence of the recombinant amino-terminal portion of human 
TIMP-3 (N-TIMP-3) or human recombinant TIMP-3. A1D1 digested with either heparin or zinc 
jound media fractions contained BC-3 positive bands ranging in molecular weight from 30- 
>250kD, indicating that the bound fractions from both columns contain ‘IGD aggrecanase activity’. 
The'IGD aggrecanase activity’ was decreased by preincubation with human recombinant TIMP-3 
or N-TIMP-3 (Figure 6.4). Therefore the enzyme(s) possessing ‘aggrecanase activity’ present in 
tie heparin or zinc bound media fractions were inhibited by the amino-terminal region of TIMP-3. 
ADAMTS-4 and -5 have previously been shown to be inhibited by the amino-terminal region of 
TIMP-3 (Kashiwagi et ai, 2001).
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6.6 Summary
q TIMP-3 was present in the culture system of chondrocytes embedded in agarose both in the 
medium and in detergent extracts of agarose plugs.
□ TIMP-3 was present as both Iree’ TIMP-3, i.e. not associated with other molecules, and as 
higher molecular weight complexes some of which are not dissociated even under reducing 
conditions.
□ High molecular weight isoforms of ADAMTS-4 and -5 were shown to interact with the amino- 
terminal domain of TIMP-3.
□ The isoforms of ADAMTS-4 and -5 unable to bind to the amino-terminal region of TIMP-3 may 
lack the domains necessary for this interaction or may be associated with endogenous TIMP-3.
□ Both TIMP-3 and a recombinant protein comprising the amino-terminal domain of TIMP-3 (N- 
TIMP-3) were able to inhibit the ‘IGD aggrecanase activity’ of heparin and zinc chelator bound 
media fractions (described previously in Chapter 5).
q ADAMTS-4 and -5 have been previously shown to be inhibited by both TIMP-3 and N-TIMP-3 
(Kashiwagi eta!., 2001)
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Chapter 7: Investigation of the Effects of Cycloheximide on the 
Presence of ADAMTS-4 and -5 within Extracellular Matrix Secreted by 
Chondrocyte-Agarose Cultures 
7.1 Introduction
In order to determine whether the isoforms of ADAMTS-4 and -5, and the TIMP-3, present in 
experimental chondrocyte-agarose cultures result from de novo protein synthesis in serum free 
conditions, experimental cultures were treated with or without of IL-1a in the presence of 
cycloheximide or its carrier (DMSO). Cycloheximide is an antibiotic produced by Streptomyces 
Griseus. Its main biological activity is the inhibition of translation via blocking of the peptidyl 
synthetase activity of eukaryotic ribosomes (Ma et ai, 2000, and Lusska et ai, 1992) resulting in 
inhibition of protein synthesis leading, at high concentrations, to subsequent cell growth arrest and 
cell death. Cycloheximide is widely used at low concentrations for controlled inhibition of protein 
synthesis and detection of short lived proteins. It has been utilised in previous studies to show that 
the degradative mechanisms leading to the induction of ‘IGD aggrecanase activity’ in cartilage 
explant cultures requires de novo protein synthesis (Arner et al., 1998).
In this chapter the effect of cycloheximide treatment on the extracellular matrix synthesised 
in the model system of chondrocytes embedded in agarose was analysed (using an assay) to 
determine the proportion of sulphated GAG in the matrix which is released to the medium. The 
composition of this released sulphated GAG was also analysed using M’Abs, which detect 
neoepitopes generated by cleavage within the core protein of aggrecan, as described in Chapter 4 
(Figure 4.1). Also in Chapter 4 the aggrecanolysis within the IGD detected in the presence of IL-1a 
was found to be due to the activity of aggrecanases rather than MMPs. Therefore the isoforms of 
ADAMTS-4 and -5  present in the culture system of chondrocytes embedded in agarose were 
investigated in Chapter 5. The effects of cycloheximide on the isoforms of ADAMTS-4 and -5 
present will be analysed using the mono- and polyclonal antibodies described in Chapter 5 (see 
Figure 5.1).
Both ADAMTS-4 and -5  have been shown to be inhibited by the amino-terminal portion of
TIMP-3 (Kashiwagi et ai, 2001) and in this thesis TIMP-3 was shown to be present in this culture
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system (Chapter 6). Therefore the effects of cycloheximide treatment were analysed using the 
polyclonal antibody raised against the carboxy-terminal region of TIMP-3 described in Chapter 6.
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12 Materials
• Dimethyl sulphonyl oxide (DMSO) was obtained from Sigma Aldrich, Poole, Dorset, UK.
• Cycloheximide in DMSO was obtained from Sigma Aldrich, Poole, Dorset, UK.
• Monoclonal antibody Anti-TS-4N was produced by Dr. Clare Hughes and Dr. Chris Little 
using methods described previously (Hughes et ai, 1995).
• Polyclonal antibodies Anti-ADAMTS-4 Prodomain (RP2-ADAMTS-4), Anti-ADAMTS-4 
Spacer domain (RP1-ADAMTS-4), Anti-ADAMTS-5 Prodomain (RP2-ADAMTS-5) and Anti- 
ADAMTS-5 Spacer domain (RP1-ADAMTS-5) were all obtained from Triple Point Biologies 
Inc., Forest Grove, OR, US.
• Horseradish peroxidase-linked goat anti-mouse antibody was obtained from Amersham, 
Buckinghamshire, UK.
• Horseradish peroxidase-linked goat anti-rabbit secondary antibody was obtained from 
Amersham, Buckinghamshire, UK.
• Blocking agent was obtained from Amersham, Buckinghamshire, UK.
• Enhanced Chemiluminescence (ECL) Western blotting Detection reagent was obtained 
from Amersham, Buckinghamshire, UK.
• Hyperfilm ECL was obtained from Amersham, Buckinghamshire, UK.
• Recombinant human ADAMTS-4 and -5  were a kind gift from Dr. Carl Flannery, Wyeth, 
Boston, US.
• All other reagents are listed in Chapter 2 Section 2.1, Chapter 4 Section 4.2 and Chapter 6 
Section 6.2.
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y Methods
ri1 Treatment of Chondrocyte-Agarose Cultures with Cycloheximide in the 
pmence or Absence of IL-1a
Porcine articular chondrocytes were isolated, embedded in agarose and precultured as described 
n Chapter 2 Sections 2.2.1 and 2.2.2. Following the 21 day preculture period the plates were 
ashed 3 x 20 minutes in serum free DMEM with 50pg/ml gentamicin before culture in serum free 
3MEM with 50Mg/ml gentamicin and 25pg/ml Phosphitan™C with either 5pg/ml cycloheximide in 
fttethyt Sulphonyl Oxide (DMSO) or DMSO alone in the absence (control) or presence of 10ng/ml 
unan recombinant lnterleukin-1 a (IL-1a). Each treatment was performed on triplicate plates. 
Folowing the culture period the medium was removed and stored along with the agarose plugs at 
-8(fC for later analysis.
12 Analysis of Experimental Medium Collected Following 96 hours Treatment with 
orwithout Cycloheximide in the Presence or Absence of IL-1a
Hie metabolic activity of the chondrocytes present in the chondrocyte-agarose cultures was 
analysed using the Lactate assay as described in Chapter 2 Section 2.2.5. Proteoglycans present 
nthe agarose plugs were extracted as described in Chapter 2 Section 2.2.3. The concentration of 
sulphated GAG released to the culture medium, and present in the guanidine extracts and alkaline 
J-efcninations was analysed using the DMMB assay described in Chapter 2 Section 2.2.4. 
Western blot analysis was carried out on media samples and guanidine extracts as described in 
Chapter 2 Section 2.2.8. Positive controls for these analyses were prepared as described in 
Chapter 2 Sections 2.2.6 and 2.2.7.
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7.3.3 Western Blot Analysis of ADAMTS-4 and -5 Isoforms Present in Media Samples 
and Detergent Extracts of Agarose Plugs Detected Using Enhanced 
Chemiluminescence (ECL)
Heparin and zinc chelator bound media fractions and detergent extracts of agarose plugs 
(prepared in Chapter 4 Section 4.3.1 and Chapter 2 Sections 2.2.9 and 2.2.10) (all 50pl per lane) 
along with recombinant human ADAMTS-4 and -5 (0.5pg per lane) were prepared in Laemmli 
sample buffer (Laemmli 1970) containing 10% (v/v) p-mercaptoethanol and electrophoresed in 
duplicate on 10% SDS-PAGE slab gels in running buffer. The gels were then transferred onto 
Nitrocellulose membrane (0.22pm) in transfer buffer at 100V for 60 minutes. Following their 
electrophoretic transfer the membranes were subjected to Western blot analysis as described in 
Chapter 5 (Section 5.3.2).
7.3.4 Western Blot Analysis of TIMP-3
Media samples and detergent extracts of agarose plugs (all 50pl per lane) along with recombinant 
human TIMP-3 (1pg protein per lane) were electrophoresed, transferred and subjected to Western 
blot analysis as described in Chapter 6 Section 6.3.3.
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7.4 Results
7.4 .1  Analysis of Lactate and Sulphated GAG Released from Cultures During 
Treatment Time
Media samples were analysed using the Lactate assay kit. The results of this analysis showed that 
treatment with cycloheximide and its carrier (DMSO) to have no effect on the metabolic activity of 
the chondrocytes present in the chondrocyte-agarose culture system (results not shown). 
Therefore at the concentrations utilised in these experiments cycloheximide was not causing 
apoptosis and any effects noted were the result of inhibition of de novo protein synthesis.
In order to determine the effect of cycloheximide on the proportion of sulphated GAG 
released to the medium during the 96 hours experimental treatment time the DMMB assay was 
utilised. Sulphated GAG was measured in the experimental medium, guanidine extracts of agarose 
plugs and alkaline p-eliminated extracts of agarose plugs. The concentration of sulphated GAG in 
the media, guanidine extracts and alkaline p-eliminations was adjusted to per plate and the raw 
results are shown in Table 7.1.
Statistical analysis of the data obtained for the percentage of the total sulphated GAG 
released to the medium during the 96 hours treatment time was carried out using Minitab 1.3. 
Since specific comparisons were required a series of paired t-tests were carried out. Cultures were 
compared which had been treated with carrier (DMSO) in the absence (control) or presence of IL- 
1a and treated with cycloheximide in the absence (control) or presence of IL-1a. The results of 
these analyses are shown in Table 7.2.
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Table 7.1 Tabulated results of three separate experiments on triplicate plates, giving a total n of 9, showing 
the mean GAG (pg/plate) released from cultures treated with cycloheximide (CHX [5pg/ml]) or carrier 
(DMSO) in the absence (control) or presence of IL-1a (10ng/ml). The GAG released was measured in the 
culture medium, in guanidine extracts of the agarose plugs and in alkaline p-eliminations of agarose plugs 
following guanidine extraction. From the results of concentration of sulphated GAG in each of these samples 
mean results for the total GAG (pg) per plate was calculated and thus the percentage of the total GAG 
released to the culture medium during the 96 hour treatment time (%).
Treatment GAG (pg/PLATE) Percentage o f 
T o ta l GAG 
Released to  
Medium (%)
Medium Guanidine
Extract
Alkaline
P-Elimination
Total
Control + DMSO 88.82 104.6 204.88 398.3 22.3
IL-1a + DMSO 264.20 0.0 38.09 302.3 87.4
Control + CHX 64.14 95.3 211.31 370.8 17.2
IL-1a + CHX 92.18 109.1 181.21 382.5 24.1
Control + DMSO 305.44 816.76 299.2 1421.4 21.49
IL-1a + DMSO 553.53 166.14 120.4 840.1 65.89
j Control + CHX 172.74 448.71 165.6 787.1 21.95
IL-1a + CHX 181.09 388.07 86.3 655.5 27.63
Control + DMSO 150.92 216.48 201.3 568.7 26.54
IL-1a+ DMSO 330.77 110.03 40.1 480.9 68.78
Control + CHX 57.01 128.99 217.9 403.9 14.15
IL-1a + CHX 67.78 142.82 195.6 406.2 16.69
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Table 7.2 Tabulated results of paired t-tests with 95% confidence intervals of the mean for the raw data 
tabulated in Table 7.1. The data shows the mean percentage of the total GAG released to the medium and 
the p-value obtained when comparing the pairs of data, from cultures treated with cycloheximide (CHX 
[5pg/ml]) or its carrier (DMSO) in the absence (control) or presence of IL-1a (10ng/ml) for 96 hours.
Treatment
Mean Percentage of 
Total GAG Released to 
Medium from 3
EXPERIMENTS IN TABLE 7.1 
(%)
P-Value
Control + DMSO 
vs
IL-1a + DMSO
23.44
0.0274.02
Control + CHX 
vs
IL-1a ♦ CHX
17.8
0.05922.81
100
80
60
5?
40
20 n
Control + DMSO IL-1a+DMSO Control + CHX IL-1a + CHX
Figure 7.1 Histogram of the mean values for the percentage of the total sulphated GAG released to the 
culture medium in cultures treated with cycloheximide (CHX [5pg/ml]) or its carrier (DMSO) in the absence 
(control) or presence of IL-1a (10ng/ml) for 96 hours. Errors shown are Standard Errors.
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in control cultures in the presence of carrier (DMSO) -23% of the total GAG was released to the 
afore medium during the 96 hours treatment time (Tables 7.1 and 7.2 and Figure 7.1). The 
'eiease of sulphated GAG to the medium was increased in cultures treated with IL-1a to -74% of 
Aetotal GAG present (Table 7.1 and 7.2 and Figure 7.1). A p-value of 0.02 was obtained from a 
naired t-test comparing cultures treated with or without IL-1a in the presence of DMSO indicating a 
statistically significant increase in the sulphated GAG released to the culture medium of IL-1a 
Tested cultures compared to the percentage release seen in control cultures.
In contrast, in control and IL-1 a treated cultures in the presence of cycloheximide (CHX) 
.18 and 23%, respectively, of the total GAG was released to the medium during the 96 hours 
treatment time (Table 7.1 and 7.2 and Figure 7.1). A p-value of 0.05 was obtained from a paired t- 
testcomparing cultures treated with and without IL-1 in the presence of cycloheximide (Table 7.2). 
Iteindicated that in the presence of cycloheximide there was no statistically significant difference 
n the percentage of the total GAG released to the medium during the treatment time between 
control and IL-1 a treated cultures.
7A2 Analysis of Aggrecan Catabolites by Western Blotting
Inorder to determine whether the prevention of the release of sulphated GAG to the medium of IL- 
1a treated cultures, compared to controls, caused by treatment with cycloheximide equated to a 
decrease in detectable enzyme activity against aggrecan a series of Western blots were 
performed, using previously characterised M’Abs, which specifically recognise neoepitopes 
resulting from catalytic cleavage within the IGD of the aggrecan core protein, namely; BC-3, BC- 
14, BC-13 and BC-4 (Hughes e ta i, 1995, Hughes et a i, 1992 and for reviews see Caterson et ai, 
1995and Caterson eta i, 2000).
Deglycosylated samples of media and guanidine extracts of agarose plugs from control 
cultures treated with or without cycloheximide and IL-1 a treated cultures with or without 
cycloheximide were electrophoresed, alongside purified aggrecan (A1D1) digested with 
recombinant human ADAMTS-4 or MMP-13, under reducing conditions on 4-12% SDS-PAGE gels
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and subjected to Western blot analysis. The results of these analyses are shown in Figures 7.2 
and 7.3.
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Figure 7.2 Western blot analyses of MMP-generated aggrecan metabolites containing the IGD neoepitopes 
(A) ^FFG V... detected in deglycosylated media samples by M’Ab BC-14 (20ng GAG equivalent per lane) 
and (B)...DIPEN341 detected in deglycosylated guanidine extracts by M’Ab BC-4 (20^g GAG equivalent per 
lane). Western blot analysis of deglycosylated media samples and guanidine extracts from cultures treated 
for 96 hours (1) Control cultures + DMSO, (2) IL-1a (10ng/ml) + DMSO, (3) Control + cycloheximide (CHX 
[5pg/ml]) and (4) IL-1 a (10ng/ml) + cycloheximide (CHX [5pgml]). Positive controls (+VE) were 
deglycosylated samples of purified porcine aggrecan (A1D1) digested with recombinant human MMP-13 
(20ng GAG equivalent per lane).
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Figure 7.3 Western blot analyses of aggrecanase-generated aggrecan metabolites containing the IGD 
Teoepitopes (A) 374ARGSV... detected in deglycosylated media samples by M’Ab BC-3 (20pg GAG
equivalent per lane) and (B) . NITEGE detected in deglycosylated guanidine extracts by M ’Ab BC-13 
20yg GAG equivalent per lane). Western blot analysis of deglycosylated media samples and guanidine 
extracts from cultures treated for 96 hours (1) Control + DMSO, (2) IL-1a (10ng/ml) + DMSO, (3) Control + 
cycloheximide (CHX [5Mg/ml]) and (4) IL-1 a (10ng/ml) + cycloheximide (CHX [5pg/ml]). Positive control of 
purified aggrecan (A1D1) digested with recombinant human ADAMTS-4 not shown.
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Western blot analysis was carried out using M’Abs BC-14 and BC-4 to detect MMP-generated 
aggrecan catabolites (Figures 7.2 A and B, respectively) and BC-3 and BC-13 to detect 
aggrecanase-generated aggrecan catabolites (Figures 7.3 A and B, respectively). The Western 
blots shown in Figures 7.2 A and B demonstrated no MMP-generated aggrecan catabolites in any 
of the treatments tested. Thus it may be concluded that no MMP activity against aggrecan within 
tie IGD is detectable in this culture system under the conditions used.
Western blot analysis of deglycosylated media samples from IL-1 a treated cultures (Figure 
J.3A Lane 2) showed increased levels of aggrecanase-generated aggrecan metabolites bearing 
the^ARGSV... neoepitope compared to cultures treated with carrier alone (Figure 7.3A Lane 1). 
The aggrecan catabolites detected in the IL-1 a treated cultures were of high molecular weight, with 
aladder of bands being detected between >250 -  150kD. However, in the cultures treated with IL- 
la in the presence of cycloheximide levels of aggrecanase-generated aggrecan catabolites (Figure 
7.3A Lane 4) were increased marginally when compared to cultures treated with cycloheximide 
alone (Figure 7.3A Lane 3), but this staining was significantly decreased compared to cultures 
treated with IL-1 a and carrier (Figure 7.3A Lane 2). This data indicates that in the presence of 
cycloheximide IL-1 a induced ‘IGD aggrecanase activity’ is markedly reduced, this correlating with 
the analysis of sulphated GAG released to the medium shown in Figure 7.1. Western blot analysis 
showed aggrecan metabolites bearing the ...NITEGE373 neoepitope detected by M’Ab BC-13 to be 
present in equal amounts in guanidine extracts of agarose plugs from all cultures tested (Figure 
7.3B).
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7.4.3 Western Blot Analyses of ADAMTS-4 and -5  Isoforms Present in Detergent 
Extracts of Agarose Plugs Following the Experimental Period
Inorder to determine whether the presence of cycloheximide during the treatment period in serum 
free medium affected the generation of isoforms of ADAMTS-4 and -5, detergent extraction of the 
agarose plugs was carried out. Aliquots of the detergent extracts (50pl per lane) were 
electrophoresed under reducing conditions on 10% SDS-PAGE slab gels and subjected to 
Western blot analysis with newly characterised monoclonal antibody Anti-TS-4N (characterised in 
Chapter 5 Section 5.4.1, 5.4.2 and 5.4.3) as well as polyclonal antibodies to the pro- and spacer 
domains of ADAMTS-4 and -5  (characterised in Chapter 5 Sections 5.4.3). Results from this 
analysis (Figures 7.4 A-E) showed a similar set of banding patterns whether or not control or IL-1 a 
treated cultures were incubated in the presence or absence of cycloheximide. However, the 
density of staining for some of these bands was reduced in the presence of cycloheximide.
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Figure 7.4 Western blot analyses of detergent extracts of agarose plugs (50pl/lane) from cultures treated for 
96 hours with (1) Control + DMSO, (2) IL-1a (10ng/ml) + DMSO, (3) Control + cycloheximide (CHX [5pg/ml]) 
and (4) IL-1 a (10ng/ml) + cycloheximide (CHX [5pg/ml]). Western blots were probed with antibodies to (A) 
The amino-terminal prodomain of ADAMTS-4 (a-TS-4 Pro), (B) The amino-terminal end of the 
metalloproteinase domain of ADAMTS-4 (a-TS-4N), (C) The carboxy-terminal spacer domain of ADAMTS-4 
(a-TS-4 Spacer), (D) The amino-terminal prodomain of ADAMTS-5 (a-TS-5 Pro) and (E) The spacer domain 
of ADAMTS-5 (a-TS-5 Spacer).
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lie series of bands detected are the same as those seen previously for cultures treated in the 
$ence (control) or presence of IL-1 a for 96 hours described in Chapter 5 (Sections 5.4.4 and 
;4$) (see Figure 7.4).
No differences were detectable in the high molecular weight isoforms present in the 
leiergent extracts of agarose plugs between any of the culture treatments tested i.e. between 
ijures treated with cycloheximide or carrier (DMSO) in the presence or absence of IL-1 a (Figure 
4). All of the antibodies raised against sequences in ADAMTS-4 detected bands at 100, 75 and 
SkDas well as a broad band at ~60kD (Figures 7.4 A, B and C). The polyclonal antibody to the 
iKlomain of ADAMTS-4 also detected an immunopositive band at 240kD. The polyclonal 
tfbodies raised against sequences in ADAMTS-5 both detected bands at 75 and 60kD (Figures 
4Dand E). The antibody to the prodomain of ADAMTS-5 also detected high molecular weight 
ttdsat 100 and 250kD (Figure 7.4D).
The low molecular weight isoforms detected by all of the antibodies in the detergent 
xtracts of agarose plugs from cultures treated in the presence of cycloheximide are greatly 
ecreased in intensity compared to those detected in the extracts from cultures treated in the 
bsence of cycloheximide. The antibody raised against the spacer domain of ADAMTS-5 detected 
32kD band in detergent extracts of agarose plugs from cultures treated with IL-1 a in the absence 
I cycloheximide (Figure 7.4E). This band is absent from control cultures and those treated with 
(doheximide. This data indicates de novo protein synthesis in serum free medium to be required 
rlruncation ADAMTS-4 and -5 resulting in small isoforms.
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Ill Western Blot Analysis of ADAMTS-4 and -5 Isoforms Present in the 
fjperimental Medium of Control and IL-1 a Treated Cultures in the Presence and 
Absence of Cycloheximide
norder to determine whether cycloheximide affected the production of isoforms of ADAMTS-4 and 
.§ released to the medium of cultures treated in the absence (control) or presence of IL-1 a 
jescribed in Chapter 5 (Section 5.4.6) a series of similar Western blots were carried out on media 
anples partially purified via passage over a Heparin-Sepharose column. The Heparin-Sepharose 
jlumn supernatant was further purified via passage over a Zinc Chelator column, and bound 
tactions from both columns were taken for analysis (as described in Chapter 5 Section 5.4.6).
Aliquots of the eluents (50pl per lane) were electrophoresed under reducing conditions on 
WSDS-PAGE slab gels and subjected to Western blot analysis with newly characterised M’Ab 
Wi-TS-4N (characterised in Chapter 5 Sections 5.4.2 and 5.4.3) as well as polyclonal antibodies 
Dthe pro- and spacer domains of ADAMTS-4 and -5  (characterised in Chapter 5 Section 5.4.3). 
he resulting blots showed multiple isoforms of ADAMTS-4 and -5  to be present in the medium 
m cultures treated with cycloheximide or carrier (DMSO) in the absence (control) and presence 
(IL*1 a (Figures 7.5 and 7.6).
• Zinc Chelator Bound Media Fractions
Media Samples Partially Purified via Passage over Heparin-Sepharose and Bound by a Zinc
Chelator Column
he zinc chelator bound isoforms of ADAMTS-4 and -5 detected showed no differences between 
levarious treatments tested (Figure 7.5) i.e. cultures treated in the absence (control) or presence 
(IL-1a with cycloheximide or carrier (DMSO). As expected in the control and IL-1 a treated 
ultures the isoforms of ADAMTS-4 and -5 detected are the same as those described in Chapter 5 
fiction 5.4.6. Staining revealed a complex pattern of bands with the polyclonal antibodies to the 
fodomains of ADAMTS-4 and -5 (Figures 7.5 A and D), with more simplistic patterns appearing 
iththe M’Ab Anti-TS-4N and the polyclonal antibodies to the spacer domains of ADAMTS-4 and - 
(Figures 7.5 C and E).
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•gure 7.5 Western blot analyses of ADAMTS-4 and - 5  isoforms bound to Zinc Chelator column and eluted 
35mM imidazole (50pl per lane) from media samples treated for 96 hours with (1) Control + DMSO, (2) IL- 
b(lOng/ml) + DMSO, (3) Control + cycloheximide (CHX [5pg/ml]) and (4) IL-1 a (10ng/ml) + cycloheximide 
3HX [5pg/ml]) Western blots were probed with antibodies to (A) The amino-terminal prodomain of 
DAMTS-4 (a-TS-4 Pro), (B) The amino-terminal end of the metalloproteinase domain of ADAMTS-4 (a-TS- 
1). (C) The carboxy-terminal spacer domain of ADAMTS-4 (a-TS-4 Spacer), (D) The amino-terminal 
domain of ADAMTS-5 (a-TS-5 Pro) and (E) The spacer domain of ADAMTS-5 (a-TS-5 Spacer).
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rhe predominant ~70kD zinc chelator bound isoform of ADAMTS-4 was detected by all of the 
t^odies raised against domains of the enzyme in media samples from all of the treatment 
jndftions tested i.e. the absence (control) and presence of IL-1 a with cycloheximide or carrier 
DMSO) (Figures 7.5 A, B and C).
The polyclonal antibody to the prodomain of ADAMTS-4 detects numerous high molecular 
(eight zinc chelator bound bands at 100, 110, 240 and 260kD in the medium from all treatment 
andffions tested (Figure 7.5A). However, only the 100kD isoform was detected by the antibody to 
he metalloproteinase domain of ADAMTS-4 (Figure 7.5B) and the 110 and 240kD isoforms of the 
protein were detected by the polyclonal antibody to the spacer domain of ADAMTS-4 (Figure 
’SC). Both antibodies to the pro- and metalloproteinase domains of ADAMTS-4 detected a zinc 
jielator bound band of 55kD in medium from all experimental conditions tested (Figure 7.5 A and 
!)•
The predominant ~70kD zinc chelator bound isoform of ADAMTS-5 is detected by both the 
ntibodies to the pro- and spacer domains of the enzyme in media samples from all treatment 
andrtions tested (Figure 7.5 D and E). The polyclonal antibody to the pro-domain of ADAMTS-5 
jetected high molecular weight zinc chelator bound bands, at 100 and 240kD, in the media from all 
lAures tested (Figure 7.5D). However, the antibody raised against the spacer domain of 
€AMTS-5 does not detect this isoform of the enzyme (Figure 7.5E).
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• Heparin Bound Media Fractions
Media Samples Partially Purified via Passage over a Heparin-Sepharose Column
Hie immunopositive bands detected in control and IL-1 a treated cultures using antibodies to
various domains of ADAMTS-4 and -5 were the same as those previously detected under 
jjperimental conditions which did not include DMSO (Chapter 5 Section 5.4.6). Hence any 
shanges detected in the presence of cycloheximide were due to the effects of the cycloheximide 
Iself and not its carrier (DMSO). In these systems increased prevalence of co-migrating 37kD 
soforms were detected by antibodies to different domains of ADAMTS-4 and -5 in IL-1 a treated 
cultures compared to controls (Chapter 5 Section 5.4.6 Figures 5.8 A-E and Figures 7.6 A-E Lanes 
1 and 2) with an additional 55kD isoform of ADAMTS-4 being detected by the antibody to the 
spacer domain of the protein (Chapter 5 Section 5.4.6 Figure 5.8C and Figure 7.6C Lanes 1 and 
2). Interestingly, in the cultures treated with cycloheximide there was no increase in the 37kD 
soforms of ADAMTS-4 and -5 in the IL-1 a treated cultures (Figures 7.6 A-E Lane 4) compared to 
jontrol cultures treated with cycloheximide (Figures 7.6 A-E Lane 2).
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Figure 7.6 Western blot analyses of ADAMTS-4 and - 5  isoforms bound to a Heparin-Sepharose column and 
eluted in 0.8M sodium chloride (50pl per lane) from media samples treated for 96 hours with (1) Control + 
DMSO, (2) IL-1 a (10ng/ml) + DMSO, (3) Control + cycloheximide (CHX [5pg/ml]) and (4) IL-1 a (10ng/ml) + 
cycloheximide (CHX [5pg/ml]). Western blots were probed with antibodies to (A) The amino-terminal 
prodomain of ADAMTS-4 (a-TS-4 Pro), (B) The amino-terminal end of the metalloproteinase domain of 
ADAMTS-4 (a-TS-4N), (C) The carboxy-terminal spacer domain of ADAMTS-4 (a-TS-4 Spacer), (D) The 
amino-terminal prodomain of ADAMTS-5 (a-TS-5 Pro) and (E) The spacer domain of ADAMTS-5 (a-TS-5 
Spacer).
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7.4.5 Western Blot Analysis of TIMP-3 Present in the Experimental Medium and 
Detergent Extracts of Control and IL-1 a Treated Cultures in the Presence or 
Absence of Cycloheximide
In order to determine whether treatment with cycloheximide affects the synthesis and secretion of 
HMP-3, a commercially available polyclonal antibody raised against the carboxy-terminal region of 
the protein was utilised (as described in Chapter 6 Section 6.4.1). Aliquots of detergent extracts of 
agarose plugs and experimental media samples (50pl of each per lane) from control and IL-1 a 
treated cultures in the presence of cycloheximide or carrier (DMSO) for 96 hours were 
electrophoresed under reducing conditions on 12% SDS-PAGE slab gels and subjected to 
Western blot analysis using the polyclonal Anti-TIMP-3 antibody. The results are shown in Figure 
7.7.
The major immunopositive band detected by the antibody to the carboxy-terminal region of 
TIMP-3 in the detergent extracts of agarose plugs migrated as a doublet at 24 and 27kD (Figure 
7.7A indicated by red arrow). These two bands were detected in equal intensity in detergent 
extracts of agarose plugs from all cultures tested. The same doublet of TIMP-3 bands was 
detected in equal intensity in the media samples from all cultures tested (Figure 7.7B indicated by 
red arrow). This represents non-associated TIMP-3 which may be ‘free’ TIMP-3 or may have been 
fcsociated by the gel running conditions.
Additional immunopositive bands were detected in the range of 55-1 OOkD in both detergent 
extracts of agarose plugs and experimental media samples (Figures 7.7 A and B respectively). 
These bands were detected in equal intensity in experimental media samples and detergent 
extracts of agarose plugs from all cultures tested. A low molecular weight immunopositive band 
was detected at 17kD in media samples from agarose cultures treated in the presence of 
cycloheximide. This band was absent from media samples from cultures treated in the absence of 
cycloheximide (Figure 7.7B).
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Figure 7.7 Western blot analysis of TIM P-3 present in aliquots of (A) Detergent extracts of agarose plugs 
and (B) Media samples (50pl per lane) from cultures treated for 96 hours with (1) Control + DMSO, (2) IL-1a 
HOng/ml) + DMSO, (3) Control + cycloheximide (CHX [5pg/ml]) and (4) IL-1a (10ng/ml) + cycloheximide 
(CHX [5pg/ml]). Western blots were probed with a commercially available polyclonal antibody raised against 
the carboxy-terminal region of TIMP-3.
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7,5 Discussion
The effect of cycloheximide on the metabolism of the chondrocytes embedded in agarose under 
specified experimental conditions was investigated. The Lactate assay was used as an indicator of 
oed viability, as the chondrocytes were metabolically active in the presence of cycloheximide any 
effects recorded were the result of inhibition of protein synthesis and not apoptosis.
Cycloheximide treatment caused retardation of the increased release of sulphated GAG to 
the medium seen in the cultures treated with IL-1a alone (Table 7.1 and Figure 7.1). The increased 
release of sulphated GAG to the medium seen in the IL-1a treated cultures was shown to be due 
tolGD aggrecanase activity’ as previously reported (Chapter 4 and Gendron et al, 2003, Hughes 
ef a/., 1995, and Arner et a/., 1998). This activity was decreased in the cultures treated with 
cycloheximide. This data correlates with previously published results from Arner eta!., 1998, which 
showed de novo protein synthesis to be required for ‘IGD aggrecanase activity’.
Isoforms of ADAMTS-4 and -5  were detected in equal amounts in zinc chelator bound 
fractions from media samples from all experimental culture conditions tested (Figures 7.5 and 7.4, 
respectively). In detergent extracts of agarose plugs high molecular weight isoforms of ADAMTS-4 
and -5 were detected in apparent equal intensity in all treatments tested. However, the lower 
molecular weight isoforms of ADAMTS-4 and -5 were greatly decreased in intensity in 
cycloheximide treated cultures (both control and IL-1a treated) (Figures 7.4 A-E Lanes 3 and 4) 
compared to cultures treated with carrier (DMSO) (Figures 7.4 A-E Lanes 1 and 2). These results 
vxficate that de novo protein synthesis in serum free conditions must be required for generation of 
these low molecular weight isoforms. The small isoforms may result from alternative splicing 
occurring in serum free conditions which were not generated due to the presence of cycloheximide. 
Alternatively, another protease with a rapid turnover may be responsible for generation of these 
small isoforms by catalysis of higher molecular weight forms of ADAMTS-4 and -5. Each of the 
wforms of ADAMTS-4 and -5  present in zinc chelator bound fractions of media samples and 
detergent extracts of agarose plugs are discussed in detail in Chapter 5 Section 5.5.
As previously reported in this thesis the predominant heparin bound isoforms of ADAMTS-4 
and -5 co-migrate at 37kD (Figure 7.6) with an additional 55kD isoform of ADAMTS-4 being
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detected by the antibody to the spacer domain of the protein (Figure 7.6C). The co-migrating 37kD 
eoforms of ADAMTS-4 and -5 were detected at increased prevalence in IL-1a treated cultures 
compared to controls. The addition of the cycloheximide carrier (DMSO) had no effect on this 
banding pattern (Figures 7.6 A-C Lanes 1 and 2). Interestingly, in the cultures treated with 
cycloheximide in the presence of IL-1a there was no increase in the 37kD isoforms of ADAMTS-4 
and -5 (Figures 7.6 A-E Lane 4) compared to the levels detected in cultures treated with 
cycloheximide alone (Figures 7.6 A-E Lane 2). It has recently been reported that carboxy-terminal 
truncation enhances the ‘IGD aggrecanase activity’ of ADAMTS-4 (Gao et al., 2002), thus implying 
a role for the carboxy-terminally truncated 37kD isoforms of ADAMTS-4 and -5  in the increased 
aggrecanase activity’, detected at the site within the IGD, in the presence of IL-1a (Figure 7.3C). 
This is also suggested by the fact that the co-migrating 37kD immunopositive bands of ADAMTS-4 
and-5 are detected in equal intensity in the cultures treated with cycloheximide in the presence or 
absence of IL-1a. Alternatively, the enzyme responsible for catabolism of ADAMTS-4 and -5 
resulting in the 37kD isoform may be rapidly turned over and therefore swiftly lost from cultures 
where de novo protein synthesis has been inhibited. For example MT4-MMP has been shown to 
cleave ADAMTS-4 resulting in truncated isoforms able to cleave aggrecan at the Glu373-Ala374 bond 
within the interglobular domain in a chondrosarcoma cell line (Gao eta i, 2004).
The major TIMP-3 immunopositive bands detected in both detergent extracts of agarose 
plugs and media samples showed no major differences between any of the experimental culture 
conditions tested (Figure 7.7). Immunopositive bands containing TIMP-3 associated with other 
matrix proteins were detected at 55, 60, 70, 75 and 100kD. The ability of TIMP-3 to interact with 
constituents of the extracellular matrix is unique among members of the TIMP family (Pavloff et al., 
1992 and Yu et al., 2000). TIMP-3 bands were also detected at 24 and 27kD either corresponding 
to Iree’ TIMP-3 or TIMP-3 dissociated under reducing conditions. Additional TIMP-3 
immunopositive bands were detected at 17kD in media samples from cultures treated with 
cycloheximide which were absent from cultures treated with carrier (DMSO). This may correspond 
toa degraded form of TIMP-3 which is removed by a protease with a rapid turnover. Therefore in 
the presence of cycloheximide, synthesis of the degrading protease is inhibited and as a result 
partially degraded forms of TIMP-3 are detectable. ADAMTS-4 has recently been shown to cleave
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TlMP-4, but not TIMPs-1, 2 and -3 at the A192-Q193 site and Neutrophil elastase has been shown to 
cleave TIMP-1 at the Val69-Cys70 bond (Zang et al., 2004). However, no such activity has yet been 
described against TIMP-3.
7 ,6  Summary
3 De novo protein synthesis in serum free conditions is required for ‘aggrecanase activity’ within 
the interglobular domain of aggrecan.
3 De novo protein synthesis is also required for the generation of co-migrating heparin binding 
37kD isoforms of ADAMTS-4 and -5, which in the absence of cycloheximide are increased in 
cultures treated with IL-1a compared to untreated controls. These isoforms may result from 
enzyme autocatalysis, alternative splicing or catalytic processing by another enzyme such as 
MT4-MMP (Gao etal., 2004).
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8 General Discussion
In this investigation the model culture system of chondrocytes embedded in agarose was used to 
study the degradation of aggrecan by ADAMTS-4 and -5, and the synthesis, sequestration and 
activation these aggrecanases in cartilaginous extracellular matrices. Chondrocyte-agarose 
cultures secrete an extracellular matrix rich in aggrecan during the preculture period in the 
presence of serum. The aggrecan was degraded in serum free conditions resulting in the release 
of sulphated GAG to the culture medium. The proportion of the total GAG present released to the 
medium during the treatment time was substantially increased by the presence of IL-1a. In 
chondrocyte-agarose cultures treated with IL-1a >70% of the total GAG present was released to 
the medium in just 24 hours, in contrast to achieve release of >70% of the total GAG present from 
bovine nasal cartilage explant cultures treatment with IL-1 for 7 days was required (Little et al, 
2002b) similarly only 65% of the total GAG present was released from bovine articular cartilage 
explant cultures treated with IL-1 in 15 days (Sandy et al., 1991a). Thus the model system of 
chondrocytes embedded in agarose is extremely useful for the rapid analysis of the effects of 
pharmaceutical agents on the metabolism of chondrocytes. Further analysis of chondrocyte- 
agarose cultures as a model system should be carried out. This may include analysis of mRNA 
and protein levels for various matrix macromolecules, including types II and VI collagen, aggrecan 
and other proteoglycans, as well as matrix proteases, such as MMPs, ADAMTSs and cathepsins, 
and inhibitors such as TIMPs.
Aggrecan degradation detected as sulphated GAG release to the culture medium was 
found to be due to cleavage at the ‘aggrecanase site* within the IGD of the aggrecan core protein. 
No MMP activity against the IGD of aggrecan was detected. This finding corresponds with 
numerous previously published results, which detected increased aggrecanase-generated 
aggrecan catabolites in the medium of explant cultures treated with IL-1 (Gendron et al., 2003, 
Hughes etal., 1995, and Arner etal., 1998).
The focus of this investigation was aggrecan degradation, and within the culture period 
used the major cause of aggrecan degradation was due to ‘IGD aggrecanase activity’. Since the 
activities of ADAMTS-4 and -5 against the ‘aggrecanase site’ within the IGD of aggrecan are
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distinguishable, and they are thought to be key players in the degradation of aggrecan in 
diseases such as osteoarthritis and rheumatoid arthritis (Sandy et al., 1992, and Lohmander et al., 
1993), their secretion, sequestration and activation in this model system was investigated using a 
range of mono- and polyclonal antibodies that recognise different domains of ADAMTS-4 and -5.
Numerous immunopositive bands were detected with antibodies to ADAMTS-4 and -5 in 
both detergent extracts of agarose plugs and media samples indicating multiple isoforms of the 
enzymes to be present in this culture system. Detergent extracts of agarose plugs may contain 
proteins which are membrane-bound or associated as well as intracellularly located or sequestered 
within the extracellular matrix. Media samples were partially purified via passage over a Heparin- 
Sepharose column followed by a Zinc-Chelator column.
The high molecular weight ADAMTS-4 and -5 isoforms detected in detergent extracts of 
agarose plugs and zinc chelator bound media fractions were unlikely to be involved in the massive 
ncrease in ‘IGD aggrecanase activity’ detected in IL-1 a treated cultures compared to controls 
since they appeared not to be upregulated by IL-1 a treatment. The enzyme isoforms detected may 
be inactive, due to them possessing a prodomain, or catalytically active due to removal of their 
prodomain by Furin (Molloy et al., 1992, Gao et al., 2002, Tortorella et al., 1999, Abbaszade et al., 
1999, and Wang et al., 2004) but inactivated by sequestration within the matrix or the presence of 
proposed endogenous physiological inhibitors such as TIMP-3 (Kashiwagi et al., 2001) or ct2 
Macroglobulin (Tortorella et al., 2004). Furthermore the Furin-cleaved intact form of recombinant 
human ADAMTS-4 has been shown to preferentially cleave aggrecan at the KEEE1667-1668GLGS 
and GELE1480-1481GRGT sites within the carboxy-terminal GAG binding region rather than the 
NITEGE373-374ARGSV (‘aggrecanase site’) within the IGD of aggrecan (Tortorella etal., 2000b).
Recently published data showed a recombinant form of human ADAMTS-4 to bind to the
cell surface and extracellular matrix of the cells in which it was expressed (293-EBNA cells)
(Kashiwagi etal., 2004). This interaction was dissociated by addition of heparin allowing release of
the recombinant enzyme into the culture medium. Furthermore, Pratta et al., 2003 reported
addition of heparin to IL-1 treated bovine monolayers inhibited ‘IGD aggrecanase activity.
Therefore, it could be concluded that the active form of aggrecanase must have the ability to bind
heparin. Thus implicating the isoforms of ADAMTS-4 and -5 bound by the Heparin-Sepharose
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column as complicit in the IGD aggrecanase activity’ seen in the presence of IL-1 a in the culture 
system of chondrocytes embedded in agarose, and potentially as the active aggrecanase(s) in 
cartilage degradation in arthritis.
The heparin bound ADAMTS-4 and -5 isoforms detected co-migrated at ~37kD and were 
present in apparently increased amounts with increasing time in serum free medium and in IL-1 a 
treated cultures compared to controls. This is similar to previously published results indicating 
treatment with IL-1 p to increase the prevalence of lower molecular weight isoforms of ADAMTS-4 
incell lysates from bovine chondrocyte monolayers (Pratta etal., 2003).
Generation of apparently increased levels of co-migrating 37kD isoforms of ADAMTS-4 and 
•5 in IL-1 a treated cultures was inhibited by cycloheximide, and therefore required de novo protein 
synthesis in the presence of IL-1 a for their generation. As previously reported, de novo protein 
synthesis was also required for ‘IGD aggrecanase activity’ detected in the presence of IL-1 (Arner 
et al., 1998). This further implicates the co-migrating 37kD isoforms of ADAMTS-4 and -5 to be 
involved in the ‘IGD aggrecanase activity’ detected in IL-1 treated cultures.
The co-migrating 37kD isoforms of ADAMTS-4 and -5 may result from enzyme catalysis by 
autocatalysis due to a lack of suitable substrate. Chondrocyte-agarose cultures treated in the 
presence of IL-1 a release over 70% of the sulphated GAG present to the medium in 24 hours (see 
Chapter 4). Therefore following 24 hours of treatment in the presence of IL-1 a 70% of the 
substrate for ADAMTS-4 and -5  has been lost to the medium consequently by 48 hours of 
treatment in the presence of IL-1 a the enzymes themselves may be undergoing autocatalysis. 
Alternatively, the 37kD isoforms of ADAMTS-4 and -5  may result from alternative splicing or 
catalytic activation by another enzyme. Since these 37kD isoforms of ADAMTS-4 and -5 are 
increased in IL-1 a treated cultures compared to controls they may play a role in the increased ‘IGD 
aggrecanase activity’ detected in these cultures (see Chapter 4).
The possibility of alternatively spliced forms of ADAMTS-4 and -5 could be investigated by 
PCR analysis using primers recognising sequences located in various areas of the enzymes. This 
may allow elucidation of which domains of ADAMTS-4 and -5 are expressed in the presence or 
absence of IL-1 a.
193
A model for the generation of 55 and 40kD isoforms of ADAMTS-4 was recently described 
in which catalysis occurs at the cell surface via membrane bound MT4-MMP (Gao et al., 2004) In 
this model cleavage occurs at the Lys694-Phe695 bond within the cysteine-rich domain resulting in a 
-55kD isoform and at the Thr^-Phe582 bond within the thrombospondin-1 like domain resulting in 
a~40kD isoform. The 40kD isoform described using human peptide sequence by Gao et al., 2004 
may have a molecular weight of ~37kD in porcine chondrocytes. A similar mechanism may be 
proposed for generation of 37kD isoforms of ADAMTS-5. To further investigate this possibility 
MMP specific inhibitors, such as TIMP-1 or -2, may be utilized. Inhibition of ‘IGD aggrecanase 
activity’ by the presence of such inhibitors would indicate MMP activity to be necessary for 
activation of ‘aggrecanase’.
Previously published data suggested lower molecular weight isoforms of ADAMTS-4 and -5 
to result from truncation of the proteins resulting in loss of the carboxy-terminal regulatory regions 
of the enzymes (Pratta et al., 2003, Kashiwagi et al., 2004, Gao et al., 2002, Gao et al., 2004 and 
Flannery et al., 2002). Interestingly, full length Furin cleaved recombinant human ADAMTS-4 
showed little catalytic activity against the ‘aggrecanase site’ (NITEGE373-374ARGSV) within the IGD 
of aggrecan, preferentially cleaving the GELE1480-1481GRGT site within the carboxy-terminal GAG 
binding region ( Tortorella et al., 2000b, and Kashiwagi et al., 2004). Whereas truncated forms of 
ADAMTS-4 lacking the carboxy-terminal spacer domain showed apparently increased catalytic 
activity to the NITEGE373-374ARGSV (‘aggrecanase site’) within the IGD of the aggrecan core 
protein as well as increased non-specific catalytic activity to other matrix proteins such as decorin 
and fibromodulin (Kashiwagi et al., 2004). This implies that generation of lower molecular weight 
Boforms of ADAMTS-4 and -5 may either constitute ‘activation’ of these enzymes as predicted by 
Pratta etal., 2003, or it may represent a deregulation of the enzymes leading to more promiscuous 
catalytic activity (Gao et al., 2002, Gao et al., 2004, and Kashiwagi et al., 2004). Therefore the high 
molecular weight enzyme isoforms may be required to  play normal physiological roles, whereas 
the low molecular weight forms are likely to be the enzyme isoforms involved in the destruction of 
aggrecan and other proteoglycans in articular cartilage during arthritis. This suggests targeting of 
anzyme inhibitors against the active sites of ADAMTS-4- and -5 to be inopportune as such inhibitors 
would not distinguish between high and low molecular weight forms of the enzymes and may
194
therefore disrupt the physiological role played by the high molecular weight isoforms of the 
proteins.
Media fractions from IL-1 a treated cultures were found to possess soluble ‘aggrecanase 
activity’ against the IGD of exogenously added aggrecan (A1D1) which was absent from media 
samples from control cultures. The heparin bound media fractions from IL-1 a treated cultures 
consistently contained apparently high levels of ‘IGD aggrecanase activity’, whereas in contrast the 
activity of the zinc bound media fractions against the IGD of exogenous aggrecan was extremely 
variable. This may suggest the ‘IGD aggrecanase activity’ detected in the zinc bound media 
fractions to be due to contamination with low molecular weight heparin binding catalytically active 
soforms of ADAMTS-4 and / or 5. Alternatively, catalysis of the high molecular weight zinc bound 
soforms may occur to form lower molecular weight catalytically active isoforms of the enzymes 
(Flannery et al., 2002, and Gao et al., 2004).
The ‘IGD aggrecanase activity’ detected in heparin bound media fractions from IL-1 a 
treated cultures was ablated by addition of monoclonal antibody Anti-TS-4N to the digestion mix. 
This indicates the ‘IGD aggrecanase activity’ detected in these cultures to be predominantly due to 
soforms of ADAMTS-4 rather than ADAMTS-5. Furthermore, monoclonal antibody Anti-TS-4N 
detected a single band at 37kD by Western blot analysis implying a low molecular weight 
ADAMTS-4 isoform to be responsible for the detected ‘aggrecanase activity’. This is similar to 
previously published results which show immunodepletion of media taken from IL-1 a stimulated 
cartilage using an ADAMTS-4 polyclonal antibody led to a 75% reduction in ‘IGD aggrecanase 
activity’, whilst immunodepletion with an ADAMTS-5 antibody led to only a 15% decrease in ‘IGD 
aggrecanase activity’ (Tortorella et al., 2001). These results suggest that an antibody affinity 
column could be produced, using monoclonal antibody Anti-TS-4N, and used to purify isoforms of 
ADAMTS-4 possessing ‘IGD aggrecanase activity’.
The ‘aggrecanase activity’ of both the heparin and zinc bound media fractions, from IL-1 a 
treated cultures, against the IGD of exogenous aggrecan was inhibited by the presence of TIMP-3 
ora recombinant protein comprising the amino-terminal domain of TIMP-3 (N-TIMP-3). Therefore 
the enzyme(s) possessing ‘IGD aggrecanase activity’ present in the heparin or zinc bound media
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fractions from, IL-1 a treated cultures, were inhibited by the amino-terminal region of TIMP-3. 
ADAMTS-4 and -5 have previously been shown to be inhibited by the amino-terminal region of 
TIMP-3 leading to its nomination as a physiological inhibitor of these enzymes in vivo (Kashiwagi et 
1 2001).
In order to determine whether TIMP-3 is present in the model system of chondrocytes 
embedded in agarose an antibody to the carboxy-terminal region of the protein was used. 
Endogenous TIMP-3 was detected in this culture system as low molecular weight free’ TIMP-3 (i.e. 
TIMP-3 not associated with other molecules) and high molecular weight bands of TIMP-3 
associated with matrix components or enzymes. This ability of TIMP-3 to bind to extracellular 
matrix components is unique among members of the TIMP family (Pavloff et al., 1992, and Yu et 
i, 2000) and may be further investigated using the TIMP-3 antibody to co-immunoprecipitate the 
TIMP-3 and any associated macromolecules. No differences were apparent in the total level of 
TIMP-3 protein present between control and IL-1 a  treated cultures. Interestingly, lower levels of 
free’ TIMP-3 were detected in IL-1 a  treated cultures compared to controls, possibly indicating 
higher levels of bound TIMP-3 in these cultures. Overall, TIMP-3 synthesis was not upregulated by 
treatment with IL-1 a. Therefore TIMP-3 synthesis may not be involved in the compensation 
mechanisms employed by chondrocytes in this model system when exposed to catabolic 
stimulants such as IL-1 a. Levels of TIMP-3 detected were also unaffected by treatment with 
cycloheximide, indicating de novo protein synthesis following treatment in serum free conditions to 
be unnecessary for generation of the TIMP-3 protein detected.
The amino-terminal region of TIMP-3 is thought to be a physiological inhibitor of ADAMTS-4 
and-5 (Kashiwagi et al., 2001) and has been shown to be a potent inhibitor of ‘IGD aggrecanase 
activity* in the culture system of chondrocytes embedded in agarose when added exogenously. 
TIMP-3 protein has also been detected endogenously in this culture system. Therefore the ability 
of the ADAMTS-4 and -5 isoforms previously detected in this model system to bind to the amino- 
terminal region of TIMP-3 was investigated using a recombinant protein comprising the amino- 
terminal domain of TIMP-3 (N-TIMP-3). The ADAMTS-4 and -5 able to bind to N-TIMP-3, when 
used as a purification column, were only those enzyme isoforms predicted to be intact apart from
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cleavage at the Furin site. Interestingly, none of the low molecular weight 37kD isoforms of 
ADAMTS-4 or 5 were able to bind to the N-TIMP-3. This is in contrast to previously published work 
using binding to N-TIMP-3 as a purification method for ADAMTS-4 isoforms. Here multiple 
isoforms of ADAMTS-4 were detected bound by N-TIMP-3, these ranged in molecular weight from 
37-45kD (Kashiwagi et al., 2004). In the culture system of chondrocytes embedded in agarose the 
binding of ADAMTS-4 and -5 to N-TIMP-3 may be hindered by the presence of endogenous TIMP- 
3rather than the lack of an appropriate site of interaction on the enzyme isoform. In the published 
study samples were incubated with N-TIMP-3 under dissociative conditions allowing for no such 
nteraction between endogenous TIMP-3 and ADAMTS-4 (Kashiwagi et al., 2004), although it is 
possible that such conditions may also have interfered with binding of ADAMTS-4 isoforms to N- 
TIMP-3. None the less it is interesting to speculate why addition of exogenous N-TIMP-3 inhibited 
the‘IGD aggrecanase activity’ of media samples from IL-1 a treated cultures whilst N-TIMP-3 was 
unable to bind the ADAMTS-4 isoforms thought to be responsible for this ‘IGD aggrecanase 
activity’ (i.e. the low molecular weight 37kD ADAMTS-4 isoform detected by M’Ab Anti-TS-4N).
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